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The human kidney is a major target organ for drug-induced toxicity. Various environmental 
toxins and marketed drugs can cause nephrotoxicity and increase the incidence of acute kidney 
injury (AKI), which can in turn amplify the long-term risk of chronic kidney diseases [1, 2]. 
There is currently a lack of reliable pre-clinical models for predicting nephrotoxicity [3]. Animal 
models are affected by interspecies variability. A major problem with respect to in vitro models 
is the identification of appropriate cell types and endpoints. Therefore, nephrotoxicity of drug 
candidates is typically only detected during late stages of drug development [4]. This is a major 
obstacle in the development of new drugs with reduced nephrotoxic effects and leads to high 
costs for the pharmaceutical industry. Goal of my thesis was to develop an in vitro model that 
predicts nephrotoxicity in humans with high accuracy. 
My work focused on the use of renal proximal tubular cells (PTCs), which are most susceptible 
to toxic effects of drugs and chemicals in the human kidney due to their roles in drug transport 
and metabolism [3]. Human primary PTCs (HPTCs) were used to overcome interspecies 
variability associated with animal cells and functional changes of standard immortalized cell 
lines. I first investigated different culturing substrates for human primary cells, and the results 
revealed unexpectedly that uncoated tissue culture polystyrene (TCPS) was most suitable for 
HPTCs [5]. It has also been demonstrated in the thesis that variable cellular responses towards 
the same toxicants were mainly affected by cell type-specific effects [6], highlighting the 
importance of using the most relevant cell type.  
The HPTC-based in vitro model for nephrotoxicology developed here employed drug-induced 
increases in mRNA expression levels of the pro-inflammatory interleukins (IL)-6 and IL-8 as 
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endpoint. Pro-inflammatory responses play an important role in the pathophysiology of AKI, 
including drug-induced AKI [7]. The HPTC-based in vitro model was validated with 41 well-
characterized drugs and chemicals and the major performance metrics ranged between 0.76 and 
0.85, indicating that 76% - 85% of predictions made with this model would be correct [8]. This 
work established the first in vitro model that predicts nephrotoxicity in humans with high 
accuracy. Stem cell-derived HPTC-like cells [9] were employed in a next step. Also the HPTC-
like cell-based in vitro model was validated with the same set of 41 compounds. The predictivity 
of this model was also high [10]. This work demonstrated the first successful application of stem 
cell-derived human renal cells. All results were compared to results obtained with renal standard 
cell lines and widely used endpoints, which were associated with poor predictivity. 
Further, I addressed the underlying mechanisms of drug-induced IL-6 and IL-8 up-regulation in 
PTCs. The results showed that this was dependent on the nuclear translocation of NF-B p65. 
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1. Introduction  
1.1 Nephrotoxicity and drug-induced acute kidney injury (AKI) 
The kidney is a major target organ for drug-induced toxicity apart from the liver. Due to its 
essential role in the excretion process, it receives 25% of resting cardiac output and is therefore 
frequently exposed to large amounts of drugs and chemicals in blood circulation [11]. Various 
agents, such as heavy metals, fungal toxins or other environmental toxins, and a large number of 
drugs have been shown to be nephrotoxicants [1, 2]. The use of such nephrotoxic chemicals and 
drugs can lead to acute kidney injury (AKI). AKI is a complex disorder and usually characterized 
by functional and/or structural injury of the kidneys, leading to an acute decline in their functions 
[12]. In the United States, an estimated 1% of all hospital admissions are affected by AKI, which 
also develops in 5% to 7% of hospitalized patients [13, 14]. This incidence rate increases 
drastically to 30% to 60% in the intensive care unit (ICU) patients [15]. Among all hospital- and 
community-acquired AKI cases, about 20% are attributed to drug- or toxicant-induced 
nephrotoxicity [2, 16]. 
 
Several mechanisms are involved in the toxicity of nephrotoxicants, including vasoconstriction, 
altered intraglomerular hemodynamics, tubular cell toxicity, interstitial nephritis, crystal 
deposition, thrombotic microangiopathy, osmotic nephrosis and rhabdomyolysis [1, 2, 17]. 
Among these mechanisms, direct tubular damage is the most common cause of AKI. The renal 
proximal tubular epithelial cells (PTCs) are a major target for the toxic effects of nephrotoxicants, 
due to their primary functions of glomerular filtrate concentration as well as drug transport and 
metabolism [18, 19]. Several drugs with known evidence of PTC toxicity are widely used to treat 
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various conditions such as cancer, sepsis, or used as immunosuppressants after transplantation, 
as briefly discussed below. 
 
One such example is cisplatin (also known as cis-dichlorodiammine platinum (II)), one of the 
most widely used chemotherapeutic agents in the treatment of cancers. Cisplatin is taken up by 
PTC through the organic cation transporter 2 (OCT 2) and the copper transporter Ctr1 [20]. It 
damages the nuclear and mitochondrial DNA inside the cells and results in apoptosis or necrosis 
[20, 21]. Diuresis and dose reduction are partially successful in lowering the nephrotoxicity of 
cisplatin [22, 23], but limits the anticancer efficacy of the drug. Despite these renoprotective 
techniques, the incidence of cisplatin-induced AKI remains high in cancer patients [24]. 
Therefore there is an urgent need to identify new substitutes with similar antitumor potency and 
less nephrotoxicity. 
 
Aminoglycoside antibiotics, such as gentamicin, tobramycin and amikacin, are effective drugs in 
clinical use to treat sepsis, a systemic response to infections. Aminoglycosides are taken up by 
the PTC via the megalin (MEG)/cubilin endocytotic receptor complex [25, 26]. Cellular 
accumulation of aminoglycosides can lead to disruption of protein turnover as well as 
mitochondrial dysfunction, which often results in PTC death and AKI [27]. 
 
It is also well established that AKI can amplify long-term risk of chronic kidney disease (CKD) 
and end stage renal disease (ESRD) [28-30], further increasing morbidity and mortality. For 
ESRD patients, the most effective treatment is kidney transplantation. Calcineurin inhibitors, 
such as cyclosporine and tacrolimus, are often used in immunosuppressive regimens to prevent 
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allograft rejection due to their clinical effectiveness. However, these drugs are also commonly 
associated with nephrotoxicity, which may lead to acute changes in renal heamodynamics [31] 
and apoptosis-inducing direct tubular epithelial cell toxicity [32, 33]. Calcineurin inhibitors are 
also known to cause chronic nephrotoxic effects such as striped interstitial fibrosis and arteriolar 
hyalinosis, leading to chronic allograft dysfunction [34-37]. In fact, nephrotoxicity is the major 
pitfall of the current calcineurin inhibitor-based immunosuppressive regimens in transplant 
recipients, and this problem greatly limits the effectiveness of such treatments. 
 
Due to such adverse side-effects of existing drugs, it is essential to develop new drugs with 
similar efficacy but less nephrotoxicity. However, nephrotoxicity is typically detected only 
during late stages of drug development. 2% of drug attrition during pre-clinical studies is due to 
nephrotoxicity, and in phase 3 clinical trials this percentage increases drastically to 19% [4]. The 
major reason for this is the low predictivity of animal tests, usually due to interspecies variability. 






1.2 In vitro models for the prediction of drug-induced nephrotoxicity 
The interest in in vitro models has been growing strongly in recent years due to legislation 
changes in the EU (Registration, Evaluation, Authorization and Restriction of Chemicals 
(REACH) and Cosmetics Directive) and new initiatives in the USA (ToxCast and Tox 21). 
However, there are currently no regulatory approved in vitro models for the prediction of 
nephrotoxicity. The European Centre for the Validation of Alternative Test Methods (ECVAM) 
funded a prevalidation project that was based on the use of two animal cell lines and 15 
compounds, and the endpoints used were transepithelial electrical resistance (TEER) and 
fluorescein isothiocyanate (FITC) influx [38]. This study was published more than a decade ago 
and there was no follow-up on this approach. No further validation study specific to in vitro 
nephrotoxicology was performed since then. 
 
There have been other studies which attempted to develop or validate models for in vitro 
nephrotoxicology [3, 39-44]. However, one major problem in these studies was that only very 
limited numbers of test compounds were used, and it was not possible to determine the 
predictivity of the models. In a recent study on organ-specific toxicity, 621 compounds 
(including 273 hepatotoxicants, 191 cardiotoxicants, 85 nephrotoxicants, and 72 non-toxic 
compounds) were used on multiple organ-specific cell lines (human hepatoma cell line, rat 
myocardial cell line and rat kidney epithelial cell line) [45]. Adenosine triphosphate (ATP) 
content was used as the endpoint, and major performance metrics such as sensitivity and 
specificity were calculated. However, the results of this study showed that the model could not 
achieve accurate prediction of organ-specific toxicity. This implies that the choice of appropriate 
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cell types and endpoints could have an essential impact on the performance of an in vitro model 
for the prediction of organ-specific toxicity.  
 
ADME (absorption, distribution, metabolism and excretion) properties can also affect how 
different cell types respond to drugs in vivo, but drug attrition due to ADME properties has 
substantially declined during recent years [46, 47], due to pharmacokinetics modeling and better 
absorption models (for example, the Caco-2 cell line as a model for intestinal epithelial 
permeability [48]). On the contrary, toxicity prediction could not be improved and still remains 
as the major reason for drug attrition [46, 47]. Nevertheless, bioavailability and biodistribution 
principles have limited relevance to in vitro toxicity models, where the choice of cell types and 
endpoints would have a greater impact on predictive performance of such models.  
 
For an in vitro nephrotoxicity model, PTCs are the most appropriate cell type as they are the 
major target for toxic effects of drugs and chemicals in the kidney. Their vulnerability to 
toxicants is due to their roles in glomerular filtrate concentration and the transport of drugs and 
organic compounds [1, 49]. PTCs actively transport a large variety of drugs, organic compounds 
and xenobiotics from blood circulation to the glomerular filtrate and also metabolise such 
compounds. A wide spectrum of drug transporters as well as drug metabolizing enzymes is 
expressed in PTCs [3, 18, 19]. These expression patterns are essential in regulating the cellular 
responses towards the toxic effects of drugs and chemical compounds. This is well demonstrated 
by the differences in drug response between cells from different organ systems [50, 51], as well 
as between animal and human PTCs. For example, human PTCs express only one multidrug 
resistance (MDR 1) gene which encodes the P-glycoprotein transporter (which participates, for 
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instance, in the removal of paraquat from PTCs [52]), but mice have MDR 1a and MDR 1b [53, 
54]. Another example would be OCT1, which plays an important role in cationic drug secretion 
in the rodent kidney, but is expressed at extremely low levels in the human kidney [55]. Flavin-
containing monooxygenases also show marked interspecies differences in their expression 
patterns in the kidney [18]. Such interspecies variability explains why high predictivity with 
respect to human responses is difficult to achieve with preclinical animal models. Therefore it 
remains challenging to accurately detect drug-induced nephrotoxicity in early stages of drug 
development [4]. 
 
With respect to human cells, the human kidney-2 (HK-2) cell line is commonly used for 
nephrotoxicity testing (for example, see [56, 57]). However, one major problem with the use of 
cell lines is the functional changes that had occurred in the cells during immortalization. HK-2 
cells were derived from human PTC and immortalized with human papilloma virus-16 (HPV-16) 
E6/E7 genes [58]. Although these cells demonstrate functional features of PTC and express PTC 
markers, it has been shown that they lack the expression of certain drug transporters, such as 
organic anion transporter 1 (OAT 1), OAT 3, OCT 2, as well as breast cancer resistance protein 
(BCRP) [59]. The expression levels of MEG were also low in HK-2 cells [59], leading to 
reduced uptake of gentamicin [60]. As aminoglycoside antibiotics such as gentamicin are major 
nephrotoxicants in humans [61], the insensitivity towards such drugs [57] greatly undermines the 
usefulness of HK-2 cells in nephrotoxicology. Due to functional changes and changes in drug 
transporter expression associated with immortalization [59, 62, 63], HK-2 are in general less 
sensitive towards nephrotoxicants than human primary renal proximal tubular cells (HPTCs) [64], 




Our group has been working extensively on characterization of HPTCs and in vitro cultivation 
conditions, and this work addressed culturing substrates [5, 65-67], coatings [67, 68], culture 
media and growth factors [69, 70].  The work also included development of bioreactors [66, 67, 
71], co-culture/three-dimensional (3D) models [65, 70, 72] and genetic engineering [69]. Here 
my objective was to develop an in vitro model for the prediction of drug-induced nephrotoxicity 
based on HPTCs, and validate this model in a retrospective study with a large number of 
environmental toxicants and drugs with well-characterized effects on human kidneys. 
 
For primary cell-based in vitro models, it is crucial to select an appropriate culture substrate to 
support optimal performance of the cells, as different substrates interact differently with cells and 
in turn affect cell performance. As HPTCs usually grow on a basal lamina in vivo, it is generally 
believed that extracellular matrix (ECM) coatings could possibly improve the performance of 
HPTCs on synthetic substrates. Indeed, a previous study from our group showed that laminin and 
collagen IV ECMs could sustain differentiated monolayers of HPTCs in static cultures on multi-
well plates [68]. Our other studies have also shown that a double coating with 3,4-dehydroxy-L-
phenylalanine (DOPA) and collagen IV could improve HPTC performance in bioreactor units of 
bioartificial kidneys, where cells were cultured under dynamic conditions [66, 67].  
 
To our surprise, our more recent data indicated that under static conditions, the stiffness of the 
underlying substrate seemed to play a dominant role in supporting primary cell performance [5]. 
However, the impact of material stiffness on the performance of cultured primary human soft 
tissue cells has not been systematically characterized before. Therefore it is important to 
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investigate how this factor can affect the performance of HPTCs and to identify a suitable 
material for the in vitro nephrotoxicology model.  
 
In addition to cell types and cell culture substrates, another important aspect of developing an in 
vitro nephrotoxicology model is to identify appropriate endpoints. For toxicity testing, endpoints 
that measure general cytotoxicity are frequently used. These include cell death, metabolic 
activity or ATP depletion. However, use of such endpoints for determining organ-specific 
toxicity does not give convincing results. For instance, in a recent study using liver-, kidney PT- 
and heart-derived cell lines [45], ATP depletion was measured after treatment with organ-
specific toxicants. The majority of test compounds gave similar results with all three cell lines 
[45]. 
Many potential novel biomarkers for AKI, such as kidney injury molecule-1 (KIM-1) and 
neutrophil gelatinase-associated lipocalin (NGAL), showed up-regulation in PTCs in vivo after 
kidney injury or as a result of drug-induced nephrotoxicity [73-78]. However, the EU-funded 
Predict IV project reported that up-regulation of these biomarkers was greatly compromised in 
vitro, and no consistent results could be obtained with HPTC-based models or with a model 
based on a newly established PTC line1. Up-regulation of potential novel AKI biomarkers was 
also not observed in a recently developed 3D model [79]. In addition to potential novel AKI 
biomarkers, pro-inflammatory cytokines such as IL-6, IL-8 and IL-18 are also often up-regulated 
in injured or diseased kidneys [80-82]. In fact, pro-inflammatory cytokines play an important 
role in the pathophysiology of AKI [7], and they had also been suggested as potential biomarkers 
                                                 




for the detection of nephrotoxicant-induced AKI [83]. It is thus interesting to further evaluate 
these biomarkers in cultured PTCs treated with PT-specific nephrotoxicants to address their 
usefulness in the prediction of drug-induced nephrotoxicity. 
 
For screening of large numbers of new drug candidates, it is also important that the in vitro 
model is economically self-sustainable and compatible with industry-scale procedures. This 
would be, however, difficult to achieve with the use of solely human primary cells. Stem cell-
derived HPTC-like cells [9], which can be propagated in relatively large numbers inexpensively, 





1.3 Application of stem cell-derived HPTC-like cells 
Primary cells, such as HPTCs, are often associated with problems such as the limited cell source 
and proliferative capacity [63, 84], functional changes during passaging [85], inter-donor 
variability [8, 86] as well as de- and trans-differentiation in vitro [65, 87]. Stem cell-based 
methods would be highly interesting in view of these limitations.  
 
Very recently, various protocols have been developed for the differentiation of human or murine 
embryonic (ESCs) or induced pluripotent stem cells (iPSCs) into cells of the renal lineage [88-
93]. These protocols generally involve multiple steps of differentiation to recapitulate different 
stages in embryonic kidney development. Embryonic kidney precursor structures or [90, 93] or a 
spectrum of different renal cell types [91, 92] were typically obtained. Although useful for 
regenerative medicine, such heterogeneous cell populations are only of limited applicability in in 
vitro drug safety screening. 
 
In contrast, our group was previously involved in developing a one-step feeder-free protocol for 
the differentiation of human embryonic stem cells (hESCs) into HPTC-like cells [9]. The results 
revealed that hESC-derived HPTC-like cells displayed gene and protein expression patterns 
similar to HPTCs. They were also able to form polarized epithelial and tubular structures in vitro, 
and displayed functional characteristics of HPTC [9]. Such morphological and functional 
similarity to HPTCs suggests that the hESC-derived HPTC-like cells could be applied in in vitro 
models for drug testing. Nevertheless, it is important to address the ethical and legal 
controversies associated with the use of hESCs. A potential solution would be to use human 
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1.4 Role of inflammation in drug-induced nephrotoxicity in humans 
In the development of in vitro models for the prediction of drug-induced nephrotoxicity, it is 
important to understand the cellular pathways and molecular processes underlying the 
potential endpoints. In another study from our group, it was found that the nuclear factor 
kappa B (NF-B) often translocated into the cell nuclei of HPTCs when the cells were 
exposed to known nephrotoxicants (Xiong et al., unpublished results). NF-B induces or 
regulates the transcription of genes by binding to B elements in promoter and enhancer 
sequences of the target loci, which includes genes associated with inflammation [94-97]. On 
the other hand, as mentioned earlier, it is also established that inflammation plays an 
important role in the pathogenesis of AKI [7, 98]. It is therefore interesting to further 
investigate the relationship between drug-induced nuclear translocation of NF-B and the 
inflammatory responses of the renal proximal tubular cells.  
 
In mammals, 15 possible different homo- or heterodimers of NF-B can be formed from the 
different combinations of the five Rel family proteins: p50 (also known as NF-B1, a 
cleavage product of p105), p52 (also called NF-B2, a cleavage product of p100), p65 (also 
called RelA), RelB and c-Rel [99]. The Rel family proteins dimerize with each other via the 
shared Rel-homology domain, which also contains a nuclear translocation signal [99]. 
Among these subunits, p65 is the most interesting and relevant for my study. Firstly, the 
transcription activation domain can only be found in the p65, RelB and c-Rel subunits [94]. 
The p65/p50 dimer is the most abundant form of NF-B in cells and also the best 
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characterized [99]. Furthermore, p65 is DNA-binding subunit in the canonical pathway of 
NF-B activation as well as in the hybrid pathway (which also links to the non-canonical 
pathway) [99]. The canonical pathway is also a rapid response to a wide range of external 
stimuli [100], making it more relevant to the effects of acute nephrotoxicity. 
 
In this thesis, I developed and validated an in vitro model for the prediction of drug-induced 
nephrotoxicity using HPTCs cultured on polystyrene-based multiwall plates. The endpoints 
used were increased expression levels of the pro-inflammatory cytokines IL-6 and IL-8. The 
relationships between the up-regulation of these cytokines and the nuclear translocation of 
NF-B p65 in human proximal tubular cells were investigated. The results showed that high 
accuracy in the predictions of nephrotoxicity in humans could be achieved with HPTCs. 
Furthermore, limitations associated with the use of primary cells were addressed by using 
stem cell-derived HPTC-like cells. These were shown to be a viable alternative and high 




2. Hypotheses and Goals 
Goals of my thesis were to: 
1. Determine the most suitable culturing substrate for developing in vitro models for the 
prediction of toxicity. My work addressed the hypothesis that the stiffness of materials 
has a major impact on proliferation and differentiation of relevant human primary cell 
types. Other substrate features such as surface roughness and water contact angle have 
also been addressed in a larger study [5] in which my work focused on investigating the 
effects of substrate stiffness. In this study, substrate stiffness was also the only parameter 
which turned out to be correlated with cell performance [5]. I evaluated the performance 
of primary human umbilical vein endothelial cells (HUVECs) and HPTCs on synthetic 
substrates of different stiffness. HUVECs are subsequently used for testing toxicity of 
hemostatic agents (Section 4.2), whereas HPTCs are the major model cell type for 
prediction of drug-induced nephrotoxicity (Section 4.3). 
2. Compare toxicity of mesocellular foam (MCF)-26 with commonly used layered clay-
based hemostatic agents and address cell type-specific responses towards toxicants in 
vitro. It is important to assess the toxicity of these materials in skin-related cell types such 
as epidermal keratinocytes, dermal fibroblasts and endothelial cells due to direct exposure 
to hemostatic materials at wound sites. In addition to such cell types HPTC were included 
for comparison. Cell type-specific responses were investigated by comparing the toxic 
effects of different hemostatic agents in various cell types. This work was done in 




3. Identify suitable endpoints (with the use of HPTCs) for an in vitro model that should 
predict human PT toxicity. The hypothesis was that pro-inflammatory markers, including 
cytokines IL-6 and IL-8, would be up-regulated in HPTCs in response to PT-specific 
nephrotoxicants. The endpoints were validated with 41 well-characterized drugs and 
environmental toxicants. Also, all results were compared with the data obtained with 
other PT-derived cell types. 
4. Evaluate the usefulness of stem cell-derived HPTC-like cells as alternative to HPTCs for 
the prediction of human PT toxicity in vitro. A similar validation process with 41 well-
characterized compounds was performed with hESC- and hiPSC-derived HPTC-like cells 
in order to examine the hypothesis that comparable predictivity could be achieved with 
these cell types due to their functional similarities to HPTCs. 
5. Investigate the underlying mechanisms of nephrotoxicant-induced up-regulation of the 
pro-inflammatory cytokines IL-6 and IL-8. It was hypothesized that the observed changes 
in their expression levels were mediated by the NF-B pathway, based on findings 
obtained from another study by our group (Xiong et al., unpublished results). The 
connection between up-regulation of IL-6 and IL-8 and activation of the NF-B pathway 





3. Materials and Methods 
3.1 Static culture of commercial primary cells and cell lines 
Two batches of HPTCs (Lot.-Nr. 58488852, HPTC 1 and Lot.-Nr. 61247356, HPTC 5) were 
obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). They were 
cultivated as described [5, 66, 67, 72] and used at passage (P) 4 and P 5.  
Three batches of HUVECs (HUVEC 1-3; Lot.-Nr. 3516, 5025 and 5117, respectively) and three 
batches of primary adult human epidermal keratinocytes (HEK 1-3; Lot.-Nr. 6539, 6937 and 
6940, respectively) were purchased from ScienCell Research Laboratories (Carlsbad, CA, USA). 
Multiple batches of primary adult human dermal fibroblasts (HDF) were purchased from 
ScienCell Research Laboratories, ATCC, and Promocell GmbH (Heidelberg, Germany).  
HK-2 [58], LLC-PK1 [101, 102] and NIH/3T3 cell lines were obtained from ATCC. 
All cell types were cryopreserved before use and were cultivated in their respective culture 
media recommended by the vendors (as described [72]). 
3.2 Isolation of HPTCs from human kidney tissue samples 
Three batches of HPTCs (HPTC 2-4) were isolated from anonymized fresh normal human 
kidney tissues obtained from the Tissue Repository of the National University Health System 
(NUHS, Singapore). Nephrectomy samples were derived from patients with renal cancer. 
Associated normal tissue was identified by a pathologist before being used for HPTC isolation. 
The use of human kidney tissue samples was reviewed and approved by the Institutional Review 
Board (NUS-IRB reference code: 11-143).  
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All HPTC isolation procedures were performed under sterile conditions. Upon surgical removal, 
tissue samples were preserved and transported in ice-cold cell culture medium (Dulbecco’s 
Modified Eagle’s Medium (DMEM)/Ham’s F12 (Invitrogen, Carlsbad, CA, USA)) 
supplemented with transferrin (5 g/ml), insulin (5 g/ml), hydrocortisone (0.02 g/ml), 
epidermal growth factor (10 ng/ml), prostaglandin E1 (0.05 g/ml), selenium (3.95 g/ml), tri-
iodothyronine (3.36 pg/ml) and penicillin/streptomycin (1%). All supplments were obtained from 
Sigma-Aldrich, Singapore. HPTC isolation procedures were performed as described in [103]. For 
overnight cell attachment (16 h; after isolation or passaging), fetal bovine serum (2%) has been 
added to the culture medium. Cells were subsequently cultivated in serum-free complete 
DMEM/Ham’s F12 medium. HPTC 2-4 were cryopreserved at P 2 or P 3 and subsequently used 
in experiments at P 3 and P 4.  
3.3 Differentiation of hESC and hiPSC into HPTC-like cells 
HUES 7 cells (P 11) were obtained from the Harvard Stem Cell Institute (Harvard University, 
Cambridge, MA, USA). iPS(Foreskin)-4 cells were obtained from the WiCell Research Institute 
(Madison, WI, USA). Undifferentiated stem cells were cultivated in mTeSR1 medium (Stemcell 
Technologies, Singapore) in multi-well plates coated with growth factor-reduced Matrigel (BD, 
Franklin Lakes, NJ, USA). Differentiation into HPTC-like cells was performed as described in 
[9]. Briefly, stem cells were seeded into Matrigel-coated dishes and cultivated for 20 days in 
complete renal epithelial growth medium (REGM) supplemented with growth factors (REGM 
BulletKit, Lonza BioScience, Singapore). 0.5% fetal bovine serum, 10 ng/ml of bone 
morphogenetic protein (BMP)2 and 2.5 ng/ml of BMP7 (R&D Systems, Minneapolis, MN, USA) 
were also added to the medium for differentiation. Differentiated HUES 7-derived and 
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iPS(Foreskin)-4-derived HPTC-like cells were harvested after 20 days and cryopreserved before 
use. Stem cell-derived HPTC-like cells were subsequently cultivated in complete REGM (as 
described above). The differentiation procedures were performed by Dr. Wei Seong Toh and Dr. 
Karthikeyan Kandasamy (IBN, A*STAR, Singapore). 
The Institutional Review Board of the National University of Singapore approved work with 
hESC and hiPSC cells (NUS-IRB reference code: 13-437). 
3.4 Cell culture materials for evaluating substrate-specific cell performance 
The following commercial cell culture materials were tested for cell performance: tissue culture 
polystyrene (TCPS, BD, Franklin Lakes, NJ, USA), Thermanox coverslips (TX) consisting of a 
polyester film with modified surface for optimal cell adherence (Nunc, Roskilde, Denmark), 
cover glass (CG, VWR Singapore, Singapore) and Cyclopore polycarbonate (PC-1) membranes 
(Whatman, Germany). 
Low density polyethylene (PE) films (cling ware) were purchased from The Glad Products 
Company (Oakland, CA, USA) and high density PE films (sandwich bags) were obtained from 
the National Trades Union Congress (NTUC) Fairprice Co-operative Ltd. (Singapore). Both PE 
products do not contain additives or plasticizers, and they were both treated with corona 
discharge using a high frequency generator (BD-10AV, Electro-Technic Products, Inc., Chicago, 
IL, USA). The surface treatment of these PE materials were performed by Dr. Ming Ni (IBN, 
A*STAR, Singapore).  
Hexafluoroisopropanol was used to dissolve poly(lactic acid) (PLA) at a concentration of 150 
g/ml and this PLA solution was subsequently used to produce PLA films and electrospun 
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membranes. PLA films were produced by casting the PLA solution into aluminum cups, which 
were then left in a solvent-saturated environment for 72 h to allow slow evaporation of the 
solvent. Electrospun PLA membranes were generated by loading the PLA solution in a syringe 
fitted with a 26-gauge metal needle. The flow rate applied was 0.24 ml/h and a voltage between 
10 and 15 kV was used across a pair of oppositely charged electrodes separated at a distance of 
10 cm. The PLA materials were graciously prepared and provided by Dr. Meng Fatt Leong and 
Dr. Andrew Wan (IBN, A*STAR, Singapore). 
 
3.5 Test materials for assessing cell type-specific toxicity 
Kaolin, bentonite, montmorillonite were purchased from Sigma-Aldrich (St. Louis, MO, USA) 
and graciously provided by Prof. Galen Stucky (Department of Chemistry and Biochemistry and 
Materials Department, University of California, Santa Barbara, USA). A mesocellular foam with 
a cell window size of 26 nm (MCF-26) was synthesized as described in [6] and provided by Prof. 
Galen Stucky’s team. Silver nanoparticles (Ag NPs; 10 nm) were obtained from Meliorum 
Technologies (Rochester, NY, USA). Dimethyl sulfoxide (DMSO) was purchased from Sigma-
Aldrich. 
3.6 Adhesion of test materials to the cell surface 
HUVEC were cultivated for 24 h on glass coverslips (Menzel-Gläser, Braunschweig, Germany) 
and subsequently exposed to test materials at 1 mg/ml for 10 minutes. Cells were then repeatedly 
washed with 10 ml of 1X PBS and fixed with 3.7% formaldehyde in PBS. Dark field imaging of 
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the cells was performed with CytoViva® high resolution imaging system (CytoViva, Auburn, AL, 
USA), which is compatible with visualizing small particles adhered onto cell surfaces. 
3.7 Cell viability assays 
The neutral red uptake (NRU) assay was performed as described [104] and as recommended by 
the International Standard for the Biological Evaluation of Medical Devices (Part 5: Tests for In 
vitro Cytotoxicity, ISO 10993-5:2009 (E)), with the following modifications: different cell types 
were used and cells were seeded at a density of 50,000 cells/cm2 into 96-well microplates. Cells 
were cultivated for 24 h and were then treated overnight with test materials. Before the NRU 
assay was performed the cells were washed with phosphate-buffered saline (PBS). Data 
acquisition and analysis was performed as described [72]. The NRU assay was used for the 
generation of all data on cell viability shown in section 4.2.  
3.8 Test compounds for validation of endpoints for in vitro nephrotoxicity 
41 compounds were selected and tested with various HPTC batches. The detailed list of these 
compounds is shown in Table 1, where they were classified into 3 categories. All test compounds 
were purchased from Sigma-Aldrich (St. Louis, MO, USA) except the following: compounds 3-5, 
8, 14, 18-20, 23, 30, 34 and 37 were purchased from Merck (Darmstadt, Germany), compound 1 
from PAA Laboratories GmbH (Pasching, Austria), compound 10 from ChemService (West 
Chester, PA, USA) and compound 22 from Tocris Bioscience (Bristol, UK). Stock solutions (10 
mg/ml) of compounds 1,2, 4-6, 9-18, 23, 25, 28, 30-36, and 40 were prepared with 
biotechnology grade water (1st Base, Singapore). Stock solutions of other compounds (6.8 
mg/ml -100 mg/ml depending on the solubility of the individual compound) were prepared with 
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dimethyl sulfoxide (DMSO; Sigma-Aldrich; compounds 3, 7, 8, 19, 22, 27 and 41) or ethanol 
(compounds 20, 21, 24, 26, 29, 37 and 39). Vehicle controls were included in experiments using 
the respective solvents. All stock solutions were stored at 4˚C and protected from light. Stock 
solutions of metal oxides and inorganic salts (compounds 11-16 and 18) were stored for up to 12 




Table 1. Test compounds used for the validation of endpoints for in vitro nephrotoxicity. The 41 test 
compounds were divided into three groups. Group 1 (compounds 1-22) represents nephrotoxicants that 
directly damage PT. Group 2 (compounds 23-33) comprises nephrotoxicants that do not directly damage 
PT and injure the kidney by different mechanisms. Group 3 (compounds 34-41) represents non-
nephrotoxic compounds. The nephrotoxic effects in humans are compiled and described in Appendix ii, 
Table S1. 
 
3.9 Drug treatment 
Cryopreserved cells were thawed at 37˚C and seeded into 24-well microplates at a density of 5 x 
104 cells/cm2 (HPTC, HK-2 and LLC-PK1) or 1 x 105 cells/cm2 (HPTC-like). Stem cell-derived 
HPTC-like cells had lower proliferation rates compared to HPTC, HK-2 and LLC-PK1. 
Group 1 Group 2 Group 3 
PT-specific nephrotoxicants Non-PT-specific nephrotoxicants 
Non-nephrotoxic 
compounds 
No. Compound No. Compound No. Compound 
1 Gentamicin 23 Vancomycin 34 Ribavirin 
2 Tobramycin 24 Phenacetin 35 Glycine 
3 Rifampicin 25 Acetaminophen 36 Dexamethasone 
4 Tetracycline 26 Ibuprofen 37 Melatonin 
5 Puromycin 27 Furosemide 38 Levodopa (DOPA) 
6 Cephalosporin C 28 Lithium Chloride 39 Triiodothyronine 
7 5-Fluorouracil 29 Lindane 40 Acarbose 
8 Cisplatin 30 Ethylene glycol 41 Atorvastatin 
9 Ifosfamide 31 Valacyclovir   
10 Paraquat 32 Lincomycin   
11 Arsenic(III) oxide 33 Ciprofloxacin   
12 Bismuth(III) oxide     
13 Cadmium(II) chloride     
14 Copper(II) chloride     
15 Germanium(IV) oxide     
16 Gold(I) chloride     
17 Lead acetate     
18 Potassium dichromate     
19 Tacrolimus     
20 Cyclosporin A     
21 Citrinin     
22 Tenofovir     
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Therefore, a higher seeding density was required for HPTC-like cells to form confluent epithelia. 
Cells were cultivated for 72 h in commercial renal epithelial cell medium purchased from ATCC 
(HPTC) or Lonza BioScience (Singapore; HPTC-like cells). Both media contained 0.5% fetal 
bovine serum. Cells were then treated with various compounds at concentrations 1, 10, 100 and 
1000 g/ml for 16 h. Respective solvents were used as vehicle controls for the test compounds 
and all data were subsequently normalized to these vehicle controls. 
3.10 Quantitative real-time polymerase chain reaction (qPCR) 
Total RNA was isolated from cells treated with various compounds using NucleoSpin® RNA II 
(Macherey-Nagel, Düren, Germany) or RNeasy® Mini Kit (Qiagen, Hilden, Germany). 
SuperScript® III First Strand Synthesis System (Invitrogen, Carlsbad, CA, USA) and MyCycler® 
thermal cycler (Bio-Rad, Hercules, CA, USA) were used for cDNA synthesis. qPCR (up to 40 
cycles) was then performed with the 7500 Fast Real-Time PCR System (Applied Biosystems, 
Carlsbad, CA, USA). Procedures were carried out according to the manufacturers’ instructions 
with the software included in the device. The Sequence Detection Software 7500 Fast version 
2.0.5 was used for data analysis. Relative gene expression levels were determined with the 2-CT 
method [105]. In cases where percentages of GAPDH expression were shown, expression of 
different target genes were normalized to GAPDH expression of the same samples by using the 
2-CT method [106-108]. Primers were designed with the Primer Express Software version 3.0 
(Applied Biosystems). Details of all primers used (purchased from Sigma-Aldrich) are provided 




Table 2. Details of primer pairs and amplicons. The sequences of the primer pairs (forward: F, reverse: R) 
for the different markers are shown. The sizes of the amplicons are provided in base pairs (bp).  
Marker Primer Pairs Amplicon (bp) 
Vimentin 
(VIM) 











R 5’-TGCACTCAGCCGTCGATACA-3’ 120 
Interleukin-6 
(IL-6) 















R 5’-GACGGTGCCATGGAATTTG-3’ 76 
3.11 qPCR-based prediction of drug-induced nephrotoxicity 
All calculations were performed using Microsoft Office Excel 2003 and 2010. Compounds were 
predicted as PT-specific nephrotoxicants if the increase of expression of at least one of the 
marker genes (IL-6 or IL-8) was equal to or higher than a threshold value at any of the 
compound concentrations tested. Such compounds were thus defined as positive in the in vitro 
model. Threshold values examined for HPTC, HK-2 and LLC-PK1 cells ranged from 0.3 to 4.0. 
Threshold values between 0.1 and 5.0 were examined for stem cell-derived HPTC-like cells.  
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Standard terms and definitions of various performance metrics are illustrated and provided in 
Figure 1. True positives (TP) were defined as PT-specific nephrotoxicants in humans (Table 1, 
compounds 1-22, group 1) which gave positive results in the in vitro model. True negatives (TN) 
were defined as non-nephrotoxic compounds (Table 1, group 3, compounds 34-41) or 
nephrotoxic compounds that do not damage the PT in humans (Table 1, group 2, compounds 23-
33) that gave negative results in the in vitro model. The sensitivity was calculated by dividing the 
number of TP by the total number of PT-specific nephrotoxicants (group 1, compounds 1-22). 
The specificity was calculated by dividing the number of TN by the total number of non-PT-
damaging compounds (groups 2 and 3, compounds 23-41). Balanced accuracy was defined as the 
average of sensitivity and specificity. The positive predictive value (PPV) was calculated by 
Figure 1. Standard terms and definitions used for the statistical analysis. This matrix illustrates the 
definitions of true positives (TP), false positives (FP), false negatives (FN) and true negatives (TN) based 
on positive (+) and negative (-) clinical and in vitro data. Definitions of predictive performance metrics 
are provided. In cases where percentages were shown, the resultant values from the above equations were 
multiplied by 100%. Adapted from [8]. Reproduced by permission of The Royal Society of Chemistry. 
34 
 
dividing the number of TP by the total number of positives identified by the in vitro model. The 
negative predictive value (NPV) was calculated by dividing the number of TN by the total 
number of negatives identified by the in vitro model. The receiver operating characteristic (ROC) 
curves were generated by plotting sensitivity against (1-specificity) at all threshold values 
ranging from 0.3 - 4.0 for HPTC, HK-2 and LLC-PK1 cells, and 0.1-5.0 for HUES 7-derived 
HPTC-like cells.  
3.12 Enzyme-linked immunosorbent assay (ELISA) 
The levels of IL-6 and IL-8 proteins in the cell culture supernatant of HPTC 1 and HPTC 4 were 
quantified by ELISA after drug treatment. Cells were cultivated for 72 h and subsequently 
treated with drugs for 16 h. ELISA kits specific for human IL-6 and IL-8 were purchased from 
Invitrogen (Carlsbad, CA, USA). The experimental procedures were performed as described in 
the manufacturer’s instructions. 
3.13 Gene knockdown by RNA interference (RNAi) 
Cells were seeded into 6-well, 24-well or 96-well tissue culture microplates at 25,000 cells/cm2. 
After 24h, cells were transfected with Ambion® p65 (RELA) small interfering RNA (Life 
Technologies, Carlsbad, CA, USA) and X-tremeGENE siRNA transfection reagent (Roche, 
Mannheim, Germany). Ambion® non-target siRNA and GAPDH siRNA were used as controls 
(Life Technologies). Amounts of siRNA used were 12 pmol/well, 40 pmol/well and 160 
pmol/well for 96-, 24-, and 6-well microplates respectively. Cells were transiently transfected 




Immunostaining was performed as described [68]. Briefly, cells were seeded in 96-well 
microplates at densities of 16,000 cells/cm2 (LLC-PK1 cells) and 50,000 cells/cm2 (HPTC and 
HK-2 cells), due to different doubling rates of various cell types. Cells were cultivated for 72 h 
and were then treated with test compounds for 16 h. After fixation for 10 min with 3.7% 
formaldehyde in phosphate-buffered saline, cell nuclei were stained with 4',6-diamidino-2-
phenylindole (DAPI; Merck), NF-B p65 was detected with a human NF-B p65-specific 
primary antibody (Abcam, Cambridge, England, UK) and a fluorochrome-conjugated secondary 
antibody, which was obtained from Life Technologies. 
3.15 High content screening (HCS) 
Images of fixed cells stained with DAPI and by immunofluorescence were captured with the 
ImageXpress Micro High Content Screening System (Molecular Devices, Sunnyvale, CA, USA). 
3 replicates were imaged for each cell type and each treatment condition. From each replica 9 
fields were imaged. Cell nuclei were counted after cells were treated with test compounds for 16 
h and fluorescence intensity was measured on each individual image from which average values 
were derived. Data acquisition and analysis was performed by MetaXpress® 2.0 (Molecular 
Devices). For immunofluorescence of NF-B p65, both nuclear and cytoplasmic fluorescence 
levels were measured. Calculations of NF-B p65 / cytoplasmic NF-B p65 ratios were based on 
average cytoplasmic and nuclear levels of fluorescence intensity normalized to cell number. 
Cells which had a nuclear NF-B p65 / cytoplasmic NF-B p65 ratio ≥ 1 were defined as 
positive (+). Compartmentalization of cell nuclear and cytoplasmic regions was performed using 




Protein expression levels of NF-B p65 in HPTC and HK-2 cells were examined by 
immunoblotting after transient transfection with p65 siRNA. Cell lysates were prepared with 
Pierce® radioimmunoprecipitation assay (RIPA) buffer (Thermo Scientific, Waltham, MA, USA) 
supplemented with 1 mM phenylmethylsulfonyl fluoride (Sigma-Aldrich) and 1× protease 
inhibitor cocktail (Nacalai Tesque, Kyoto, Japan). Protein concentrations in lysates were 
determined using Pierce® bicinchoninic acid (BCA) assay kit and absorbance was measured 
with a microplate reader (Tecan Safire2 TM, Männedorf, Switzerland). Proteins samples were 
treated with NuPAGE® sample reducing agent (Life Technologies) according to the 
manufacturer’s instructions. 10-20 mg of protein samples were loaded into NuPAGE® Novex® 
4-12% Bis-Tris precast gels (Life Technologies). Gels were run in NuPAGE® 2-(N-
morpholino)ethanesulfonic acid (MES) sodium dodecyl sulfate (SDS) running buffer (Life 
Technologies) at a voltage of 80V for 30 minutes followed by 100V for 60 minutes. Samples 
were transferred onto polyvinylidene fluoride (PVDF) membranes using the iBlot® Gel Transfer 
Device (Life Technologies). Rabbit anti-p65 primary antibody (Abcam) was added to the 
membranes in Tris-buffered saline (TBS) containing 1% Tween-20 and 10% bovine serum 
albumin (BSA). Donkey anti-rabbit horseradish peroxidase-conjugated secondary antibody (GE 
Healthcare, Buckinghamshire, UK) was used to detect primary antibodies bound to the PVDF 
membranes. Samples were visualized by chemiluminescence using Pierce® ECL western 




3.17 Standard toxicity assays 
Cells were treated in the same way as for the IL-6/IL-8-based assay. Cellular ATP depletion was 
measured with the Molecular Probes® ATP determination kit (Life Technologies). Compound 11 
was also tested with the CellTiter-Glo® Assay (Promega, Madison, WI, USA). Assay kits for 
determining GSH depletion (GSH-Glo™ glutathione assay) and LDH leakage (CytoTox-ONE™ 
homogeneous membrane integrity assay) were purchased from Promega. All assays were 
performed according to the manufacturers’ instructions. Assay readouts were obtained using a 
Safire2 TM microplate reader (Tecan). 
3.18 Statistics 
Microsoft Excel 2010 was used for all calculations. The unpaired t-test was used for statistics 
and all data were compared with corresponding vehicle controls. Normal distribution of the data 
was confirmed using SigmaStat (3.5) (Systat Software Inc., Chicago, IL, USA). Z’ values were 






4.1 Evaluation of culturing substrates suitable for in vitro toxicology with primary human 
endothelial and renal cells 
Endothelial and renal cells are widely used for in vitro toxicology studies [3, 110]. Proper cell 
performance under in vitro conditions is essential. Prior to my PhD thesis, extensive work has 
been carried out in the lab on the systematic characterization of culturing conditions affecting the 
performance of human primary cells, in particular HPTC. As mentioned in the introduction, 
major areas that have been investigated included coatings [67, 68], cell culture medium 
composition and growth factors [69, 70], as well as the development of reliable cell sources, co-
cultures, microfluidic and 3D models [65-67, 70-72]. I performed during my thesis part of the 
experiments for the evaluation of culturing substrates suitable for the in vitro culture of primary 
endothelial and renal cells. The work on endothelial cells was performed with HUVECs.  
Previous data from our group suggested that cell numbers and differentiation of HPTCs and 
HUVECs were mainly affected by substrate stiffness (all of the results described in [5]). To 
further investigate the effects of substrate stiffness on cell morphology, cell numbers, 
cytoskeleton arrangement and the differentiation of such adherent cell types, I investigated 
HUVECs seeded on 3 stiff materials: TCPS, CG, and TX. A more compliant substrate, 
polycarbonate membranes (PC-1), was tested for comparison (Fig. 2). Young’s modulus is a 
measure of the stiffness of materials. The Young’s modulus values for the three stiff materials 
were 3,500 megapascals (MPa; TCPS), 90,000 MPa (CG) and 2,700 MPa (TX), whereas that of 
PC-1 was only 63.5 ± 16.0 MPa [5]. Only synthetic materials were included here and no 
extracellular matrix coatings were used. To develop an in vitro model for predicting organ-
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specific toxicity of presumably large number of test compounds, it is important that the culture 
platform is inexpensive and relatively easy to prepare in a large scale. In addition, my previous 
data showed that coatings are not required [72]. 
Fig. 2 shows immunostaining of various cellular components and markers of HUVECs cultured 
on the different substrates. The results showed low cell numbers and poor morphology on TX 
(Fig. 2 c, g, k, o) and especially on PC-1 (Fig. 2 d, h, l, p). The organization of the actin 
cytoskeleton of cells cultured on the stiff materials (TX, TCPS and CG) was different in 
comparison to PC-1: actin stress fiber formation was observed only on the three stiff materials, 
but not on PC-1 (Fig. 2 a-h). Actin stress fibers are a typical feature of endothelial cells, also in 
vivo [111, 112].  
Apart from the features outlined above, proper cell differentiation is also an essential indicator of 
cell performance on biocompatible materials. Here, I examined cell differentiation of HUVECs 
on the same materials as described above by performing immunostaining of two endothelial cell 
markers CD31 (also called platelet endothelial cell adhesion molecule-1 (PECAM-1)) and 
CD146 (also called melanoma cell adhesion molecule (MCAM) or cell surface glycoprotein 
MUC18). The results showed that both markers were expressed and showed characteristic 
enrichment at cell junctions on TCPS and CG, forming typical chicken wire-like patterns (Fig. 2i, 
j, m, n). Largely confluent cell layers were also generated on TX, but CD31 and CD146 
expression was suboptimal and their subcellular localization was disturbed, suggesting partial de-
differentiation of the cells (Fig. 2 k, o). Cell attachment and growth was most compromised on 
PC-1, where HUVECs did not form a confluent monolayer, and endothelial cell marker 
expression and subcellular localization were severely disturbed (Fig. 2 l, p). These results 
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Figure 2. Detection of F-actin fibres, CD31 and CD146 in HUVECs. HUVECs were grown on various 
materials as indicated (TCPS: tissue culture polystyrene; CG: cover glass; TX: Thermonax coverslips; PC-
1: polycarbonate). Cell nuclei were stained with DAPI (blue). (a-h) display F-actin (red). (e-h) shows 
enlarged boxed areas displayed in (a-d). Arrowheads indicate some areas of stress fiber formation. (i-p) 
shows immunostaining of CD31 (red; i-l) and CD146 (green; m-p). Representative images from different 
batches of HUVECs are shown. Scale bars: 25 m (e-h) and 50 m (a-d; i-p). Adapted with permission 
from [5] Copyright 2012 Elsevier Ltd. 
suggested a strong correlation between substrate stiffness and cell performance, as HUVECs 
were only able to form properly differentiated endothelia on the 2 stiffest materials (TCPS and 
CG). Notably, the chemistry and surface chemical structures and other features of these two 





In addition, immunostaining of the tight junctional protein zonula occludens-1 (ZO-1) and the 
endothelial glycoprotein von Willebrand factor (vWF) was performed in the case of TCPS. The 
results showed robust vWF expression and tight junction formation (Fig. 3). 
 
My work on HUVECs described here was performed in the context of a larger study and 
essentially similar results had been obtained with respect to HPTC [5]. 
However, the above results were derived from testing cell performance on different materials 
with varying physical and chemical properties. To further confirm that substrate stiffness was the 
major determinant of cell performance, materials with similar chemical composition but different 
stiffness were tested. For these experiments, HPTCs and HUVECs were seeded on electrospun 
PLA membranes (Young’s modulus = 28 ± 7 MPa, n = 3) or PLA films (Young’s modulus = 482 
± 75 MPa, n = 3). Both materials were derived from the same PLA solution (see Materials and 
Methods). Immunostaining was performed to assess cell differentiation on these materials.  
 
Figure 3. Immunostaining of ZO-1 (green) and vWF (red) in HUVECs cultivated on TCPS. Cell nuclei 
were stained with DAPI (blue). Scale bar: 50 m. Adapted with permission from [5] (Supplementary 




Fig. 4 showed that HPTCs were able to form confluent monolayers on both electrospun PLA 
membranes and PLA films after 3 days of culturing. However, enrichment of ZO-1 at cell 
boundaries was only observed on the stiffer PLA films, whereas in HPTCs cultured on the more 
compliant electrospun PLA membranes, ZO-1 was diffusely distributed in the cytoplasm (Fig. 4 
a, b). Absence of ZO-1 enrichment at cell boundaries indicates de-differentiation of HPTCs [68]. 
Figure 4. Cell performance on PE and PLA films and membranes. (a-f) HPTCs or HUVECs were seeded 
( 5 x 104 cells/ cm2) on electrospun PLA membranes (a, c, e) or PLA films (b, d, f). Specimens were 
fixed after 3 days and ZO-1 (a and b, red), CD31 (c and d, green) and CD146 (e and f, red) were detected 
by immunostaining (DAPI: blue). Arrowheads in (b) and (f) indicate ZO-1 or CD146 enrichments at cell 
boundaries. Three replicas were analyzed for each cell type and material and from each sample at least 7 
images were captured. The figure shows representative results. Scale bars: 100 m. Adapted with 
permission from [5] Copyright 2012 Elsevier Ltd. 
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On the other hand, HUVECs could only form a monolayer on PLA films. Typical chicken wire-
like patterns were obtained for CD31 staining only on this substrate, and CD146 enrichment was 
observed in at least some of the cells (Fig. 4 d, f). HUVEC numbers were substantially reduced 
on the electrospun PLA membranes, where cells failed to proliferate and form confluent 
endothelia (Fig. 4 c, e).  
Overall, these results suggested that substrate stiffness was indeed a major determining factor of 
the performance of soft tissue-derived human primary cells under in vitro culturing conditions. 
TCPS appeared to be among the most suitable materials for developing in vitro models with 
respective cell types due to its high substrate stiffness, which was associated with excellent cell 
performance. This was observed here, as well as in my previous work [72]. It is important to note 
that this thesis shows only part of the characterization with a large variety of different substrates 
and their effects on various aspects of HPTC performance. Here I focused on the work 
performed by myself, and the full picture with all of the results is provided in [5]. With all of the 
16 different substrates tested in [5] a thorough material characterization was performed and in 
addition to stiffness also surface roughness, hydrophilicty, chemical composition, pore size, 
porosity, surface charge and protein adsorption were determined. With respect to all of these 
features a correlation analysis was performed and only substrate stiffness correlated with cell 
performance for both HUVECs and HPTCs [5]. Further, it was also shown that consistent HPTC 
performance was only obtained on TCPS in terms of both marker gene expression and 
functionality (as assessed by responsiveness to parathyroid hormone and gamma-glutamyl 
transferase (GGT) activity [5]. In addition, our lab has performed extensive characterization of 
PTC performance on ECM coatings [68] and other coatings [66, 67]. Performance of every type 
of PTC used was tested on coated and uncoated substrates, and no differences were found 
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between uncoated TCPS and TCPS coated with the most appropriate ECM coatings (collagen IV 
and laminin [68]) when HPTC derived from ATCC were used and our own isolated batches of 
HPTC. Further work on substrate optimization and more tests were also regularly performed by 
other staff in the lab (unpublished work). It regularly turned out that uncoated TCPS was the best, 
also for HPTC. In fact, coating was not recommended for the maintenance of the commercially 
obtained HPTC batch used in this thesis, according to the instructions from the vendor (ATCC). 
Lastly, TCPS is readily available in suitable formats as it is commonly used in tissue culture 
multi-well plates. Therefore, in the subsequent studies, non-ECM-coated TCPS-based multi-well 





4.2 Cell type-specific cytotoxicity of chemical compounds 
4.2.1 Cell type-specific cytotoxicity of layered clays and MCF-26 
After confirming that TCPS was the most suitable culturing substrate, it was then important to 
select appropriate cell types for developing in vitro models for predicting organ-specific toxicity. 
Immortalized cell lines such as the standard murine fibroblast cell line NIH/3T3 are commonly 
used in toxicity testing by pharmaceutical companies. In case of in vitro nephrotoxicology, renal 
cell lines were widely used [3]. However in my previous work [72], the results suggested that in 
the case of nephrotoxicity, HPTCs were far more sensitive than immortalized cell lines to the 
cytotoxic effects of cadmium-based quantum dots. Also, the porcine cell line LLC-PK1 
demonstrated different uptake dynamics as compared to human cell line HK-2 or HPTCs. These 
and other results [3] highlighted the importance of using the most appropriate cell type for 
assessing the toxicity of a chemical compound in vitro.  
In this section of the thesis, I developed a model for testing toxicity of hemostatic agents on 
relevant skin cell types such as fibroblasts, keratinocytes and endothelial cells. Renal proximal 
tubular cells were also included for comparison, though they were not of primary importance in 
this model. Test compounds used here included aluminum silicate-based layered clays (kaolin, 
bentonite and montmorillonite) and MCF-26. Layered clays, such as kaolin, are frequently used 
as the hemostatic agent in battle gauzes on the battlefields to promote blood clotting [113, 114]. 
In practice, different cell types at the wound sites such as HEKs, HDFs and endothelial cells are 
directly exposed to these hemostatic agents. However, layered clays have been shown to have 
profound cytotoxic effects on HUVECs, primary murine neurons and RAW267.4 murine 
macrophage-like cells, but not on HeLa cells or murine neuroblastoma cells [115-117]. Such 
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cell-type specific toxic effects on relevant human cell types needed to be further addressed. On 
the other hand, MCF-26 demonstrated similar hemostatic potency as the most effective 
commercial hemostatic agents [118], and can be potentially used as an alternative hemostatic 
agents, but its cytotoxicity to relevant human cell types was not clearly understood. In this part of 
the thesis, cytotoxicity of MCF-26 was also thoroughly investigated and compared with layered 
clays using the different relevant cell types mentioned above. 
First, I investigated the differences between various cell types in terms of how they responded to 
the cytotoxic effects of kaolin. Different concentrations of kaolin were applied. In order to 
address inter-donor variability of the primary cells, three different batches (each from a different 
donor) of HDFs, HEKs and HUVECs were included in the tests. Human primary (HPTC) and 
immortalized (HK-2) renal proximal tubular cells were included for comparison with the skin 
cell types commonly found at wound sites. Lastly, immortalized NIH/3T3 mouse fibroblasts, a 
widely used standard cell line in toxicology studies, was also included as a control. In order to 
assess cell viability, the neutral red uptake (NRU) assay was performed on various cell types 
after overnight treatment with the different compounds. The NRU assay was found to be most 
reliable as the results were linearly related to cell numbers [72], whereas in the commonly used 
MTS assay, absorbance readings become saturated at high cell seeding density (Fig. 5). 
Therefore, all cell viability data shown in this section (4.2) were obtained with the NRU assay. 
  This assay is also recommended by the International Standard ISO 10993-5:2009(E).
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Kaolin was applied to the cells at concentrations up to 250 g/ml in order to determine its effects 
on cell viability. Dose-response curves were displayed in Fig. 6. The left-hand columns in Table 
3 summarizes the IC50 values as well as the percentages of cell viability at the highest 
concentration used (250 g/ml) for each tested cell type and batch. The results indicated that the 
cytotoxic effects of kaolin were strongly cell type-specific. The viability of NIH/3T3 fibroblasts 
was not significantly reduced by kaolin (P > 0.05) and the proliferation of two batches of human 
primary skin fibroblasts (HDF1 and HDF2) even appeared to be promoted by the presence of 
kaolin (P < 0.05; Fig. 6 and Table 3). This could be due to hormesis, a common observation in a 
broad spectrum of biological models, including in vitro skin biology, where sub-lethal doses of 
toxicants can transiently lead to increased cell growth [119]. In contrast, in all other tested cell 
types and batches, there was a dose-dependent decrease of cell viability. Among the different cell 
types, HUVECs were in general the most sensitive: the IC50 values of the three different batches 
Figure 5. Relationship between absorbance measure with the MTS assay and cell numbers. HPTC and 
HK-2 cells were seeded at different densities and the MTS assay was performed after 24 hours. The 
absorbance readings obtained with the MTS assay (mean +/- s.d., n = 3) were plotted against the seeding 
densities. Adapted from [6] (Supplementary Information). Reproduced by permission of The Royal 
Society of Chemistry. 
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Figure 6. Dose-dependent effects of kaolin on cell viability. Kaolin was applied at concentrations of up 
to 250 g/ml to the cell types indicated on the right-hand side. Three different batches each of HDF, 
HEK and HUVEC were tested. Cell viability was determined with the NRU assay and all values were 
normalized to the values obtained with untreated control cells (set to 1). Error bars show the s.d. ( n = 3). 
Adapted from [6]. Reproduced by permission of The Royal Society of Chemistry. 
of HUVEC ranged between 50~125 g/ml. There was also substantial cell death observed in the 
case of HEK, where the IC50 values ranged between 180~250 g/ml (Table 3, the cell viability 
of HEK1 and HEK2 was slightly above 50% at 250 g/ml). The human renal cells tested 
(HPTCs and HK-2 cells) were only moderately affected by the cytotoxic effects of kaolin and 
their IC50 values were clearly above 250 g/ml.  
 
 
Overall, these results demonstrated strong cell type-dependent cytotoxic effects of kaolin. The 
sensitivity of tested cell types could be ranked in the order HUVEC > HEK > HK-2/HPTC > 
NIH/3T3 > HDF. While the cell viability of HUVECs fell drastically even at low concentrations 
of kaolin, the fibroblastic cell types (either immortalized murine cell line or primary human 
49 
 
fibroblasts) did not display any significant reduction in cell viability, even at the highest 
concentration of kaolin applied. It is also important to note that, although some inter-donor 
variability was observed among different batches of a same cell type, cell-type specificity had a 
more prominent influence in determining how cells responded to kaolin treatment. 
Table 3. Cell viability (%) at the maximal concentrations of kaolin, bentonite, montmorillonite and MCF-
26 and IC50 values. Adapted from [6] with modifications. Reproduced by permission of The Royal 
Society of Chemistry. 
 Cell Type 
Kaolin Bentonite Montmorillonite MCF-26 
IC50  
(g/ml) 












% at 7 
mg/ml 
HUVEC 1 125 ± 47 39 ± 5 11 ± 1 18 ± 1 65 ± 3 18 ± 0 6.3 ± 0.2 50 ± 3 
HUVEC 2 48 ± 4 35 ± 2 17 ± 2 37 ± 3 33 ± 2 25 ± 3 2.1 ± 0.8 27 ± 7 
HUVEC 3 51 ± 2 21 ± 2 17 ± 4 34 ± 2 95 ± 13 33 ± 4 0.7 ± 0.0 21 ± 2 
HDF 1 > 250 138 ± 14 300 ± 85 45 ± 3 272 ± 99 29 ± 1 2.0 ± 0.2 13 ± 3 
HDF 2 > 250 119 ± 8 > 1000 60 ± 3 335 ± 32 38 ± 5 5.6 ± 1.4 40 ± 8 
HDF 3 > 250 107 ± 3 468 ± 18 52 ± 4 454 ± 120 57 ± 1 5.0 ± 0.7 41 ± 3 
HEK 1 > 250 58 ± 2 > 1000 60 ± 6 > 1000 78 ± 6 > 7.0 92 ± 9 
HEK 2 >250 51 ± 12 58 ± 14 41 ± 6 > 1000 62 ± 2 > 7.0 60 ± 4 
HEK 3 181 ± 44 46 ± 2 34 ± 10 41 ± 2 > 1000 69 ± 2 > 7.0 78 ± 3 
NIH/3T3 > 250 96 ± 5 > 1000 56 ± 1 461 ± 22 38 ± 2 > 1000 ND 
HK-2 > 250 62 ± 6 > 1000 82 ± 4 > 1000 66 ± 2 > 1000 ND 
HPTC > 250 77 ± 9 > 1000 55 ± 3 280 ± 27 34 ± 2 > 1000 ND 
 
Further tests where only kaolin was incubated in cell culture medium in cell-free multi-well 
plates revealed that kaolin interfered with the absorbance measurements of the multi-well plate-
based NRU assay (data not shown). Therefore, kaolin was only tested at concentrations ≤ 250 
g/ml, as higher concentrations would exaggerate the readings for the NRU assay, which would 
then lead to overestimation of cell viability. 
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Next, I tested the cytotoxicity of other layered clays (bentonite and montmorillonite) and MCF-
26. These compounds could be used at higher concentrations of up to 1000 g/ml as they 
interfered less strongly with the absorbance readings of NRU assay as compared to kaolin (data 
not shown). The same cell types were used as in the case of kaolin and the results of the NRU 
assays are summarized in Fig. 7 and Table 3. 
The NRU results showed that both layered clays tested had substantial cytotoxic effects. Similar 
to the case of kaolin, HUVEC were also most sensitive to the effects of bentonite (black graphs 
in Fig. 7) and montmorillonite (grey graphs) and the IC50 values ranged between 11 ~ 17 g/ml 
Figure 7. Dose-response curves. HUVEC, HDF and HEK were treated with up to 1000 g/ml of 
bentonite (black), montomorillonite (grey) or MCF-26 (red). Cell viability was determined by NRU 
assay and all values were normalized to the values obtained with untreated control cells. Error bars show 
the s.d. (n = 3). Adapted from [6]. Reproduced by permission of The Royal Society of Chemistry. 
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(bentonite) and 33 ~ 95 g/ml (montmorillonite) (Table 3). Although the cytotoxic effects of 
bentonite and montmorillonite on the other cell types were more variable, in general, the IC50 
values of at least one of these two compounds were clearly below 1000 g/ml in all cell types 
and batches tested, with exception of HK-2 cells and HEK batch 1 (Table 3).  
On the other hand, when cells were treated with MCF-26, cell viability was generally higher as 
compared to layered clays (red graphs in Fig. 7). As more than 50% of the cells were still viable 
at the highest tested concentration, IC50 values for MCF-26 could not be calculated within the 
tested range of 1 ~ 1000 g/ml. This was also observed in the case of HUVECs, which were the 
most sensitive to the cytotoxic effects of the other tested compounds. These results showed that 
MCF-26 had strongly reduced cytotoxicity in comparison to layered clays. Therefore much 
higher concentrations in the mg/ml range (up to 7 mg/ml) were tested in addition. Such 
concentrations were also more clinically relevant as MCF-26 demonstrated its efficacy in 
promoting blood clotting when used in the mg/ml range on human plasma [6]. The IC50 values 
were summarized in table 3 and the results again revealed prominent cell type-specific effects. In 
this case the HEKs were the least sensitive with IC50 values of > 7.0 mg/ml in all three batches.  
Again, inter-donor variability was observed and the IC50 values of the different batches of HDF 
and HUVEC ranged between 2.0 ~ 6.3 mg/ml with the exception of HUVEC batch 3, where an 
IC50 value of ~ 0.7 mg/ml was determined (Table 3). This discrepancy from the previous result, 
where cell viability remained above 50% when treated with up to 1000 g/ml of MCF-26 for this 
batch (red graph, HUVEC 3, Figure 7), can probably be explained by the fact that this cell batch 
was used at a higher passage number (P6) when MCF-26 was tested at higher concentrations (P4 
was used in the other experiments). Nevertheless, the lowest IC50 value obtained with this cell 
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batch and MCF-26 (0.70 mg/ml, Table 3) was still ~ 7-fold higher than the highest value 
obtained with this cell batch and a layered clay (95.0 +/- 12.5 mg/ml, Table 3, montmorillonite).  
Such drastic differences between the toxic effects of MCF-26 and the tested layered clays, 
especially in HUVECs, could be due to differences in the uptake and/or adherence of the clay 
materials onto cell surfaces. This question was further addressed experimentally. Figure 8 shows 
that when cells were incubated with kaolin and other layered clays, these compounds adhered 
strongly to cell and substrate surface and could not be completely removed by repeated washing 
(Fig. 8 e - j). In contrast, adherence of MCF-26 was weaker and this compound was largely 
removed by washing (Fig.8 c, d). A comparison of washed and unwashed cells is also shown in 
supplementary data, Figure S1. 
As such, these results confirmed that the hemostatic agent MCF-26 was less cytotoxic to relevant 
human cell types than currently used layered clays (bentonite, montmorillonite and kaolin). The 
IC50 values were in the mg/ml range when relevant primary human cell types were tested. More 
importantly, these results showed strong cell type specificity in terms of how cells responded to 
the same test compound. In case of MCF-26 HUVEC and HDF were more sensitive to the 
cytotoxic effects at high concentrations of > 1000 g/ml, whereas HEK cells displayed cell 






Figure 8. Adhesion of layered clays and MCF-26 to the cell surface. HUVEC were exposed for 10 
minutes to 1 mg/ml of kaolin, bentonite, montmorillonite or MCF-26 (control: untreated). Cells 
were washed subsequently and images were captured with the CytoViva® system after fixation. 
Particles of test compounds appear white on the images. The left-hand images show fields of cells 
(scale bars: 100 m), whereas the right-hand images show individual cells (scale bars: 10 m). 
Adapted from [6]. Reproduced by permission of The Royal Society of Chemistry. 
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4.2.2 Cell type-specific cytotoxicity of silver nanoparticles (Ag NPs) 
In order to compare the cell type-specific cytotoxic effects of layered clays and MCF-26 to the 
effects of other cytotoxic compounds, we also performed NRU assays with Ag NPs and DMSO. 
Ag NPs are widely applied as antibacterial agents in consumer products, cosmetics and wound 
dressings [120, 121]. However, the cytotoxicity of Ag NPs, which is due to the leaching of silver 
ions, is well documented in the literature and is often controversially discussed with respect to 
the use of such products [121, 122]. Here we show that the IC50 values of Ag NPs were in the 
same range as those of layered clays (Table 3 and Table 4). Again, sensitivity towards the 
cytotoxic effects of Ag NPs was mainly dependent on the cell types tested: HUVEC and HK-2 
cells displayed the lowest IC50 values, whereas cell viability of HEK and NIH/3T3 cells 
remained well above 50% even at the highest concentration of Ag NPs applied (417 g/ml). 
DMSO is a mildly cytotoxic organic solvent that is frequently used for the cryopreservation of 
cells and for dissolving pharmaceuticals in clinical applications [123, 124]. The IC50 values of 
DMSO ranged from ~ 25 mg/ml to > 100 mg/ml (Table 4) and were about 1 - 2 orders of 
magnitude higher than the IC50 values obtained with MCF-26 (Table 3). However, HUVEC 
again displayed the highest sensitivity and lower IC50 values as compared to most of the other 
cell types. The lowest IC50 value was obtained here with HK-2 cells, which were relatively 







Table 4. IC50 values and cell viability (%) at the maximal concentrations of Ag NPs and DMSO. The 
maximal concentration of Ag NPs was 417 g/ml and the maximal concentration of DMSO was 100 
mg/ml. The table provides the mean values ± s.d. (n = 3). Adapted from [6] (Supplementary Information). 














Together, the results obtained here showed strong cell type-specific effects with respect to the 
cytotoxicity of the compounds tested. Endothelial cells were generally most sensitive. NIH/3T3 
cells and also human primary fibroblasts were most insensitive. It should be noted that such 
fibroblastic cell types are most frequently used for cytotoxicity assays [44]. This emphasizes the 
Cell Type 
Ag NPs (10 nm) DMSO 
IC50 (g 
/ml) 




% at 100 
mg/ml 
HUVEC 1 140 ± 49 32 ± 3 85 ± 3 41 ± 2 
HUVEC 2 66 ± 19 29 ± 3 39 ± 4 32 ± 6 
HUVEC 3 77 ± 5 38 ± 6 46 ± 2 31 ± 1 
HDF 1 > 417 81 ± 8 > 100 63 ± 4 
HDF 2 137 ± 12 22 ± 2 > 100 79 ± 6 
HDF 3 347 ± 6 22 ± 3 > 100 88 ± 4 
HEK 1 > 417 72 ± 13 > 100 108 ± 3 
HEK 2 > 417 79 ± 19 > 100 103 ± 1 
HEK 3 > 417 128 ± 14 > 100 117 ± 7 
NIH/3T3 > 417 62 ± 10 > 100 52 ± 7 
HK-2 84 ± 3 29 ± 6 25 ± 4 27 ± 4 
HPTC 343 ± 19 39 ± 1 > 100 74 ± 5 
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necessity to work with relevant and preferably primary human cell types, which are more 
sensitive than respective cell lines [72]. Although when using human primary cells, inter-donor 
variability also plays a role in affecting the cellular responses towards toxic compounds, my 
results showed that cell type specificity had a dominant effect. Further, the results showed that 
MCF-26, which has strongly hemostatic effects [118], has much lower cytotoxicity than widely 
used hemostatic agents [115-117] and Ag NPs, which are also widely applied [121, 122]. 
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4.3 Identification and validation of endpoints suitable for in vitro prediction of drug-
induced nephrotoxicity in humans 
4.3.1 Model design and identification of suitable endpoints for in vitro nephrotoxicology 
As demonstrated in the previous section, different cell types can respond very differently to the 
same compound. Therefore in organ-specific toxicology studies, it is essential to employ the 
most relevant cell type for in vitro analysis. In this part of the thesis, my focus was to develop in 
vitro models for prediction of drug-induced nephrotoxicity. For this application HPTCs are the 
most appropriate cell type due to their physiological role in filtrate concentration and xenobiotic 
clearance in humans. It is also important to note that use of human primary cells can avoid issues 
associated with interspecies variability and problems associated with cellular changes due to 
immortalization, as demonstrated in a previous study [72]. 
Routine characterization of all batches of HPTC used in this section was performed by Dr. 
Karthikeyan Kandasamy (IBN), based on quantification of the expression levels of 31 different 
marker genes by qPCR [8] (Supplementary data, Figure S2). Some of these markers were further 
examined at the protein level by immunostaining and immunoblotting. These characterization 
procedures were regularly performed as a quality control step to ensure consistent cell 
phenotypes across different batches of HPTC. Cells were seeded and cultivated in uncoated 
TCPS-based multi-well plates. As shown in section 4.1 and previous studies, performance of 
primary human renal and endothelial cells was best sustained on uncoated TCPS as compared to 
other materials with or without extracellular matrix coating [5, 67]. High seeding density was 
used and cells were cultivated for three days before drug exposure to generate a differentiated 
epithelium with tight junction formation. To obtain appropriate cell type-specific responses in 
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vitro, it is essential to ensure that cells are well differentiated with their proper phenotypes 
adequately expressed. Also, control experiments showed that HPTC responded more sensitively 
to nephrotoxicants when seeded at the high densities used here (data not shown). 
To identify a suitable endpoint, I first assessed the relative gene expression levels of different 
marker genes related to PT injury with respect to untreated negative controls. Among these 
markers assessed, kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated 
lipocalin (NGAL) often show up-regulation in the tubular epithelium in vivo after injury and are 
potential novel biomarkers for the early detection of AKI [73-76, 125]. Interleukin (IL)-18 is up-
regulated in the PT epithelium in diseased and injured kidneys and might be a useful biomarker 
for detecting kidney toxicity [73, 126, 127]. Here I also included the mesenchymal marker 
vimentin (VIM), which is also up-regulated in injured kidneys [128, 129]. 
IL-6 and IL-8 are key pro-inflammatory cytokines and can be expressed in PT and PT-derived 
cells in vivo and in vitro [72, 130-133]. Different studies previously showed that up-regulation of 
IL-6 and IL-8 occurred in injured or diseased kidneys [80-82]. It is also well established that 
these pro-inflammatory cytokines play a pivotal role in the pathophysiology of AKI, also in case 
of drug-induced AKI [7, 134]. Significant nephrotoxicant-induced up-regulation of IL-6 has also 
been demonstrated in a kidney culture model using purified murine PTs [135]. 
To examine the effects of nephrotoxicants on the expression patterns of these six marker genes in 
vitro, two batches of HPTC (HPTC 1 and 4) were exposed to high doses of gentamicin and 
CdCl2 overnight and marker gene expression levels were subsequently analyzed by qPCR. All 
expression levels obtained were normalized to those of glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), which was used as the endogenous control. For the expression level 
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of a specific marker gene to be a suitable endpoint for detecting nephrotoxicity of drugs in vitro, 
it is most desired that the gene is only expressed at relatively low levels in negative control cells 
and that its expression is highly inducible by nephrotoxicants. In this case, the candidate marker 
gene should also be consistently up-regulated in response to different nephrotoxicants and such 
responses should not be drastically affected by inter-donor variability. The results obtained from 
qPCR revealed that expression levels of IL-6 and IL-8 were significantly and consistently 
elevated by both nephrotoxicants in both batches of HPTCs (Fig. 9). IL-8 showed the highest 








Fig. 9 also showed that, among the other candidate marker genes, NGAL displayed consistent 
up-regulation when treated with nephrotoxicants. However, the magnitudes of up-regulation 
were limited. The fold increases ranged between 1.8 and 3.5, which were considerably lower 
than those of IL-6 and IL-8 in both HPTC batches. VIM was up-regulated only in HPTC 1. Up-
regulation of KIM-1 and IL-18 was inconsistent, and only induced by one of the compounds and 
only in one cell batch. The low levels of induction of NGAL expression and the partial 
Figure 9. Marker gene expression in response to nephrotoxicants. Two batches of HPTC (1 and 4, derived 
from different donors) were treated with 2.5 mg/ml gentamicin (light gray bars) and 10 g/ml CdCl2 (dark 
gray bars). Vehicles controls (set to 1) were shown as white bars. High doses of test compounds were used 
to ensure the induction of cellular responses to these nephrotoxicants. The relative expression levels (y-
axis) of the marker genes shown on the x-axis were determined by qPCR. Mean fold changes (normalized 
to vehicle controls) in expression were shown with standard deviation (s.d.; n = 3). Asterisks indicate 
significant differences (P < 0.05) in comparison to vehicle controls. Adapted from [8]. Reproduced by 
permission of The Royal Society of Chemistry. 
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irresponsiveness of KIM-1 observed here were consistent with the results obtained with other in 
vitro models based on human primary renal proximal tubular cells and a PT-derived cell line2. It 
is important to note that primary PTCs were isolated from disruption of kidney tissues, thus it is 
not unexpected that such cells always exhibit some degree of cellular injury response. Here my 
results showed that VIM, NGAL and KIM-1, even in untreated negative control cells, were 
already expressed at relatively high levels in terms of percentages of the endogenous control, 
GAPDH (Fig. 10). This is also consistent with a previous study in case of VIM [87]. Such high 
background expression levels of injury markers VIM, NGAL and KIM-1 in cultured HPTC 
might provide insights to the reason why there was a lack of further up-regulation when cells 
were exposed to nephrotoxicants. Among all candidate marker genes, only expression levels of 
IL-6 and IL-8 were consistently < 0.1% of GAPDH expression in control cells. This again 
strengthened my hypothesis that among all marker genes tested the expression levels of IL-6 and 
IL-8 appeared to be the most reliable endpoints for predicting drug-induced nephrotoxicity in 
vitro. 
                                                 




In order to further investigate the expression levels of these two marker genes as predictive 
endpoints, I next performed ELISA on both batches of HPTC to assess the concentration of 
secreted IL-6 and IL-8 protein in cell culture supernatants after cells were treated overnight with 
either gentamicin or CdCl2. Results showed that only CdCl2 was able to induce a significant 
increase in secreted levels of both interleukins. This occurred in one of the cell batches (HPTC 4, 
                  
Figure 10. Marker gene expression in response to nephrotoxicants. Data were derived from the same 
experiment as Fig. 9. The expression levels of the marker genes shown on the x-axis were determined 
by qPCR and expressed as percentage (y-axis) of GAPDH expression of the respective samples. Mean 
percentage values (normalized to vehicle controls) were shown with standard deviation (s.d.; n = 3). 





Fig. 11). CdCl2 treatment also caused an elevation of IL-8 levels in the supernatants of HPTC 1 
after CdCl2 exposure, but no increase in IL-6 protein was observed in this cell batch. Gentamicin 
appeared to be ineffective, as no elevated secretion of either interleukin was observed in either 
cell batch. Together, these results suggested that the level of secreted IL-6 or IL-8 proteins would 
not be a good endpoint for predicting drug-induced nephrotoxicity in vitro, as there was both 
significant inter-donor variability in the responses, and inconsistency in results when different 
nephrotoxicants were used. This could be due to the fact that some nephrotoxicants, including 
the aminoglycoside gentamicin, are inhibitors of protein synthesis [136, 137]. Therefore a more 
upstream endpoint, such as mRNA levels as determined by qPCR, would be more reliable for 
predicting drug-induced nephrotoxicity in vitro. 
  
Figure 11. Protein concentrations of IL-6 and IL-8 in cell culture supernatants. Two batches of HPTC (1 
and 4, derived from different donors) were treated with 2.5 mg/ml gentamicin (light grey bars) and 10 
g/ml CdCl2 (dark grey bars). Vehicles controls were shown as white bars. High doses of test compounds 
were used to ensure the induction of cellular responses to these nephrotoxins. The protein concentrations 
of IL-6 and IL-8 in cell culture supernatants were measured by ELISA. Mean values were shown with s.d. 






4.3.2 Validation of the predictive performance with 41 test compounds 
Next, I proceeded to validate the predictive performance of the in vitro model by using 41 well-
characterized test compounds (see Table 1).  Most of these compounds were drugs that are 
routinely applied in clinical practice. Some compounds, such as CdCl2 and lindane, are well-
characterized environmental toxicants. There is an abundance of human and animal in vivo and 
in vitro data available in literature for all of the 41 compounds selected here. I first selected 
compounds based on their classification in published compound lists [1, 38, 45, 49], which 
categorized them according to their nephrotoxicity in humans and as well as their toxic effects on 
different parts of the human kidney or the nephron. Extensive literature search based on PubMed, 
Google and the ChemIDplus Advanced database 3  was then performed to obtain further 
information on the test compounds and to confirm their classification. Details in humans on the 
nephrotoxic effects of all 41 compounds selected here as well as respective references are 
provided in appendix (see supplementary data, Table S1).  
22 compounds were classified as nephrotoxicants which directly damage the PT in humans 
(group 1, Table 1, compounds 1-22). Some of the Group 1 compounds also have other adverse 
effects on the kidney in addition to such direct PT-specific damage. Group 2 consisted of 11 
compounds (Table 1, compounds 23-33) that are nephrotoxic in humans, but do not directly 
injure PTCs. In addition, 8 non-nephrotoxic compounds were included (group 3, Table 1, 
compounds 34-41). The validation was performed by treating cultured HPTC with the 41 
compounds and subsequently examining expression levels of IL-6 and IL-8 in these cells by 
                                                 





qPCR. Three batches of HPTC derived from different donors were used to address inter-donor 
variability. For comparison, all experiments were also repeated with immortalized human (HK-2) 
and porcine (LLC-PK1) renal PT cell lines, which are standard cell lines commonly used for 
nephrotoxicology studies [3].  
 
In all experiments, cells were exposed to the compounds for 16 hours after 3 days of cultivation 
at confluent densities. In preliminary tests, a wide range of concentrations covering 5 orders of 
Figure 12. Dose-response curves for expression of IL-6 and IL-8. HPTC 1 were treated with PT-specific 
nephrotoxicants (copper (II) chloride, cisplatin and paraquat; left-hand panels), non-PT-specific 
nephrotoxicants (ethylene glycol, valacyclovir and lindane; middle) or non-nephrotoxic compounds 
(acarbose, glycine and dexamethasone; right-hand panels) at concentrations indicated on the x-axis 
(logarithmic scale). The figure shows expression levels of IL-6 (grey curves) and IL-8 (black curves) 
relative to those of the vehicle controls (mean  ± s.d., n = 3). In the case of cisplatin, marker gene 
expression levels could not be determined at the highest tested concentration due to massive cell death. 







magnitude (0.01  1000 g/ml) of each compound were used. Due to the absence of any 
significant drug-induced responses at the two lowest concentrations (0.01 and 0.1 g/ml, data not 
shown), only concentrations of 1, 10, 100 and 1000 g/ml were tested for all compounds in all 
cell types. This choice of concentrations ensured that uninformative low concentrations below 
the current lower limit (1 g/ml) were eliminated from the tests. The concentration range was 
also capped at an upper limit (1000 g/ml), beyond which solubility issues with many 
compounds were observed. This would in turn undermine the accuracy of the test results. All 
qPCR results obtained were normalized to respective vehicle controls and presented as relative 
expression (fold changes) of IL-6 and IL-8. 
Fig. 12 shows the dose-response curves obtained with HPTC and three test drugs selected from 
each group of compounds (categorized as in Table 1). These results revealed that different 
compounds had different effects on the expression levels of IL-6 and IL-8: some compounds 
induced up-regulation of both marker genes, while other compounds induced only one or none of 
the two marker genes (Fig. 12). Detailed results on IL-6 and IL-8 expression levels for each cell 
batch/type and all 41 compounds at every concentration tested are listed in the Supplementary 
Tables S2-S11. Highlighted in these tables are the highest levels of IL-6 and IL-8 expression 
determined for each drug and cell batch/type within the range of drug concentrations tested. 
These highest expression levels are summarized in Tables 5 and 6. It is worth noting that 
expression of at least one of the two marker genes was often substantially increased when cells 
were treated with a PT-specific nephrotoxicant (group 1, Tables 5 and 6, Fig. 12), whereas cells 
generally remained irresponsive at all test concentrations when cells were treated with 
compounds from groups 2 and 3 (Tables 5 and 6, Fig. 12).  
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Table 5. Highest expression levels of IL-6 and IL-8 in HK-2 and LLC-PK1 cells. Cells were exposed to 
the 41 compounds (as listed and numbered in Table 1) at concentrations ranging from 1 g/ml and 1000 
g/ml. This table lists the highest expression levels of both marker genes that were recorded at any 
concentration of a drug within this range. The values indicate the mean fold expression level with s.d. (n 
= 3) relative to vehicle controls. The highest expression levels shown here are highlighted in the 
Supplementary Tables S2-S5 (Appendix ii), where detailed expression levels measured at all drug 




IL-6 IL-8 IL-6 IL-8 
1 1.2 ± 0.1 1.3 ± 0.5 5.2 ± 1.0 2.7 ± 0.1
2 1.4 ± 0.2 1.1 ± 0.1 1.2 ± 0.0 2.3 ± 0.2
3 12.8 ± 1.7 5.1 ± 0.2 1.4 ± 0.2 8.4 ± 0.1
4 8.6 ± 1.3 18.8 ± 5.3 4.8 ± 0.3 8.9 ± 0.3
5 120.5 ± 26.1 30.5 ± 2.7 313.7 ± 31.4 839.4 ± 305.9
6 2.6 ± 0.3 1.9 ± 0.3 1.1 ± 0.0 1.6 ± 0.2
7 3.6 ± 0.8 14.3 ± 1.2 1.8 ± 0.1 10.1 ± 0.7
8 1.7 ± 0.1 2.5 ± 0.1 1.7 ± 0.1 1.2 ± 0.4
9 1.2 ± 0.1 1.7 ± 0.1 1.0 ± 0.1 1.7 ± 0.0
10 1.2 ± 0.1 1.4 ± 0.5 6.3 ± 0.3 20.3 ± 2.0
11 5.9 ± 0.5 2.0 ± 1.0 0.9 ± 0.1 6.9 ± 0.3
12 1.3 ± 0.0 3.0 ± 0.0 1.8 ± 0.1 4.3 ± 0.9
13 2.8 ± 0.8 3.7 ± 0.7 12.9 ± 7.2 12.2 ± 4.3
14 16.1 ± 1.1 1.2 ± 0.1 3.7 ± 0.2 37.0 ± 4.4
15 0.7 ± 0.1 1.5 ± 0.2 2.4 ± 0.0 2.5 ± 0.1
16 3.5 ± 0.5 1.9 ± 0.4 2.8 ± 0.0 1.6 ± 0.3
17 2.0 ± 0.4 2.1 ± 0.1 2.5 ± 0.2 16.3 ± 4.3
18 0.6 ± 0.0 0.6 ± 0.1 0.9 ± 0.0 1.4 ± 0.2
19 7.8 ± 0.4 2.8 ± 0.1 7.4 ± 1.0 301.3 ± 27.5
20 1.2 ± 0.1 1.6 ± 0.3 2.4 ± 0.6 4.9 ± 1.2
21 14.7 ± 1.5 1.7 ± 0.0 1.7 ± 0.5 2.6 ± 0.3
22 2.0 ± 0.3 3.9 ± 0.5 1.5 ± 0.1 4.0 ± 0.3
23 0.8 ± 0.0 1.2 ± 0.2 0.9 ± 0.1 1.2 ± 0.1
24 0.7 ± 0.1 4.7 ± 0.6 1.3 ± 0.1 16.1 ± 0.4
25 1.2 ± 0.2 1.2 ± 0.1 2.3 ± 0.4 1.8 ± 0.3
26 0.9 ± 0.5 0.5 ± 0.2 2.1 ± 0.5 2.9 ± 1.0
27 1.0 ± 0.1 8.3 ± 0.7 2.6 ± 0.1 13.7 ± 1.2
28 1.6 ± 0.0 1.4 ± 0.1 1.0 ± 0.0 1.0 ± 0.1
29 1.5 ± 0.6 0.5 ± 0.0 0.9 ± 0.2 1.2 ± 0.1
30 1.3 ± 0.1 1.6 ± 0.1 1.1 ± 0.1 2.6 ± 0.1
31 1.4 ± 0.0 1.7 ± 0.3 1.6 ± 0.3 1.3 ± 0.0
32 0.9 ± 0.2 1.1 ± 0.2 1.6 ± 0.1 2.1 ± 0.1
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33 1.1 ± 0.1 1.2 ± 0.1 8.2 ± 2.6 9.1 ± 0.6
34 1.3 ± 0.1 1.3 ± 0.1 1.8 ± 0.0 0.8 ± 0.0
35 1.3 ± 0.1 1.5 ± 0.0 0.9 ± 0.1 1.0 ± 0.0
36 1.0 ± 0.1 0.8 ± 0.1 0.8 ± 0.0 0.7 ± 0.1
37 0.8 ± 0.0 0.3 ± 0.0 2.4 ± 0.3 2.6 ± 0.2
38 1.5 ± 0.3 1.2 ± 0.1 0.8 ± 0.0 1.1 ± 0.0
39 2.4 ± 0.6 10.2 ± 3.5 7.7 ± 0.6 164.4 ± 4.0
40 1.2 ± 0.1 1.0 ± 0.0 1.1 ± 0.0 1.1 ± 0.0








HPTC 1 HPTC 2 HPTC 3 
IL-6 IL-8 IL-6 IL-8 IL-6 IL-8 
1 16.9 ± 0.2 8.6 ± 1.3 1.7 ± 0.1 2.0 ± 0.1 1.6 ± 0.1 1.9 ± 0.3
2 8.0 ± 0.9 8.9 ± 1.2 1.4 ± 0.0 1.5 ± 0.1 1.4 ± 0.1 2.0 ± 0.1
3 38.9 ± 3.0 110.8 ± 39.0 3.6 ± 0.7 13.1 ± 3.0 5.3 ± 0.4 7.3 ± 2.7
4 6.3 ± 0.7 1.5 ± 0.1 2.3 ± 0.3 3.6 ± 0.8 23.6 ± 2.8 35.5 ± 4.4
5 8.5 ± 1.0 9.5 ± 0.6 79.5 ± 1.7 146.1 ± 3.1 80.4 ± 2.7 46.4 ± 1.2
6 3.9 ± 0.1 2.3 ± 0.2 3.6 ± 0.3 9.2 ± 0.2 1.4 ± 0.1 2.4 ± 0.6
7 3.6 ± 0.8 2.4 ± 0.2 4.8 ± 0.6 3.8 ± 0.9 12.0 ± 1.8 5.4 ± 0.4
8 3.8 ± 0.6 20.1 ± 2.2 27.9 ± 0.8 32.7 ± 0.9 12.1 ± 0.4 21.9 ± 0.8
9 1.7 ± 0.2 1.5 ± 0.2 1.3 ± 0.1 1.8 ± 0.4 2.9 ± 0.3 2.6 ± 0.2
10 3.1 ± 0.7 16.3 ± 4.6 7.5 ± 0.0 13.2 ± 0.3 11.8 ± 0.5 9.7 ± 0.2
11 3.0 ± 0.1 6.0 ± 0.1 1.6 ± 0.0 25.7 ± 3.8 31.4 ± 12.8 22.8 ± 4.0
12 1.1 ± 0.3 11.9 ± 6.2 1.9 ± 0.3 22.5 ± 2.0 4.0 ± 0.1 9.6 ± 1.8
13 6.6 ± 0.5 9.7 ± 2.5 12.9 ± 0.6 165.2 ± 14.7 10.8 ± 1.2 13.3 ± 1.4
14 10.4 ± 2.9 7.5 ± 4.4 12.4 ± 1.4 119.0 ± 5.4 0.9 ± 0.2 9.9 ± 1.1
15 1.7 ± 0.5 2.9 ± 1.7 3.6 ± 0.2 5.7 ± 0.2 2.2 ± 0.2 3.4 ± 0.5
16 10.0 ± 1.3 2.2 ± 0.7 13.6 ± 1.0 8.3 ± 0.5 5.8 ± 2.5 3.5 ± 1.0
17 3.5 ± 0.4 3.3 ± 0.1 8.6 ± 0.4 23.8 ± 2.9 2.3 ± 0.2 2.8 ± 0.4
18 1.7 ± 0.2 3.8 ± 1.0 0.8 ± 0.0 2.7 ± 0.3 0.6 ± 0.2 10.1 ± 0.9
19 24.6 ± 5.7 3.9 ± 1.3 37.6 ± 0.7 29.3 ± 4.3 38.1 ± 1.2 25.0 ± 0.8
20 1.1 ± 0.2 5.6 ± 1.3 3.4 ± 0.7 67.4 ± 3.1 1.3 ± 0.1 17.8 ± 1.6
21 3.9 ± 0.7 2.3 ± 0.7 1.3 ± 0.1 4.9 ± 0.1 2.3 ± 0.3 1.5 ± 0.1
22 1.6 ± 0.1 4.3 ± 0.4 0.7 ± 0.0 1.0 ± 0.0 1.1 ± 0.1 2.0 ± 0.2
23 1.4 ± 0.2 1.6 ± 0.3 1.4 ± 0.2 1.8 ± 0.4 1.0 ± 0.4 0.8 ± 0.2
24 1.2 ± 0.1 1.3 ± 0.1 0.8 ± 0.1 0.9 ± 0.2 6.2 ± 1.0 3.6 ± 0.3
25 1.3 ± 0.0 1.5 ± 0.1 2.9 ± 0.2 2.6 ± 0.1 0.8 ± 0.1 0.9 ± 0.0
26 2.6 ± 0.8 3.1 ± 1.4 16.1 ± 1.2 4.3 ± 0.3 2.9 ± 0.1 1.5 ± 0.3
27 1.7 ± 0.4 1.9 ± 0.5 2.6 ± 0.2 2.6 ± 0.2 9.0 ± 0.6 8.2 ± 0.7
28 0.7 ± 0.1 0.5 ± 0.1 17.4 ± 0.8 20.5 ± 0.8 1.1 ± 0.2 1.3 ± 0.3
29 1.0 ± 0.3 1.1 ± 0.4 0.8 ± 0.0 1.5 ± 0.1 0.9 ± 0.2 1.2 ± 0.0
30 1.0 ± 0.1 1.1 ± 0.1 1.8 ± 0.1 2.0 ± 0.1 1.0 ± 0.2 1.2 ± 0.3
Table 6. Highest expression levels of IL-6 and IL-8 in HPTC. Three batches of HPTC (HPTC 1-3, 
derived from different donors) were exposed to the 41 test compounds at concentrations ranging from 1 
g/ml to 1000 g/ml. The table shows the highest expression levels of IL-6 and IL-8 obtained at any 
given concentration of a test compound within this concentration range. The values indicate the mean 
fold expression level with s.d. (n = 3) relative to vehicle controls. The highest expression levels shown 
here are highlighted in the Supplementary Tables S6-S11 (Appendix ii), where detailed expression 
levels measured at all drug concentrations were listed. Adapted from [8]. Reproduced by permission of 




For further analysis of these gene expression results, the results were classified for each drug and 
cell type/batch as either positive or negative based on the highest expression levels of IL-6 and 
IL-8 obtained (Tables 5 and 6). A compound was defined as positive if the highest increase in 
gene expression (in terms of fold changes over its vehicle control, listed in Tables 5 and 6) of at 
least one of the two marker genes (IL-6 and IL-8) was equal to or higher than a given threshold 
value. Compounds that did not fulfill this condition were defined as negative compounds. 
However, the use of a stringent threshold (high fold change value) would very likely lead to 
markedly different interpretation of results as compared to a lenient threshold (low fold change). 
In order to address this issue and to select the most appropriate threshold, subsequent data 
analysis was performed based on a range of threshold levels from 0.3 to 4.0.  
The thresholding procedure is illustrated in Tables 7 and 8, using 2.0 and 3.5 as two threshold 
examples. Both tables display the highest expression levels for IL-6 and IL-8 obtained with 
HPTC 1 (derived from Table 6). These values were processed with a threshold value of 2.0 
(Table 7) or 3.5 (Table 8). Wherever at least one of the two marker genes had a highest 
expression level equal to or higher than the threshold, these values were highlighted in the 
respective tables and the corresponding compound was designated as positive (indicated as “+”). 
31 1.7 ± 0.4 1.3 ± 0.1 1.6 ± 0.3 1.2 ± 0.2 1.4 ± 0.2 1.3 ± 0.2
32 1.3 ± 0.1 1.2 ± 0.0 1.3 ± 0.1 1.4 ± 0.1 1.0 ± 0.2 1.1 ± 0.2
33 4.7 ± 0.6 5.3 ± 1.1 1.3 ± 0.1 1.6 ± 0.2 2.9 ± 0.1 3.2 ± 0.3
34 1.5 ± 0.1 1.4 ± 0.1 1.2 ± 0.1 1.4 ± 0.1 1.2 ± 0.3 1.7 ± 0.4
35 1.7 ± 0.2 2.0 ± 0.1 2.7 ± 0.8 1.3 ± 0.0 1.0 ± 0.1 1.2 ± 0.1
36 0.9 ± 0.1 1.1 ± 0.1 2.7 ± 0.1 2.9 ± 0.0 1.4 ± 0.2 1.7 ± 0.3
37 1.2 ± 0.1 1.5 ± 0.3 1.1 ± 0.3 1.4 ± 0.2 0.9 ± 0.1 1.3 ± 0.1
38 1.8 ± 0.0 1.3 ± 0.1 1.2 ± 0.2 3.1 ± 0.2 0.6 ± 0.1 1.3 ± 0.2
39 3.4 ± 1.0 1.8 ± 0.1 3.1 ± 0.3 24.0 ± 3.4 3.4 ± 0.3 5.1 ± 0.3
40 1.6 ± 0.2 1.5 ± 0.1 1.2 ± 0.0 1.3 ± 0.0 1.3 ± 0.1 1.3 ± 0.1
41 1.0 ± 0.3 3.6 ± 1.2 1.0 ± 0.0 1.6 ± 0.1 128.5 ± 21.1 38.2 ± 7.1
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A compound with highest expression levels of both markers below the threshold level was not 
highlighted and was designated as negative (indicated as “-”). Based on the numbers of positive 
and negative compounds as classified at each threshold, the sensitivity and specificity values (%) 
were calculated as illustrated in Fig. 1 4 and indicated here in Tables 7 and 8.  
  
                                                 
4 Sensitivity = number of positive test results from group 1 compounds / total number of 22 group 1 compounds; 




Table 7. Example for the thresholding procedure at threshold = 2.0. Highest expression values (compare 
Table 6) equal to or above the threshold 2.0 were bolded. Compounds with at least one bolded value were 
designated as positive (+).Adapted from [8]. Reproduced by permission of The Royal Society of 
Chemistry. 
  HPTC 1 Threshold = 2.0 
  IL-6  IL-8  + / - Test
Sensitivity / 
Specificity
1 16.9 ± 0.2  8.6 ± 1.3  +
Sensitivity = 
21 / 22 = 96% 
 
2 8.0 ± 0.9  8.9 ± 1.2  +
3 38.9 ± 3.0  110.8 ± 39.0  +
4 6.3 ± 0.7  1.5 ± 0.1  +
5 8.5 ± 1.0  9.5 ± 0.6  +
6 3.9 ± 0.1  2.3 ± 0.2  +
7 3.6 ± 0.8  2.4 ± 0.2  +
8 3.8 ± 0.6  20.1 ± 2.2  +
9 1.7 ± 0.2  1.5 ± 0.2  -
10 3.1 ± 0.7  16.3 ± 4.6  +
11 3.0 ± 0.1  6.0 ± 0.1  +
12 1.1 ± 0.3  11.9 ± 6.2  +
13 6.6 ± 0.5  9.7 ± 2.5  +
14 10.4 ± 2.9  7.5 ± 4.4  +
15 1.7 ± 0.5  2.9 ± 1.7  +
16 10.0 ± 1.3  2.2 ± 0.7  +
17 3.5 ± 0.4  3.3 ± 0.1  +
18 1.7 ± 0.2  3.8 ± 1.0  +
19 24.6 ± 5.7  3.9 ± 1.3  +
20 1.1 ± 0.2  5.6 ± 1.3  +
21 3.9 ± 0.7  2.3 ± 0.7  +
22 1.6 ± 0.1  4.3 ± 0.4  +
23 1.4 ± 0.2  1.6 ± 0.3  -
Specificity = 
14 / 19 = 74% 
 
24 1.2 ± 0.1  1.3 ± 0.1  -
25 1.3 ± 0.0  1.5 ± 0.1  -
26 2.6 ± 0.8  3.1 ± 1.4  +
27 1.7 ± 0.4  1.9 ± 0.5  -
28 0.7 ± 0.1  0.5 ± 0.1  -
29 1.0 ± 0.3  1.1 ± 0.3  -
30 1.0 ± 0.1  1.1 ± 0.1  -
31 1.7 ± 0.4  1.3 ± 0.1  -
32 1.3 ± 0.1  1.2 ± 0.0  -
33 4.7 ± 0.6  5.3 ± 1.1  +
34 1.5 ± 0.1  1.4 ± 0.1  -
35 1.7 ± 0.2  2.0 ± 0.1  +
36 0.9 ± 0.1  1.1 ± 0.1  -
37 1.2 ± 0.1  1.5 ± 0.3  -
38 1.8 ± 0.0  1.3 ± 0.1  -
39 3.4 ± 1.0  1.8 ± 0.1  +
40 1.6 ± 0.2  1.5 ± 0.1  -
41 1.0 ± 0.3  3.6 ± 1.2  +
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Table 8. Example for the thresholding procedure at threshold = 3.5. Highest expression values (compare 
Table 6) equal to or above the threshold 3.5 were bolded. Compounds with at least one bolded value were 
designated as positive (+).Adapted from [8]. Reproduced by permission of The Royal Society of 
Chemistry. 
  HPTC 1 Threshold = 3.5 
  IL-6  IL-8  + / - Test
Sensitivity / 
Specificity
1 16.9 ± 0.2  8.6 ± 1.3  +
Sensitivity = 
20/22 = 91%  
2 8.0 ± 0.9  8.9 ± 1.2  +
3 38.9 ± 3.0  110.8 ± 39.0  +
4 6.3 ± 0.7  1.5 ± 0.1  +
5 8.5 ± 1.0  9.5 ± 0.6  +
6 3.9 ± 0.1  2.3 ± 0.2  +
7 3.6 ± 0.8  2.4 ± 0.2  +
8 3.8 ± 0.6  20.1 ± 2.2  +
9 1.7 ± 0.2  1.5 ± 0.2  -
10 3.1 ± 0.7  16.3 ± 4.6  +
11 3.0 ± 0.1  6.0 ± 0.1  +
12 1.1 ± 0.3  11.9 ± 6.2  +
13 6.6 ± 0.5  9.7 ± 2.5  +
14 10.4 ± 2.9  7.5 ± 4.4  +
15 1.7 ± 0.5  2.9 ± 1.7  -
16 10.0 ± 1.3  2.2 ± 0.7  +
17 3.5 ± 0.4  3.3 ± 0.1  +
18 1.7 ± 0.2  3.8 ± 1.0  +
19 24.6 ± 5.7  3.9 ± 1.3  +
20 1.1 ± 0.2  5.6 ± 1.3  +
21 3.9 ± 0.7  2.3 ± 0.7  +
22 1.6 ± 0.1  4.3 ± 0.4  +
23 1.4 ± 0.2  1.6 ± 0.3  -
Specificity = 
17 /19 = 90%  
24 1.2 ± 0.1  1.3 ± 0.1  -
25 1.3 ± 0.0  1.5 ± 0.1  -
26 2.6 ± 0.8  3.1 ± 1.4  -
27 1.7 ± 0.4  1.9 ± 0.5  -
28 0.7 ± 0.1  0.5 ± 0.1  -
29 1.0 ± 0.3  1.1 ± 0.3  -
30 1.0 ± 0.1  1.1 ± 0.1  -
31 1.7 ± 0.4  1.3 ± 0.1  -
32 1.3 ± 0.1  1.2 ± 0.0  -
33 4.7 ± 0.6  5.3 ± 1.1  +
34 1.5 ± 0.1  1.4 ± 0.1  -
35 1.7 ± 0.2  2.0 ± 0.1  -
36 0.9 ± 0.1  1.1 ± 0.1  -
37 1.2 ± 0.1  1.5 ± 0.3  -
38 1.8 ± 0.0  1.3 ± 0.1  -
39 3.4 ± 1.0  1.8 ± 0.1  -
40 1.6 ± 0.2  1.5 ± 0.1  -
41 1.0 ± 0.3  3.6 ± 1.2  +
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Similarly, the sensitivity and specificity values based on the highest mRNA expression levels 
summarized in Tables 5 and 6 were calculated for every cell type and batch using 7 different 
threshold levels ranging from 0.3 to 4.0. The results are summarized in Table 9 and are 
graphically displayed in Fig. 13. The overall concordance values with clinical data 5 were also 











                                                 
5 Concordance with clinical data = sum of number of positive test results from group 1 compounds (true positives) 




Table 9: Determination of true positives (TP), true negatives (TN), sensitivity and specificity values. TP 
were defined as PT-specific nephrotoxicants (group 1; 22 drugs) that were correctly identified as positives 
by our assay. TNs were defined as non-PT-damaging nephrotoxicants and non-nephrotoxic drugs (group 
2 and 3; 19 drugs) that were correctly identified as negatives in our assay. TP and TN were counted at the 
threshold levels indicated ranging from 0.3 to 4.0. Sensitivity and specificity values were calculated from 
these TP and TN numbers as described in Fig. 1. These percentages obtained with respect to sensitivity 
and specificity are displayed in brackets after the respective numbers of TP and TN. Values shown were 
derived from all cell types and batches based on the results from all 41 compounds. The percentage values 
of sensitivity and specificity are graphically displayed in Fig. 13. Adapted from [8]. Reproduced by 
permission of The Royal Society of Chemistry. 
 
Thresholds HK-2 LLC-PK1 HPTC 1 HPTC 2 HPTC 3 
0.3 
TP 22 (100%) 22 (100%) 22 (100%) 22 (100%) 22 (100%)
TN 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
1.5 
TP 18 (82%) 21 (96%) 22 (100%) 21 (96%) 22 (100%)
TN 9 (47%) 7 (37%) 6 (32%) 5 (26%) 10 (53%) 
2.0 
TP 15 (68%) 18 (82%) 21 (96%) 19 (86%) 21 (96%) 
TN 15 (79%) 9 (47%) 14 (74%) 10 (53%) 13 (68%) 
2.5 
TP 14 (64%) 17 (77%) 21 (96%) 18 (82%) 17 (77%) 
TN 15 (79%) 11 (58%) 16 (84%) 11 (58%) 13 (68%) 
3.0 
TP 12 (55%) 14 (64%) 20 (91%) 17 (77%) 15 (68%) 
TN 15 (79%) 14 (74%) 16 (84%) 15 (79%) 14 (74%) 
3.5 
TP 11 (50%) 14 (64%) 20 (91%) 17 (77%) 14 (64%) 
TN 15 (79%) 14 (74%) 17 (90%) 16 (84%) 15 (79%) 
4.0 
TP 8 (36%) 14 (64%) 15 (68%) 16 (73%) 14 (64%) 





The results from Fig. 13 revealed that a threshold value of 3.5 was most appropriate for two of 
the HPTC batches (HPTC 1 and 2). At this threshold level, high sensitivity, specificity and 
overall concordance with clinical data (80% ~ 90%) were obtained for both HPTC batches. 
However, when the same threshold value (3.5) was applied to HPTC 3, the sensitivity and 
overall concordance were 64% and 71% respectively, despite the consistently high sensitivity of 
80%. Thus, the results displayed some inter-donor variability.  
 
 
Figure 13. Sensitivity, specificity and overall concordance with clinical data in three batches of HPTCs, 
HK-2 and LLC-PK1 cells. The figure graphically displays the sensitivity and specificity values shown in 
Table 9. The overall concordance values were also calculated at all thresholds (x-axis) from 0.3 to 4.0. 
Dotted lines indicate 80% for comparison. Adapted from [8]. Reproduced by permission of The Royal 
Society of Chemistry. 
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On the other hand, HK-2 and LLC-PK1 cells had different optimal threshold levels from HPTC, 
and in general, the cell lines had lower predictivity than the primary cells (Fig. 13). For example, 
in LLC-PK1 cells sensitivity, specificity and concordance values were all between 64% ~ 74% at 
the optimal threshold levels (> 3.0). These values were substantially lower than those obtained 
with HPTCs.  
Further analyses on the overall predictivity of each cell type/batch were subsequently performed 
by plotting the receiver operating characteristic (ROC) curves and subsequently comparing the 
area under curve (AUC) values. The ROC curves for each cell type/batch tested are displayed in 
Fig. 14 for either IL-6 or IL-8 or the combination of both markers. The corresponding AUC 
values are summarized in Table 10. By comparing the mean and median AUC values of the three 
HPTC batches (or the individual AUC values of each HPTC batch) with those of HK-2 and 
LLC-PK1 cells, it is again clear that the predictivity was generally higher when HPTC were used. 
These results also showed that the use of a combination of both IL-6 and IL-8 could only slightly 
improve the results as compared to when only IL-8 was used. The AUC values (Table 10) 
obtained with the marker combination ranged from 0.71 (HK-2) to 0.94 (HPTC 1), whereas the 






Figure 14. ROC curves for HPTC, HK-2 and LLC-PK1 cells. For each cell type/batch the ROC curves 
were plotted for each single marker (gray graphs) and the combination of both markers (black graphs). 
The AUC values are summarized in Table 10. For comparison, panel F simultaneously displays the ROC 
curves (for combination of both markers) obtained with all the cell types/batches tested. Adapted from 








Cell Type AUC IL-6/IL-8 IL-6 IL-8 
HPTC 1 0.94 0.85 0.90 
HPTC 2 0.81 0.72 0.80 
HPTC 3 0.82 0.71 0.84 
HPTC mean 0.85 0.76 0.85 
HPTC median 0.82 0.72 0.84 
HK-2 0.71 0.74 0.68 
LLC-PK1 0.73 0.65 0.72 
Table 10. AUC values. The table provides the AUC values of the ROC curves (Fig. 14) for every cell 
batch/type tested. For HPTC also the mean and median values are shown. AUC values were determined 
separately for either IL-6 or IL-8 or the combination of these two markers. AUC values > 0.5 represent a 
predictive model that is better than chance. Adapted from [8]. Reproduced by permission of The Royal 




Table 11 lists the most important performance metrics (balanced accuracy, sensitivity, specificity, 
PPV, NPV and AUC values; see Figure 1 for definitions). All values were calculated based on 
the combined expression data of both IL-6 and IL-8. The mean PPV for HPTC was 0.85, 
suggesting that 85% of the compounds predicted as positive were indeed PT-specific 
nephrotoxicants. The PPV values for HK-2 and LLC-PK1 cells were 0.73 and 0.74, respectively. 
The mean NPV of HPTC was 0.79, indicating that 79% of compounds predicted as negative 
were non-nephrotoxic or damage the kidney via mechanisms other than direct toxicity towards 
PTCs. In this case, the NPV values for the cell lines were 0.6 (HK-2) and 0.67 (LLC-PK1).  Also, 
the other values showed that throughout a higher predictivity was obtained with HPTCs, in 
comparison to the two cell lines. 
  
  
Cell Type  Balanced Accuracy  Sensitivity  Specificity  PPV  NPV  AUC 
HPTC 1  0.90  0.91 0.90 0.91 0.94  0.94
HPTC 2  0.81  0.77 0.84 0.85 0.76  0.81
HPTC 3  0.71  0.64 0.79 0.78 0.68  0.82
HPTC mean  0.81  0.77 0.84 0.85 0.79  0.85
HPTC median  0.81  0.77 0.84 0.85 0.76  0.82
HK-2  0.65  0.50 0.79 0.73 0.60  0.71
LLC-PK1  0.69  0.64 0.74 0.74 0.67  0.73
Table 11. Performance metrics. The table summarizes the values for the following performance metrics: 
balanced accuracy (defined as average between sensitivity and specificity), sensitivity, specificity, PPV, 
NPV and AUC. In case of sensitivity, specificity, PPV and NPV the values obtained at a threshold value 
of 3.5 (see Fig. 13) are displayed. With respect to the AUC values the results obtained with a 
combination of both markers are provided. These values are identical with those in Table 10 and are 
displayed here again for comparison.  Adapted from [8]. Reproduced by permission of The Royal 




4.3.3 Comparison of endpoints 
Next, we compared the predictive performance when either IL-6/IL-8 expression or cell death 
was used as endpoints. High content screening (HCS) was used here to determine cell numbers 
after cells were exposed to the same set of 41 compounds in the same way in previous 
experiments. As a large number of test compounds were used to treat various cell types at 
different concentrations, the HCS-based method was more appropriate in this case for 
determining cell numbers due to its high throughput. On the contrary, the neutral red uptake 
(NRU) assay employed for determining cell viability in Section 4.2 was more suitable for tests of 
smaller scales and therefore not used here. Reduction in cell numbers indicates cell death. Here 
in cases where cell numbers were decreased by more than 50% (normalized to respective vehicle 
controls) within the tested range of concentrations, IC50 values were calculated and summarized 
in Table 12. For compounds that did not cause massive cell death and more than 50% of cells 
survived up to the highest tested concentration of 1000 g/ml, the IC50 values were denoted as 
“>1000”.  
Table 12 shows that when IL-6/IL-8 expression was used as the endpoint, positive results were 
observed in 91% (20/22) of the PT-specific nephrotoxicants in HPTC 1, indicating high 
sensitivity.  In contrast, it was possible to calculate the IC50 values for only 42% (8/19) of the 
tested group 1 compounds, as in all other cases cell viability remained > 50%. Even if all of such 
cases (where > 50% cell death has occurred) were classified as positives, the sensitivity would 
still be < 0.5 when cell death was used as the endpoint. Similar results were obtained with HK-2 
and LLC-PK1 cells, where substantial cell death was observed in only 43% (6/14) and 53% (8/15) 
of group 1 compounds tested.  
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These results indicate that endpoints measuring general cytotoxicity are not necessarily useful for 
organ-specific assays. Many widely used toxicity assays are based on cell death, and determine 
either cell numbers (such as the neutral red uptake assay) or measure metabolic activity as a 
surrogate endpoint (MTS assay). 
 
Table 12. Comparison of drug effects on IL-6/IL-8 expression and cell numbers. HPTC 1, HK-2 and 
LLC-PK1 cells were exposed to the 41 test compounds. Data on IL-6/IL-8 expression were based on 
previous results (Tables 5 and 6). A result was defined as positive (+) when expression of at least one 
marker showed at any concentration an increase of 3.5-fold or above (for HPTC 1, compare Table 8). If 
marker expression values remained below 3.5-fold the result was classified as negative (-). IC50 values 
were calculated based on cell numbers determined by HCS. A value of >1000 g/ml was assigned if cell 
viability was > 50% up to the highest concentration of a compound (1000 g/ml). Cell numbers were not 

















1 + >1000 - >1000 + >1000
2 + >1000 - >1000 - >1000
3 + 707 + 632 + 795
4 + >1000 + ND + >1000
5 + >1000 + ND + ND
6 + 47 - 94 - 38
7 + ND + >1000 + 469
8 + ND - ND - ND
9 - >1000 - >1000 - >1000
10 + >1000 - >1000 + 69
11 + 21 + 7 + 19
12 + >1000 - >1000 + >1000
13 + 4 + ND + 9
14 + 147.0 + 116 + 79
15 - >1000 - ND - >1000
16 + 96 + ND - ND
17 + >1000 - ND + >1000
18 + 23 - 14 - ND
19 + 45 + 44 + 45
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20 + >1000 - >1000 + ND
21 + ND + ND - ND
22 + >1000 + >1000 + ND
23 - >1000 - >1000 - >1000
24 - >1000 + >1000 + >1000
25 - >1000 - >1000 - >1000
26 - 742 - 678 - 945
27 - >1000 + >1000 + >1000
28 - >1000 - >1000 - >1000
29 - >1000 - >1000 - >1000
30 - >1000 - >1000 - >1000
31 - >1000 - >1000 - >1000
32 - >1000 - ND - >1000
33 + >1000 - >1000 + >1000
34 - >1000 - >1000 - >1000
35 - >1000 - >1000 - >1000
36 - >1000 - >1000 - >1000
37 - >1000 - >1000 - >1000
38 - >1000 - >1000 - 71
39 - >1000 + >1000 + >1000
40 - >1000 - >1000 - >1000






In summary, an in vitro model for the prediction of drug-induced nephrotoxicity in humans has 
been developed and the results were published in [8]. The model is primarily based on HPTCs 
seeded on uncoated TCPS surfaces. Expression levels of IL-6 and IL-8 were used as endpoints 
and the model was validated with 41 test compounds. The predictivity was found to be > 80% 
when HPTCs were used, and this value was significantly higher than those obtained with 
immortalized cell lines (Table 9). This model would allow highly accurate predictions on the PT 
toxicity of drugs in an early pre-clinical stage, which is currently not possible [45]. However, one 
major limitation of this model is the difficulty in obtaining large numbers of human primary 
renal cells. Healthy human kidneys are usually used for transplantation, and large amounts of 
healthy human kidney tissues are rarely available for PT cell isolation. Despite such high 
predictivity, large-scale screening of new drugs using HPTCs inevitably involves high costs due 
to scarce cell sources. Other issues associated with the use of primary cells include limited 
proliferative capacity [63, 84], functional changes during passaging [85], inter-donor variability 
[6, 8, 72, 86] as well as trans- and de-differentiation in vitro [65, 87]. In view of these problems, 
the use of HPTC-like cells differentiated from human stem cells under controlled conditions 
could provide a potential solution. Our group has been developing protocols to differentiate 
human pluripotent stem cells into HPTC-like cells [9]. An application of such stem cell-derived 
HPTC-like cells in this in vitro model and subsequent validation results will be described in 




4.4 Application of stem cell-derived HPTC-like cells for the prediction of drug-induced 
nephrotoxicity in humans 
4.4.1 Predictive performance of hESC-derived HPTC-like cells 
As mentioned earlier, stem cell-based approaches can potentially address many issues associated 
with the use of primary cells and immortalized cell lines. In a previous study, our lab was 
involved in developing an approach to differentiate human embryonic stem cells (hESCs) into 
HPTC-like cells [9]. Based on the findings that their morphological and functional features, as  
well as protein and gene expression patterns were similar to those of HPTCs, I tested these 
HPTC-like cells in the in vitro model described in Section 4.3. Subsequently the predictivity was 
determined by using the same 41 test compounds (as listed in Table 1). 
Here, HUES 7 cells were differentiated into HPTC-like cells as described in [9]. The HPTC-like 
cells were also characterized by examining marker expression to ensure that proper cell 
phenotypes were obtained. Cell differentiation was performed by Dr. Wei Seong Toh (IBN) and 
characterization of HPTC-like cells by Dr. Karthikeyan Kandasamy (IBN). Expression of 18 
epithelial and HPTC-specific markers was assessed in HPTC-like cells and HPTC (HPTC 1, 
which had been extensively characterized [8, 9]). Among the 18 markers tested, 11 markers were 
expressed at similar or significantly higher levels in HPTC-like cells as compared to HPTCs [10]. 
These included PT-specific markers such as aquaporin (AQP) 1, glucose transporter (GLUT) 5 
and N-cadherin.  
HPTC-like cells were harvested after 20 days of differentiation and cryopreserved before further 
use (the characterizations described above had been performed on cryopreserved and reseeded 
cells). For toxicity testing, cryopreserved cells were thawed and seeded at confluent density into 
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multi-well plates. Essentially, the work was performed in the same way as before with HPTCs 
(see Section 4.3). After seeding, cells were cultivated for 3 days, and were then exposed for 16 h 
to the 41 test compounds. All compounds were tested at concentrations of 1 μg/ml, 10 μg/ml, 
100 μg/ml and 1000 μg/ml. The reasoning for the choice of concentrations was discussed earlier 
in Section 4.3. All results (IL-6 and IL-8 expression) were normalized to, and expressed as fold 
changes of the respective vehicle controls. Detailed results on IL-6 and IL-8 expression for each 
drug at every concentration tested are listed in the Supplementary Data (Tables S12 and S13), 
where the highest levels of expression determined for each compound within the concentration 
range tested were highlighted. These highlighted values were summarized in Table 13. The 
definition of a positive result was the same as previously described: a results was classified as 
positive if the highest increase in gene expression of at least one of the two markers (IL-6/IL-8) 
was equal to or higher than a threshold value. In the case of hESC-derived HPTC-like cells, the 




Table 13. Highest expression levels of IL-6 and IL-8 in hESC-derived HPTC-like cells. Cells were 
exposed to the 41 compounds (same as listed and numbered in Table 1) at concentrations ranging from 1 
g/ml and 1000 g/ml. This table lists the highest expression levels of both marker genes that were 
recorded at any concentration of a drug within this range. The values indicate the mean fold expression 
level with s.d. (n = 3) relative to vehicle controls. The highest expression levels shown here are 
highlighted in Appendix ii, Supplementary Data, Tables S12-S13, where detailed expression levels 
measured at all drug concentrations were listed. Adapted with permision from [10]. Copyright 2014 
American Chemical Society. 
 
No. Compound IL-6 IL-8 
1 Gentamicin 1.9 ± 0.1 1.0 ± 0.1
2 Tobramycin 1.5 ± 0.3 0.4 ± 0.0
3 Rifampicin 14.9 ± 5.3 87.5 ± 38.8
4 Tetracycline 16.5 ± 5.4 29.0 ± 10.4
5 Puromycin 1252.9 ± 126.5 2765.7 ± 23.6
6 Cephalosporin C 6.8 ± 0.4 3.2 ± 0.5
7 5-Fluorouracil 2.1 ± 0.3 4.3 ± 0.2
8 Cisplatin 2.1 ± 0.0 2.3 ± 0.2
9 Ifosfamide 1.2 ± 0.1 0.9 ± 0.1
10 Paraquat 8.4 ± 1.5 1.8 ± 0.5
11 Arsenic(III) oxide 8.7 ± 0.2 0.5 ± 0.0
12 Bismuth(III) oxide 42.7 ± 2.5 36.1 ± 1.2
13 Cadmium(II) chloride 7.6 ± 0.4 7.4 ± 0.5
14 Copper(II) chloride 10.2 ± 0.6 7.9 ± 0.4
15 Germanium(IV) oxide 1.0 ± 0.1 1.1 ± 0.1
16 Gold(I) chloride 46.4 ± 5.6 71.6 ± 26.2
17 Lead acetate 27.8 ± 3.0 3.9 ± 0.1
18 Potassium dichromate 1.5 ± 0.3 0.9 ± 0.1
19 Tacrolimus 45.2 ± 13.8 549.3 ± 46.2
20 Cyclosporin A 36.1 ± 10.4 242.2 ± 4.8
21 Citrinin 6.0 ± 1.4 3.5 ± 1.8
22 Tenofovir 1.5 ± 0.2 3.0 ± 0.2
23 Vancomycin 2.4 ± 0.2 3.5 ± 0.4
24 Phenacetin 0.7 ± 0.3 1.2 ± 0.6
25 Acetaminophen 0.9 ± 0.1 1.1 ± 0.2
26 Ibuprofen 0.7 ± 0.1 0.4 ± 0.0
27 Furosemide 1.6 ± 0.0 7.4 ± 1.3
28 Lithium Chloride 1.1 ± 0.1 1.0 ± 0.3
29 Lindane 0.9 ± 0.4 0.1 ± 0.0
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30 Ethylene glycol 1.2 ± 0.0 1.1 ± 0.1
31 Valacyclovir 3.2 ± 0.1 2.1 ± 0.1
32 Lincomycin 1.3 ± 0.1 1.0 ± 0.1
33 Ciprofloxacin 54.8 ± 2.9 21.3 ± 0.9
34 Ribavirin 1.1 ± 0.1 1.0 ± 0.1
35 Glycine 1.1 ± 0.2 0.8 ± 0.0
36 Dexamethasone 1.0 ± 0.1 1.1 ± 0.0
37 Melatonin 1.0 ± 0.1 2.2 ± 0.5
38 Levodopa (DOPA) 3.8 ± 0.2 0.9 ± 0.0
39 Triiodothyronine 1.8 ± 0.1 1.6 ± 0.7
40 Acarbose 1.2 ± 0.2 1.1 ± 0.1
41 Atorvastatin 12.7 ± 0.8 6.6 ± 1.4
 
The analysis of the data was performed in a similar procedure as described in 4.3. True positives 
(TP), true negatives (TN), sensitivity and specificity were defined as shown in Fig. 1. Results for 
all cut-off values in the range of 0.1 ~ 5.0 are listed in Table 14 and are graphically illustrated in 
Fig. 15 a, which also shows the overall concordance with human clinical data. The results show 
that a cut-off value of 4.0 was optimal for hESC-derived HPTC-like cells. At this value the 
highest sensitivity (68%) and specificity (84%) could be achieved (Table 14, Fig. 15 a). 
Table 14. Determination of TP, TN, sensitivity and specificity in hESC-derived HPTC-like cells. 
Adapted with permission from [10]. Copyright 2014 American Chemical Society. 
Cut-Off TP Sensitivity TN Specificity
0.1 22 100% 0 0% 
1.0 22 100% 2 11% 
1.5 20 91% 11 58% 
2.0 17 77% 12 63% 
2.5 16 73% 13 68% 
3.0 16 73% 13 68% 
3.5 15 68% 14 74% 
4.0 15 68% 16 84% 
4.5 14 64% 16 84% 




Other major performance metrics were therefore also calculated at the cut-off value of 4.0. 
Balanced accuracy, PPV and NPV were calculated (see definitions in Fig. 1) and are displayed in 
Table 15. The performance metrics of cell types discussed in the previous section 4.3 (HPTCs, 
HK-2 and LLC-PK1 cells, as displayed in Table 11) are also included in Table 15 for 
comparison. hESC-derived HPTC-like cells displayed similar specificity (84%) and PPV (83%) 
as HPTCs (mean; 84% and 85%, respectively). With respect to all other performance metrics 
listed, the HPTC-like cells performed at slightly lower levels than HPTCs. However, it is worth 
noting that all values were still substantially higher than those obtained with the human and 
animal PT-derived cell lines (HK-2 and LLC-PK1; at their respective optimal cut-off values), 
suggesting that hESC-derived HPTC-like cells can potentially serve as a viable alternative to the 
commonly used cell lines in in vitro prediction of drug-induced PT toxicity. 
To further investigate the predictive performance of the hESC-derived HPTC-like cells, I also 
plotted the ROC curves (Fig. 15 b) and calculated the AUC values (Table 15). The AUC values 
suggested that when both marker genes were used as the endpoint, HPTC-like cells (0.80, or 80% 
in Fig. 15 b and c) had slightly lower predictivity than HPTC (mean = 0.85, Table 15) but 
performed better than the PT-derived cell lines (0.71 and 0.73). In addition, predictivity appeared 
to be better when only IL-6 expression was used as endpoint (AUC value of 82%; Fig. 15 b), as 





Figure 15. Sensitivity, specificity, overall concordance and ROC curves for hESC-derived HPTC-like 
cells. (a) Graphical display of the sensitivity and specificity values shown in Table 15. The figure also 
shows the overall concordance of the results obtained in Table 13 with the PT toxicity of the compounds 
in humans as reported in literature (classification as listed in Table 1). Cut-off values (x-axis) ranged 
from 0.1 – 5.0. (b) The ROC curves were plotted using sensitivity and specificity values at all cut-off 
values indicated in Table 14, based on data listed in Table 13. ROC curves were plotted and AUC values 
calculated with respect to each single marker gene (gray curves) or the combination of both markers 
(black). The respective AUC values are indicated in the legend as percentages. An AUC value of 50% 
suggests random chance and an AUC value of 100% indicates perfect predictivity. (c) The ROC curves 
were plotted based on the results obtained with ATP depletion assay in both HPTC-like cells and HPTC 
(dashed and dotted gray curves) and GSH depletion assays (solid gray graph). The ROC curve for the 
combinatorial endpoint of IL-6 and IL-8 is also displayed here for comparison (black curve; identical to 
that in panel b). The respective AUC values (%) are indicated in the legend. Adapted with permission 
from [10]. Copyright 2014 American Chemical Society. 
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Table 15. Summary of results obtained with different endpoints and cell types. Asterisks indicate data 
that had been listed earlier in Table 11. Cell death data were derived from Table 12. Adapted with 
permission from [10] (Supplementary Information) with addition of data on hiPSC-derived HPTC-like 
cells. Copyright 2014 American Chemical Society. 












HPTC 1* 0.91 0.90 0.90 0.91 0.94 0.94 
HPTC 2* 0.77 0.84 0.81 0.85 0.76 0.81 
HPTC 3* 0.64 0.79 0.71 0.78 0.68 0.82 
HPTC mean* 0.77 0.84 0.81 0.85 0.79 0.85 
HPTC median* 0.77 0.84 0.81 0.85 0.76 0.82 
HK-2* 0.50 0.79 0.65 0.73 0.60 0.71 
LLC-PK1* 0.64 0.74 0.69 0.74 0.67 0.73 
hESC-derived 
HPTC-like 0.68 0.84 0.76 0.83 0.70 0.80 
 hiPSC-derived HPTC-like 0.77 0.74 0.75 0.77 0.74 0.76 
ATP 
Depletion 
HPTC-like 0.48 0.79 0.63 0.71 0.58 0.65 
HPTC 1 0.50 0.74 0.62 0.69 0.56 0.65 
GSH 
Depletion HPTC 1 0.45 0.74 0.60 0.67 0.54 0.60 
LDH 
Leakage HPTC 1 0.64 0.58 0.61 0.64 0.58 - 
Cell 





4.4.2 Comparison to standard toxicity assays  
In order to compare the predictive performance of the IL-6/IL-8-based assay with widely used 
standard toxicity assays, ATP depletion assays were performed with HPTC and HPTC-like cells 
using the same set of 41 test compounds at the same concentrations. ATP depletion is widely 
used for studying organ-specific toxicity, including nephrotoxicity [45, 138]. Examples of results 
obtained with some of the compounds are shown in Fig. 16 (upper row). HPTC 1, which was the 
best performing HPTC batch with the IL-6/IL-8-based assay, was used at the same passage 
numbers (P4 and P5) in the ATP depletion assay. These results showed that when HPTC 1 were 
treated with PT-specific nephrotoxicants such as copper (II) chloride, there was in some cases a 
drastic decrease in the percentage cellular ATP content with increasing compound concentration. 
When CuCl2 was applied at concentrations ≥ 500 g/ml, complete depletion of cellular ATP was 
observed. In contrast, when cells were treated with a non-PT-specific nephrotoxicants or a non-
nephrotoxic compound, such as lithium chloride and glycine, cellular ATP content remained 
often largely unaffected in the tested concentration range. IC50 values of all compounds were 
subsequently calculated and are displayed in Table 16. In cases where the IC50 values were 
below the highest tested concentration (1000 μg/ml), the compounds were defined as positives. 
Based on the number of positive compounds, sensitivity and specificity values were calculated 
and displayed at the bottom of Table 16.  
Table 16 shows that in the ATP depletion assay, HPTC and HPTC-like cells gave rise to 
comparable results. Most compounds which gave positive results (IC50 values < 1000 μg/ml) 
induced substantial ATP depletion in both cell types, and their overall sensitivity and specificity 
values were similar despite the differences in the exact magnitudes of the IC50 values (see 
bottom of Table 16). In particular, the IC50 values for compounds 5 and 6 (puromycin and 
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cephalosporin C) in HPTC-like cells were ~2-3 orders of magnitude lower than in HPTC. This 
observation is consistent with the fact that puromycin also induced exceptionally high levels of 
IL-6 and IL-8 induction in HPTC-like cells (Table 13), suggesting that this compound is indeed 






Figure 16. Dose-response curves obtained with the ATP depletion assay (upper row) and GSH depletion 
assay (lower row). HPTC 1 were treated with PT-specific nephrotoxicants (e.g. copper (II) chloride, left-
hand column), non-PT-specific nephrotoxicants (e.g. lithium chloride, middle column) or non-
nephrotoxic compounds (e.g. glycine, right-hand column) at concentrations indicated on the x-axis. The 
figures show percentage changes (mean ± s. d., n = 3) in cellular ATP or GSH content after drug 
treatment, as compared to the vehicle controls, which were set to 100%. 
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Table 16. Comparison of different assays performed with HPTC-like cells and HPTC 1. All assays were 
performed with the 41 compounds listed in Table 1 (numbered in the left column). Positive (+) and 
negative (-) results obtained with HPTC-like cells in the IL-6/IL-8-based assay at a cut-off value of 4.0 
are listed. The ATP depletion assay was performed with HPTC-like cells and HPTC 1 and IC50 values 
(g/ml) are listed. In cases where ATP levels remained above 50% of vehicle control up to the highest 
concentration tested (1000 g/ml), an IC50 value of > 1000 g/ml was indicated. The GSH depletion 
assay and LDH leakage assay were performed with HPTC 1. IC50 values are listed for the GSH assay. 
LDH leakage was presented as percentages of vehicle controls. Significant increases were marked with 
asterisks. All values represent the mean ± s. d. (n = 3). Sensitivity and specificity values are listed at the 
bottom for each assay. All results were classified as positive if the IC50 values were below 1000 g/ml 
(ATP depletion assay and GSH depletion assay) or when there was a significant increase in LDH leakage. 
Adapted with permission from [10]. Copyright 2014 American Chemical Society. 
Compound 
 HPTC-like HPTC 
 IL-6/IL-8 ATP Depletion 
ATP 
Depletion GSH Depletion LDH Leakage 
1  - > 1000 > 1000 > 1000 105% ± 13% 
2  - > 1000 > 1000 > 1000 110% ± 4%* 
3  + 981 ± 78 856 ± 22 769 ± 133 128% ± 4%* 
4  + > 1000 > 1000 > 1000 107% ± 2%* 
5  + 1 ± 0 13 ± 1 1 ± 0 106% ± 1%* 
6  + 1 ± 0 699 ± 243 837 ± 48 117% ± 5%* 
7  + > 1000 > 1000 > 1000 146% ± 7%* 
8  - 679 ± 16 889 ± 21 742 ± 17 104% ± 4% 
9  - > 1000 > 1000 > 1000 111% ± 5%* 
10  + 551 ± 129 875 ± 111 > 1000 111% ± 3%* 
11  + > 1000 > 1000 > 1000 115% ± 6%* 
12  + > 1000 > 1000 944 ± 133 108% ± 4%* 
13  + 82 ± 5 14 ± 5 > 1000 146% ± 6%* 
14  + 555 ± 53 315 ± 36 708 ± 4 100% ± 3% 
15  - > 1000 > 1000 > 1000 95% ± 2% 
16  + 229 ± 122 232 ± 4 869 ± 35  96% ± 1% 
17  + > 1000 > 1000 > 1000 109% ± 3%* 
18  - 4 ± 1 9 ± 1 81 ± 2 106% ± 22% 
19  + 654 ± 44 49 ± 5 54 ± 22 136% ± 29% 
20  + > 1000 371 ± 114 > 1000 105% ± 9% 
21  + ND > 1000 634 ± 100 109% ± 2%* 
22  - > 1000 > 1000 > 1000 118% ± 7%* 
23  - > 1000 > 1000 > 1000 102% ± 3% 
24  - > 1000 > 1000 > 1000 97% ± 4% 
25  - > 1000 > 1000 755 ± 8 90% ± 3% 
26  - 618 ± 6 858 ± 13 239 ± 125 102% ± 29% 
27  + > 1000 > 1000 > 1000 98% ± 4% 
28  - > 1000 > 1000 > 1000 95% ± 5% 
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29  - > 1000 > 1000 > 1000 110% ± 5%* 
30  - > 1000 > 1000 > 1000 107% ± 4%* 
31  - > 1000 > 1000 > 1000 109% ± 3%* 
32  - > 1000 > 1000 > 1000 108% ± 5% 
33  + > 1000 > 1000 733 ± 316 114% ± 13% 
34  - 667 ± 80 619 ± 330 > 1000 110% ± 3%* 
35  - > 1000 > 1000 > 1000 115% ± 2%* 
36  - > 1000 > 1000 > 1000 106% ± 3%* 
37  - 496 ± 59 > 1000 > 1000 101% ± 10% 
38  - 216 ± 111 94 ± 64 814 ± 12 113% ± 17% 
39  - > 1000 940 ± 3 541 ± 112 101% ± 25% 
40  - > 1000 > 1000 > 1000 110% ± 2%* 
41  + > 1000 907 ± 49 > 1000 122% ± 2%* 
Sensitivity  68% 48% 50% 45% 64% 
Specificity  84% 79% 74% 74% 58% 
      
 
Overall, the results obtained with the ATP depletion assay indicated that both the values for 
sensitivity and specificity obtained with either HPTC or HPTC-like cells were lower than the 
respective values obtained with the IL-6/IL-8-based assay. The sensitivity of the ATP depletion 
assay was particularly low (50% in HPTC and 48% in HPTC-like cells), and the IC50 values 
remained above 1000 μg/ml even with compounds that have demonstrated strong toxic effects in 
PTCs, such as arsenic (III) oxide (compound 11). To verify this unexpected result, I performed 
the ATP depletion assay with kits from two different vendors (see Materials and Methods) and 
the results remained negative. This is also consistent with the high false negative rate (~ 50%) 
obtained by measuring ATP depletion in a previous in vitro study addressing organ-specificity, 
including nephrotoxicity [45]. This conclusion was further confirmed by the analysis of the ROC 
curves (Fig. 15 c). Whereas AUC values of at least 80% (or 0.8, HPTC-like cells, Fig. 15 c; 
HPTC, Table 15) were obtained with the IL-6/IL-8-based assay, AUC values of only 65% (or 
0.65) were obtained with the ATP depletion assay with both cell types (Fig. 15 c; Table 15).  
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Another commonly used toxicity assay, the glutathione (GSH) depletion assay, was also 
performed for comparison with the IL-6/IL-8-based assay. GSH plays an important role in drug 
metabolism and protection against oxidative damages from reactive oxygen species in proximal 
tubular cells [18]. Here the same batch (HPTC 1) and passage numbers of HPTC were tested as 
previously used for determining ATP depletion. The results obtained with the GSH depletion 
assay were similar to those obtained with the ATP depletion assay (Fig. 16, bottom row; Table 
16). The sensitivity of the GSH depletion assay (45%) was even slightly lower than that of the 
ATP depletion assay (50%), whereas their specificity values were the same (74%, Table 16). The 
AUC of the ROC curve for the GSH depletion assay (60%) was also lower than that of the ATP 
depletion assay (65%), indicating an overall lower predictivity of the GSH depletion assay (Fig. 
15 c; Table 15). 
Lastly, a commonly used assay measuring cellular membrane damage was performed. This assay 
determines the degree of membrane damage induced by toxic compounds by quantifying the 
leakage of lactate dehydrogenase (LDH) from the cytoplasm. Here, the result of a test compound 
was designated as positive whenever there was a significant increase in LDH leakage as 
compared to the vehicle control (marked with asterisks in Table 16). Results obtained with 
HPTC 1 revealed that though the sensitivity (64%) was higher than those of the ATP depletion 
assay and the GSH depletion assay, the specificity value of the LDH leakage assay was only 
58%. This value was significantly lower than the respective values obtained with the other assays 
(> 70%, Table 16). The values for sensitivity and specificity were also lower than those of the 




4.4.3 Prediction of the PT toxicity of blinded compounds  
The results showed, so far, that the overall predictivity was highest when expression levels of the 
marker genes IL-6 and IL-8 were used as endpoints in combination with HPTC. HPTC-like cells 
are an alternative cell type with comparable predictivity which could overcome the limitations of 
relative scarcity and high costs associated with human primary cells. To further investigate the 
predictive performance of the model based on HPTC-like cells, blinded compounds were used to 
treat these cells. Based on the IL-6/IL-8 expression patterns their PT toxicity was predicted. 
Meanwhile, batch-to-batch variability of the HPTC-like cells was also addressed, by using a 
second batch of HPTC-like cells which had been differentiated from hESCs by a different 
colleague (Dr. Karthikeyan Kandasamy, IBN) about 6 months after the first batch was 
differentiated. The second batch of HPTC-like cells was also characterized by immunostaining 
of PT cell markers to ensure the quality of these cells [10]. 
In order to compare with results obtained earlier, blinded compounds were selected from the list 
of 41 compounds (Table 1). These compounds were added to cells by a colleague (Dr. 
Karthikeyan Kandasamy, IBN) and the identity of these compounds was only revealed to me 
after I had performed sample preparation, qPCR and data analysis. The blinded compounds were 
revealed to be cephalosporin C, tacrolimus and acarbose (compounds No. 6, 19 and 40). The 
range of concentrations tested was the same as in previous experiments. In addition, 
dexamethasone (100 μg/ml) and puromycin (100 μg/ml) were selected as negative and positive 
controls, respectively, to allow calculation of the Z’ values to monitor overall assay performance. 




Table 17. Results obtained with three blinded compounds and prediction of PT toxicity. Adapted with 
permission from [10]. Copyright 2014 American Chemical Society. 
Compound IL-6 Z’ IL-8 Z’ 
Prediction 
(Cut-Off = 4.0) 
6 3.9 ± 1.0 0.7 67.8 ± 23.1 1.0 + 
19 70.5 ± 10.5 0.9 206.1 ± 51.5 0.9 + 
40 2.4 ± 0.8 0.8 3.7 ± 1.2 0.8 - 
 
Table 17 displays the highest IL-6 and IL-8 expression levels obtained for the test compounds 
(the detailed results obtained at all tested concentrations are displayed in the appendix, 
supplementary data, Table S14). The cut-off value of 4.0 (fold changes in gene expression levels) 
as previously used for 41 test compounds with the first batch of HPTC-like cells was applied 
here for the prediction of PT toxicity of the blinded compounds. Based on this cut-off value 
compound 40 (acarbose) was correctly predicted to be non-toxic to cells of the renal PT in 
humans, whereas compounds 6 and 19 (cephalosporin C and tacrolimus) were correctly 
predicted to be toxic to this cell type (Table 17). These results are consistent to those obtained 
with the first batch of HPTC-like cells (Tables 16 and 17). 
Furthermore, these predictions were in agreement with clinical results of these compounds on PT 
toxicity. Tacrolimus has various negative effects on the human kidney, including direct toxic 
effects on renal proximal tubular cells [36, 139]. Cephalosporin antibiotics are semi-synthetic 
derivatives of cephalosporin C, and these compounds are substrates of the organic anion 
transport system of the proximal tubule. Several cephalosporins were found to be associated with 
acute tubular necrosis and there is a consistent risk of PT toxicity associated with cephalosporin-
derived compounds [140, 141]. Acarbose is an α-glucosidase inhibitor used for the improvement 
of glycemic control in adults with type 2 diabetes mellitus. Adverse effects on various human 
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organ systems including liver, lung and skin have been reported (see, for instance, 
http://chem.sis.nlm.nih.gov/chemidplus/cas/56180-94-0), but to the best of my knowledge, no 
adverse effects on the proximal tubules have been previously reported. Together, the results 
shown in sections 4.4.1 – 4.4.3 demonstrated for the first time that stem cell-derived HPTC-like 
cells can be used as an alternative cell type for in vitro nephrotoxicology. Similar predictivity can 
be achieved with HPTC-like cells and HPTCs, and the performance was in both cases better 
when IL-6/IL-8 expression was used as endpoint in comparison to standard assays. However, the 
use of hESCs is associated with ethical and legal issues as the harvesting of these cells involves 
the destruction of human embryos. To avoid such controversies, it would be more desirable to 
use human induced pluripotent stem cells (hiPSCs), which are reprogrammed adult cells [142, 






4.4.4 Predictive performance of hiPSC-derived HPTC-like cells 
Human iPS(Foreskin-4) cells were differentiated into HPTC-like cells over a period of 20 days 
using the same protocol as described for the differentiation of hESCs in [9]. Cell differentiation 
was performed by Dr. Wei Seong Toh (IBN). The hiPSC-derived HPTC-like cells had been 
cryopreserved before use. The same list of 41 test compounds (see Table 1) was used to validate 
the use of these cells in the IL-6/IL-8-based in vitro model. Drug treatment and qPCR procedures 
were performed as described in the previous sections. All results (IL-6 and IL-8 expression) were 
normalized to the respective vehicle controls and expressed as fold changes relative to the 
vehicle control. Detailed results on IL-6 and IL-8 expression for all concentrations of each test 
compound are listed in appendix, Supplementary Data, Tables S15 and S16. In these tables the 
highest levels of expression within the concentration range tested were highlighted for each 
compound. These highest values were summarized in Table 18. The definition of a positive 
result was the same as previously described: a result was classified as positive if the highest 
increase in gene expression of at least one of the two markers (IL-6/IL-8) was equal to or higher 
than a threshold value. In the case of hESC-derived HPTC-like cells, the analysis on the 










Table 18. Highest expression levels of IL-6 and IL-8 in hiPSC-derived HPTC-like cells. Cells were 
exposed to the 41 compounds (same as listed and numbered in Table 1) at concentrations ranging from 1 
g/ml and 1000 g/ml. This table lists the highest expression levels of both marker genes that were 
recorded at any concentration of a drug within this range. The values indicate the mean fold expression 
level with s.d. (n = 3) relative to vehicle controls. The highest expression levels shown here are 
highlighted in the appendix, Supplementary Data, Tables S15-S16, where detailed expression levels 
measured at all drug concentrations were listed. 
No. Compound IL-6 IL-8 
1 Gentamicin 86.0 ± 1.5 860.1 ± 30.9
2 Tobramycin 36.5 ± 7.0 86.3 ± 20.4
3 Rifampicin 27.3 ± 2.7 23.2 ± 1.5
4 Tetracycline 60.9 ± 15.6 4710.3 ± 1107.7
5 Puromycin 266.0 ± 22.2 964.2 ± 34.2
6 Cephalosporin C 4.0 ± 0.3 58.4 ± 16.5
7 5-Fluorouracil 12.6 ± 0.8 11.2 ± 1.3
8 Cisplatin 20.0 ± 1.6 0.3 ± 0.0
9 Ifosfamide 1.2 ± 0.2 1.9 ± 0.1
10 Paraquat 3.1 ± 0.9 3.3 ± 0.7
11 Arsenic(III) oxide 3.5 ± 0.5 3.8 ± 0.1
12 Bismuth(III) oxide 31.8 ± 2.0 4321.1 ± 254.3
13 Cadmium(II) chloride 11.0 ± 1.3 11.1 ± 0.9
14 Copper(II) chloride 96.5 ± 13.8 13.8 ± 1.2
15 Germanium(IV) oxide 2.3 ± 0.5 2.0 ± 0.6
16 Gold(I) chloride 23.0 ± 3.7 2.3 ± 0.2
17 Lead acetate 19.8 ± 0.7 58.7 ± 14.5
18 Potassium dichromate 0.7 ± 0.1 1.4 ± 0.3
19 Tacrolimus 61.7 ± 3.4 48.5 ± 3.3
20 Cyclosporin A 49.1 ± 6.4 1246.9 ± 70.5
21 Citrinin 5.2 ± 0.3 19.2 ± 7.7
22 Tenofovir 2.3 ± 0.5 0.3 ± 0.2
23 Vancomycin 2.2 ± 0.1 2.8 ± 0.0
24 Phenacetin 1.8 ± 0.3 3.0 ± 1.2
25 Acetaminophen 1.1 ± 0.1 1.0 ± 0.2
26 Ibuprofen 2.5 ± 0.4 0.4 ± 0.1
27 Furosemide 2.1 ± 0.4 2.8 ± 0.9
28 Lithium Chloride 1.3 ± 0.1 1.9 ± 0.3
29 Lindane 1.6 ± 0.2 1.1 ± 0.1
30 Ethylene glycol 0.9 ± 0.1 1.2 ± 0.1
31 Valacyclovir 3.5 ± 0.4 20.0 ± 1.8
32 Lincomycin 2.7 ± 0.4 9.2 ± 2.5
33 Ciprofloxacin 80.1 ± 7.6 1140.9 ± 74.3
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34 Ribavirin 1.1 ± 0.1 1.1 ± 0.2
35 Glycine 1.9 ± 0.1 6.1 ± 1.0
36 Dexamethasone 1.1 ± 0.2 1.2 ± 0.1
37 Melatonin 1.9 ± 0.1 1.8 ± 0.1
38 Levodopa (DOPA) 1.6 ± 0.3 1.8 ± 0.3
39 Triiodothyronine 0.8 ± 0.0 2.8 ± 0.2
40 Acarbose 1.0 ± 0.0 1.3 ± 0.1
41 Atorvastatin 72.2 ± 14.6 86.1 ± 35.9
 
The analysis of these data was performed with a similar procedure as described in 4.3 and 4.4.1. 
True positives (TP), true negatives (TN), sensitivity and specificity were defined as shown in Fig. 
1. The results for all cut-off values in the range of 0.3 - 5.0 are displayed in Table 19 and are 
graphically illustrated in Fig. 17 a, which also shows the overall concordance with human 
clinical data. The results show that a cut-off value of 3.5 is optimal for these hiPSC-derived 
HPTC-like cells, where both sensitivity and specificity values were above 70% (Table 19, Fig. 
17 a). 
Table 19. Determination of TP, TN, sensitivity and specificity in hiPSC-derived HPTC-like cells 
Cut-Off TP Sensitivity TN Specificity
0.3 22 100% 0 0% 
1.0 22 100% 0 0% 
1.5 21 95% 5 26% 
2.0 20 91% 9 47% 
2.5 18 82% 9 47% 
3.0 18 82% 13 68% 
3.5 17 77% 14 74% 
4.0 16 73% 14 74% 
4.5 16 73% 14 74% 






Other major performance metrics such as PPV (0.77), NPV (0.74) and balanced accuracy (0.75) 
were also calculated at the cut-off value of 3.5 and are summarized in Table 15. Furthermore, the 
receiver operating characteristic (ROC) curve was plotted and its AUC was 76% (Fig. 17 b, or 
0.76 in Table 15). Together, the results showed that the predictive performance of hiPSC-derived 
HPTC-like cells was close to that of hESC-derived HPTC-like cells. The results (Table 15) also 
showed that the performance of hiPSC-derived HPTC-like cells was better than the performance 
of standard PT cell lines (IL-6/IL-8-based endpoint). Further, the predictive performance was 
better than the performance of HPTCs or hESC-derived HPTC-like cells in combination with 
standard endpoints (Table 15). 
Figure 17. Sensitivity, specificity, overall concordance and ROC curve for hiPSC-derived HPTC-like 
cells. (a) Graphical display of the sensitivity and specificity values shown in Table 19. The figure also 
shows the overall concordance of the results with the PT toxicity of the compounds in humans as 
reported in literature (classification as listed in Table 1). Cut-off values (x-axis) ranged from 0.3 – 0.5. 
(b) The ROC curve was plotted using sensitivity and specificity values at all cut-off values as indicated 
in Table 19. The AUC value of the ROC curve was calculated with respect to the combination of both 
IL6 and IL8 expression and is indicated as percentage. A diagonal line representing an AUC value of 
50% was displayed for comparison. 
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Together, these results showed for the first time that the use of iPSC-derived HPTC-like cells is a 
viable alternative that could circumvent the ethical concerns associated with hESCs, without 
severely compromising the predictive performance of the current in vitro model. However, it is 
worth noting that qPCR-based characterization of these hiPSC-derived HPTC-like cells 
(performed by fellow colleagues in the lab) revealed differences in the expression of certain renal 
cell markers and drug transporters as compared to HPTCs in vitro (also applies to hESC-derived 
HPTC-like cells, see [10]). For example, hiPSC-derived HPTC-like cells showed low expression 
levels of efflux drug transporters (data not shown). Although such features could be due to in 
vitro culturing conditions, as previously observed [8, 9, 65, 87], they suggest that more extensive 
optimization of the differentiation procedures can possibly further enhance cell performance, 
which could potentially translate into even higher predictivity. A more extensive study on 
improving hiPSC-derived HPTC-like cells by modifying differentiation protocols and 
incorporation of bioinformatics algorithms in the data analysis is currently in progress and a 
manuscript has been recently submitted for review (see appendix iii, list of publications). As my 
contributions in this work were limited to supervising intern students and data analysis, a 
detailed report is beyond the scope of this thesis and therefore not included here. 
In conclusion, stem cell-based approaches appear to be viable alternatives to the use of primary 
cells and cell lines in in vitro nephrotoxicology. It remains highly intriguing that the IL-6/IL-8-
based endpoint consistently yielded high predictivity, although underlying mechanistic 
information was still lacking. In another study of our group, we found that nuclear translocation 
of NF-B was often observed in cases where PTCs were treated with PT-specific 
nephrotoxicants (data not shown), and there was a strong correlation with the positive results 
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from the IL-6/IL-8-based model. In order to provide mechanistic insights into pro-inflammatory 
pathways triggered by nephrotoxicants, it was thus important to further investigate the 
relationships between nuclear translocation of NF-B and IL-6/IL-8 up-regulation in PTCs. This 




4.5 Molecular and cellular mechanism of drug-induced IL-6/IL-8 expression in renal PTCs 
4.5.1 Puromycin-induced nuclear translocation of NF-B and IL-6/IL-8 expression 
As shown by data from a separate on-going study from our group, PT-specific nephrotoxicants 
often lead to nuclear translocation of NF-B in HPTCs (data not shown). It has also been shown 
in other cell types that IL-6 and IL-8 are target genes of NF-B, and the p65 (also called RelA)  
subunit of NF-B is essential for the up-regulation of these interleukins [144-146]. Thus, I 
hypothesized that drug-induced up-regulation of IL-6/IL-8 expression in human renal proximal 
tubular cells is mediated by the NF-B pathway. To test this hypothesis, I first examined drug-
induced nuclear translocation of NF-B by performing immunostaining of the p65 subunit. 
HPTCs and HK-2 cells were examined after overnight exposure to puromycin, which is a PT-
specific nephrotoxicant also used in the previous sections of this thesis (compound 5, Table 1). It 
was selected here due to its high efficacy in inducing high levels of IL-6/IL-8 expression in 
various PT-derived cell types and batches as shown in previous sections 4.3 and 4.4. 
Immunostaining results showed that in untreated HK-2 cells and HPTCs, NF-B p65 (as 
indicated by the green fluorescence) was localized primarily in the cytoplasm of cells (Fig. 18 a, 
c). In contrast, after cells were treated with puromycin (100 g/ml) for 16h, there was a decrease 
in the fluorescence level in cytoplasmic area of both HK-2 cells and HPTCs (Fig. 18 b, d), and 
cell nuclei of both cell types became enriched with green fluorescence, indicating nuclear 
translocation of NF-B p65. Translocation was observed in only part of the HK-2 cells (some 
indicated by arrowheads in Fig. 18 b), whereas in HPTC almost all cell nuclei were brightly 
stained with green fluorescence (Fig, 18 d). This difference indicated a more efficient induction 




The analysis results showed that percentage of positive cells increased from 13% to 68% in HK-
These results confirmed that treatment with puromycin could indeed lead to nuclear translocation 
of NF-B p65 in renal PTCs, in which puromycin-induced up-regulation of IL-6/IL-8 expression 
as previously observed (Tables 5, 6, 13, 18). The co-occurrence of these two effects suggested 
that puromycin was a suitable PT-specific nephrotoxicant to be used in the subsequent gene 
knockdown and inhibitor studies, for further investigations on the relationships between these 
two events.  
 
  
Figure 18. Immunostaining of NF-B p65 in HK-2 cells (a and b) and HPTC (c and d). Cells were 
either treated with the vehicle control (a and c) or puromycin (100 g/ml; b and d). Arrowheads in (b) 
indicate examples of cell nuclei with strong staining of NF-B p65. Scale bars: 100 m. 
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4.5.2 Effects of p65 silencing on nuclear translocation of NF-B and IL-6/IL-8 expression 
To investigate whether the previously observed up-regulation of IL-6/IL-8 expression after 
overnight exposure to puromycin (in primary and immortalized human renal PTCs and stem cell-
derived HPTC-like cells , Tables 5, 6, 13 and 18) was mediated by the NF-B pathway, I next 
performed siRNA transfection with HPTCs and HK-2 cells to silence NF-B p65 expression. 
The siRNA used here (see Materials and Methods) had complementary sequence to the mRNA 
of NF-B p65, and therefore when transfected into cells, would bind to the single-stranded 
mRNA. The resultant double-stranded RNA molecule would then be targeted for degradation 
[147], leading to a reduced level of p65 mRNA being translated in the transfected cells. These 
experiments were performed to find out whether a reduction in the cellular levels of functional 
NF-B p65 heterodimers could lead to inhibition of puromycin-induced up-regulation of IL-
6/IL-8 expression. 
The protein levels of p65 in HPTCs and HK-2 cells were examined by western blotting after 
siRNA-mediated gene silencing. Results showed that there was substantial decrease in levels of 
p65 protein in both HPTC and HK-2 cells after siRNA transfection as compared to the negative 
controls (Fig. 19 A, B). On the other hand, p65 levels in HPTCs and HK-2 cells transfected with 
non-target siRNA or siRNA targeting the GAPDH mRNA remained comparable to non-
transfected controls. Densitometric analysis of these results revealed that there was a ~ 50% and 
~ 81% reduction in HPTCs and HK-2 cells respectively, after transfection with p65-specific 
siRNA (Fig. 19 C, D). The negative controls for HPTC remained ~ 100% of non-transfected 
cells, but HK-2 cells transfected with non-target siRNA also exhibited ~ 31% reduction in p65 
expression, indicating the possibility of unspecific silencing in HK-2 cells.  
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Furthermore, I performed immunostaining of p65 in HK-2 cells after siRNA transfection, with or 
without puromycin treatment (100 g/ml). Immunostaining results revealed that in the untreated 
HK-2 cells, p65 protein (detected by green fluorescence) was primarily localized in the 
cytoplasm (Fig. 20 C). Cells transfected with p65-specific siRNA showed overall substantially 
lower levels of green fluorescence as compared to the controls (Fig. 20 A), indicating effective 
silencing of p65 expression. However, after cells had been treated with puromycin overnight, 
cytoplasmic p65 translocated into the nuclear region in all cases, including HK-2 cells 
transfected with p65-specific siRNA (Fig. 20 D-F). This shows that although siRNA transfection 
could reduce the overall level of p65 in the cells, it could not prevent residual p65 from 
Figure 19. Detection of p65 by immunoblotting in protein lysates of (A) HK-2 cells and (B) HPTCs. NT: 
non-target control; GAPDH: glyceraldehyde 3-phosphate dehydrogenase. The upper row of protein 
bands represents p65 and the lower row of bands represents -tubulin, the loading control. Panels C 
(HK-2) and D (HPTC) show relative protein levels of p65 quantified by densitometric analysis of the 
western blotting results, after normalization to loading controls. Asterisks indicate statistical significance 
(P < 0.05). 
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translocating into the nuclear region when cells were stimulated with puromycin (note also that 
the western blots showed the presence of residual p65 protein (Fig. 19 A, B)). 
Also high content analysis of these images revealed that there was a substantial decrease in p65 
protein levels in both nuclear and cytoplasmic regions as a result of transfection with p65-
specific siRNA (Fig. 20 G, blue bars), confirming successful knockdown of the p65 protein. 
However, when cells were treated with puromycin overnight, there was a substantial increase in 
nuclear p65 as compared to the untreated cells. This observation applied to all transfection 
conditions, including cells transfected with p65-specific siRNA. Fig. 20 H shows that the 
percentage of cells positive for nuclear translocation of NF-B increased from ~ 20% to ~ 90% 
after puromycin treatment, and there was no significant difference in such response among 
different transfection conditions and controls. The nuclear p65 / cytoplasmic p65 ratios were all 
< 1 in untreated cells, regardless of the transfection conditions. However, when cells were treated 
with puromycin overnight, this ratio increased to > 1.5 in all cases, indicating effective nuclear 
translocation of NF-B regardless of the knockdown (Fig. 20 I, blue bars). Together, these 
results suggest that partial knockdown of p65 had no observable inhibitory effects on nuclear 






Figure 20. Immunostaining of p65 in HK-2 cells (A-F). Green: p65 subunit of NF-B; Blue: DAPI 
staining of cell nuclei. Panels A-C show images of HK-2 cells without drug treatment. Panels D-F show 
images of HK-2 cells after overnight exposure to puromycin (100 g/ml). Cells in Panels A and D were 
transfected with p65-specific siRNA; B and E show cells transfected with non-target (NT) siRNA; C and 
F show non-transfected cells. G shows the mean fluorescence intensity of p65 protein levels in both 
cytoplasmic and nuclear regions of untreated or puromycin-treated cells under different transfection 
conditions. H shows the mean percentage of cells which show positive NF-B translocation. Panel I 
shows the mean values of nuclear p65 / cytoplasmic p65 ratio under different treatment and transfection 
conditions. The bars in G-I show mean values ± standard deviation (s.d.; n = 3). 
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Next, I examined the effects of siRNA-mediated knockdown of p65 on puromycin-induced IL-
6/IL-8 expression by qPCR. Fig. 21 shows relative expression levels of IL-6 and IL-8 in both 
HK-2 cells (A) and HPTCs (B). All data shown here were normalized to those of untreated 
control cells, which were set to 1 (not shown). The results show that in puromycin-treated 
HPTCs, cells transfected with p65-specific siRNA had a significantly higher mean relative 
expression level of IL-6 (~ 12) than cells transfected with non-target siRNA (~ 4) and non-
transfected controls (~ 4). This observation shows that silencing of p65 by siRNA transfection 
had an enhancing effect on IL-6 expression, which was contradictory to the expected results. On 
the other hand, mean relative expression level of IL-8 (2.6) was just marginally lower than those 
of the negative controls (3.1 and 3.5). Results on HK-2 cells were similar to those of HPTCs, 
except that there was no further enhancement in drug-induced IL-6 expression in p65 siRNA-
transfected cells. Together, these results showed that partial silencing of p65 expression did not 
have a clear inhibitory effect on puromycin-induced IL-6/IL-8 expression. This observation was 
consistent with the absence of inhibitory effects on nuclear translocation of NF-B in cells 
transfected with p65-specific siRNA. Therefore, it was tested whether inhibition of nuclear 
translocation of NF-B would be a better approach for studying the relationships with drug-




Figure 21. Marker gene expression levels determined by qPCR in HK-2 cells (A) and HPTC (B) after 
overnight exposure to puromycin (100 g/ml). Gene expression levels were displayed as fold changes and 
normalized to untreated cells (set to 1, not shown) under each transfection condition. Cells were transfected 
with either p65-specific siRNA (blue bars) or non-target (NT) siRNA (red bars). Non-transfected water 




4.5.3 Effects of inhibition of nuclear translocation of NF-B 
Since siRNA-mediated silencing of p65 did not have an inhibitory effect on puromycin-induced 
expression of IL-6 and IL-8, I next performed inhibition of nuclear translocation of NF-B p65 
in HK-2 cells and HPTCs. This was achieved by inhibiting IB kinase (IKK), by using 
commercially available IKK inhibitors BAY 11-7082 and BAY 11-7085. When IKK is inhibited, 
IBremains unphosphorylated and bound to the NF-B homo- or heterodimeric complexes, 
masking their nuclear localization sequence (NLS) and preventing their translocation into cell 
nuclei [148, 149]. 
First, I confirmed the inhibitory effect of BAY 11-7085 on nuclear translocation of NF-B p65 
by immunostaining and subsequent image analysis. Fig. 22 A shows that only ~ 12% of 
untreated HK-2 cells were positive for nuclear translocation of NF-B p65. Overnight exposure 
to puromycin (100 g/ml) sharply increased this percentage to ~ 65%. Fig. 22 C shows a 
corresponding increase in the nuclear p65 / cytoplasmic p65 ratio from 0.6 to 1.4, confirming 
active nuclear translocation of NF-B p65 in the HK-2 cells exposed to puromycin. In cases 
where 5 M (grey bars in Fig. 22) and 20 M (white bars) of BAY 11-7085 was added during 
puromycin treatment, the percentage of positive cells fell slightly from 65% to 55% (Fig. 22 A) 
and the nuclear / cytoplasmic p65 ratio changed from 1.4 to 1.1 (Fig. 22 C), showing a moderate 
inhibitory effect of BAY 11-7085 on puromycin-induced nuclear translocation of NF-B in HK-
2 cells. Furthermore, when tumor necrosis factor alpha (TNF-, 100 ng/ml) was used to enhance 
the effects of puromycin, I observed further increases in the percentage of positive cells to > 90% 
and an intensity ratio of 2.4 in the absence of any inhibitor. In this case, both parameters 
remained at such levels when 5 M of BAY 11-7085 was added to cells. Only a higher 
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concentration of the inhibitor (20 M) was able to reduce the combined effects of puromycin and 
TNF-, leading to significant decreases in both parameters to 70% and 1.2, respectively. TNF- 
alone did not have any effects on the nuclear translocation in HK-2 cells when used at this 
concentration. 
On the other hand, untreated HPTCs already appeared to be in a partially stimulated state and 40% 
Figure 22. Percentage of cells classified as positive for nuclear translocation of NF-B p65 and nuclear 
p65 / cytoplasmic p65 ratio in HK-2 cells (A, C) and HPTC (B, D). Cells were treated with puromycin 
(100 g/ml) or TNF- (100 ng/ml) or both as displayed on the x-axis. BAY 11-7085 was used at 5 M 
(grey bars) or 20 M (white bars). Black bars represent uninhibited cells. The bars show the mean ± s.d. 







of the cells were positive for nuclear translocation of NF-B p65 even in the absence of 
puromycin (Fig. 22 B). The average nuclear NF-B p65 / cytoplasmic NF-B p65 intensity ratio 
of 0.9 (and 1.3 in the presence of 5 M BAY-11 7085; Fig. 22 D) was also higher than that 
observed in HK-2 cells (0.4 ~ 0.5). However, when exposed to puromycin, HPTCs were also 
more sensitive than HK-2 cells: percentage of positive cells and nuclear / cytoplasmic p65 ratio 
increased to 100% and 2.9 respectively when treated with puromycin (100 g/ml). Addition of 5 
M of BAY 11-7085 was able to decrease the intensity ratio to 1.7 but the percentage of positive 
cells remained at 100%. This observation reflected that though there was a quantitative reduction 
in nuclear translocation of NF-B p65, there was no qualitative change in terms of classifying 
the cells as positive or negative (see definition in Materials and Methods). TNF-did not lead to 
further increases in either endpoint, but again prevented the inhibitor (5 M) from quenching the 
intensity ratio, which remained > 2.5 when cells were treated with puromycin and TNF-. A 
higher concentration of BAY 11-7085 (20 M) could not be used in this case as it induced 
massive cell death in HPTCs (data not shown). 
Together, these results suggested that BAY 11-7085 indeed had an inhibitory effect on drug-
induced nuclear translocation of NF-B p65 in human renal proximal tubular cells, and such 
effect could be antagonized by TNF-, which enhanced the stimulating effect of puromycin. 
Next, I performed qPCR to examine the effects of IKK inhibitors on drug-induced expression of 
IL-6 and IL-8. Fig. 23 shows relative gene expression levels of IL-6 and IL-8 in HK-2 cells (Fig. 
23 A, B) and HPTCs (Fig. 23 C, D). An additional IKK inhibitor, BAY 11-7082 was used here 
for comparison (Fig. 23 B, D). All data were normalized to untreated controls. 
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In HK-2 cells, there was significant reduction in puromycin-induced expression levels of both 
IL-6 (from 12.8 to 8.3) and IL-8 (from 7.8 to 4.7) when 10 M of BAY 11-7085 was used (Fig. 
23 A). BAY 11-7082 (5 M) also led to similar inhibitory effects on expression levels of both 
marker genes (Fig. 23 B). In HPTCs, the effects of both inhibitors (BAY 11-7085: 10 M and 
BAY 11-7082: 5M) were much more drastic. Drug-induced up-regulation of IL-6/IL-8 
expression was almost entirely inhibited (Fig. 23 C, D). 
Figure 23. IL-6 and IL-8 gene expression levels determined by qPCR in (A, B) HK-2 cells and (C, D) 
HPTCs. Gene expression levels were displayed as fold changes and normalized to the untreated cells (set 
to 1; black bars). White bars show marker expression levels in cells treated with puromycin (100 g/ml) 
overnight, in the presence or absence of BAY 11-7085 (10 M; A, C) and BAY 11-7082 (5 M; B, D). 
The bars show the mean ± s.d. (n = 3).  
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Together, these data provided strong evidence that nuclear translocation of NF-B p65 was 
upstream with respect to up-regulation of IL-6 and IL-8 expression on the same pathway, as 
inhibition of the translocation event by IKK inhibitors could lead to inhibition of IL-6 and IL-8 
expression. These results highlight the essential role of the NF-B pathway in drug-induced 
interleukin expression, especially in human primary renal proximal tubular cells. Together, the 
results provide mechanistic insights into the pathway activated in human renal proximal tubular 
cells by nephrotoxic drugs, and at the same time identified useful endpoints for in vitro 




5.1 Effects of substrate stiffness on primary human endothelial and renal cells 
As described in the previous sections, an in vitro model for the prediction of drug-induced 
nephrotoxicity has been developed. The first step was to determine a suitable culturing substrate 
for HPTCs. Here I used HUVECs and HPTCs to evaluate various materials of different stiffness 
and with a variety of other different features [5]. The results revealed that there was strong 
correlation between substrate stiffness and the performance of these primary cell types. TCPS 
and CG appeared to be the most suitable materials for the in vitro nephrotoxicity model.  
 
Although it was well established that surface chemistry and wettability were the major factors 
that affect the proliferation and performance of somatic cells and embryonic stem cells [150-157], 
the effects of substrate stiffness were variable. For example, there have been studies suggesting 
that high substrate stiffness promotes adhesion of HDFs [158] as well as proliferation and 
migration of epidermal keratinocytes [159]. In contrast, softer substrates promote myoblast 
differentiation [160]. More interestingly, while soft materials promotes the differentiation of 
neural stem cells into neurons, stiffer materials directs formation of glial cells [161]. These 
findings indicate that different cell types display vastly different stiffness-dependent responses 
when cultured in vitro. 
 
With respect to the results described in Section 4.1, HUVECs displayed high sensitivity to the 
stiffness of different culturing substrates. Endothelial cells are a mechanosensitive cell type [162, 
163] and they are constantly subjected to mechanical stimuli such as shear stress and hydrostatic 
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pressure of blood flow. When cultivated on TCPS and CG, HUVECs could exert greater force on 
the stiff substrates as compared to softer substrates, and this was reflected by the formation of 
actin stress fibres (see  Section 4.1) similar to those formed in vivo in endothelial cells [111, 112]. 
It was found that in endothelial cells, actin stress fibres regulate the activation of 
mechanosensitive channels [164, 165], which play an important role in mechanotransduction. 
One of the outcomes of mechanotransduction is stabilization of cell adhesion to the substrate 
[166]. Therefore, the lack of actin stress fibre formation on compliant substrates explains the 
substantially reduced numbers of cells attached and the compromised cell performance on TX 
and PC-1 as compared to TCPS and CG. 
 
HPTCs are constantly exposed to the fluid shear stress of the glomerular filtrate in vivo. Studies 
have shown that in mouse renal proximal tubular cells, the brush border microvilli on the apical 
surface appeared to play an important role in mechanosensing [167, 168]. Adhesion onto a stiff 
culturing substrate in vitro (in a static culture) can possibly compensate for the force required for 
actin stress fibre formation and subsequent mechanotransduction events. This could thus explain 
why, as described earlier, HPTCs performed better on stiff PLA films as compared more 
compliant electrospun PLA membranes in terms of proliferation and epithelium formation. 
 
Although substrate stiffness appeared to be the major factor here affecting the performance of 
HUVECs and HPTCs in static cultures, it might be that the effects of other parameters such as 
surface chemistry also play a role. Cells integrate all environmental cues, including physical and 
chemical properties of the underlying substrates. Proper cell performance can only be achieved if 
the combinatorial effects from these environmental cues are favorable. My results indicated that 
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simple static cultivation on uncoated TCPS was sufficient for proper differentiation and 
proliferation of HPTCs, and no other substrates could be identified where HPTC performance 
was better [5] (see also further explanations on page 45). This conclusion was also repeatedly 
confirmed by data from colleagues working on different types of gels with tunable stiffness and 
other synthetic substrates. It regularly turned out that HPTC performance on the TCPS controls 
was better than on gels with tunable properties and other substrates (unpublished work). 
However, the work on gels with tunable stiffness confirmed that substrate stiffness is a major 
determinant of HPTC and HUVEC performance (for full picture with extensive material 
characterization see [5]), and increasing gel stiffness correlated with improved cell performance. 
In addition, it is also most straightforward to work with TCPS (readily available in most tissue 
culture vessels such as multi-well plates). Therefore, I subsequently applied these cell culture 




5.2 Cell type-specific responses to toxicants in cultured primary cells 
As mentioned in the Results, layered clays are frequently used as the hemostatic agent in wound 
dressings [113, 114] and they have profound cytotoxic effects on different cell types [115-117]. 
MCF-26 demonstrated similar hemostatic potency as commercial hemostatic materials [118] but 
its cytotoxicity in human cell types has not been well characterized. Here, the cell type-specific 
cytotoxicity of MCF-26 and layered clays with hemostatic properties has been addressed by 
using various human primary cell types and two well-characterized standard call lines for 
comparison. Cell viability was investigated in vitro after exposure to the different compounds. 
The results based on NRU assays revealed that the cytotoxic effects of test compounds were 
strongly cell type-dependent. This is in accordance with other studies which showed similar cell 
type-specific toxic effects of layered clays [115-117]. 
 
One limitation of the NRU assay is that the absorbance readings depend on lysosome numbers in 
the cells, and therefore it might not be suitable to test compounds which affect lysosomal uptake 
of the dye. However, the NRU assay was chosen to test cell viability in this model due to its 
greater sensitivity as compared to the standard tetrazolium-based viability assays [104, 169], and 
it is also recommended by the ISO standard 10993-5:2009 (E) as mentioned before in Section 3.6 
of this thesis. 
 
The high sensitivity of HUVECs towards the toxic effects of layered clays was not surprising, as 
previous studies showed that the smectite granule-based WoundStat (WS) has caused endothelial 
damage as well as other degenerative processes in vivo [170, 171]. WS was approved by the US 
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Food and Drug Administration (FDA) in 2007 but its use was halted soon afterwards due to 
reported thromboembolic risk [113, 171], which could be associated with the adhesiveness of 
layered clays as shown by my results in Section 4.2. Also in agreement with my results, it has 
been previously reported that aluminium silicates used in such hemostatic dressings have 
cytotoxic effects on HUVECs (and also murine macrophages), whereas epithelial cells were less 
affected [115]. It was argued that such expected toxic effects indicate that the standard in vitro 
safety tests based on fibroblast cultures are inadequate [171]. This claim was further confirmed 
by my results (as described in Section 4.2) which showed that the fibroblastic cell types tested 
were in general the least sensitive to the cytotoxicity of layered clays. In particular, the response 
in HDFs when treated with kaolin showed that even the highest concentration tested (250 g/ml) 
was still in the subtoxic range for HDFs, whereas cell viability was greatly reduced in HUVECs.  
If only fibroblasts were tested here, the cytotoxic effects of kaolin would have been greatly 
underestimated. Therefore, it is important to develop test systems that detect the toxicity of these 
compounds more reliably, as demonstrated here. 
 
Similar cell type-specific effects of MCF-26 were also observed here. However, MCF-26 was 
only mildly cytotoxic to all cell types tested, and the IC50 values were substantially higher than 
those of the layered clays. This strongly supports the hypothesis that MCF-26 could be a less 
toxic alternative to currently used hemostatic agents. Currently, the reason for the reduced 
cytotoxicity of MCF-26 is unclear.  
 
It appears that toxicity of layered clays requires direct contact between the clay particles and cell 
surface, and is not due to leaching of toxic ions or trapping of cell culture medium components 
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by layered clay materials [115]. Indeed, my data and a previous study [116] showed that layered 
clays adhered strongly to the cell surface. It has been suggested that the negative charge of 
layered clays played a role in their adherence onto cell surface and cytotoxicity [116]. My results 
showed that MCF-26 adhered less strongly to the cell surface despite the fact that its zeta 
potential was similar to kaolin and bentonite in cell culture medium (data not shown), and it was 
less cytotoxic. As such, weaker adherence of MCF-26 onto cell surface, which appeared 
unaffected by surface charges, might provide an explanation why it was less toxic to various cell 
types. 
 
In addition, the absence of cellular uptake of MCF-26 might also contribute to its reduced 
cytotoxicity. On the other hand, kaolin was rapidly taken up by HDFs and HUVECs. However, 
only HUVECs displayed susceptibility to the toxic effects of kaolin, suggesting that cell type-
specific response is not solely due to differences in cellular uptake of test compounds. This also 
applies to Ag NPs, which were taken up by both HDFs and HUVECs, but in this case cell type-
specific cytotoxicity was less clear due to larger batch-to-batch variation within HDFs. 
 
Nevertheless, with respect to all the cell types tested, clear cell type-specific cytotoxic effects 
were also observed with Ag NPs: HEKs were the most resistant to the cytotoxic effects in 
comparison to other cell types such as HUVECs or HDFs. This was in agreement with a previous 
in vivo study which reported that Ag NPs promoted proliferation and migration of keratinocytes 
during wound healing and caused significant cell death only when applied at concentrations 
above 100 M [172]. The same study also showed that although Ag NPs induced the 
differentiation of fibroblasts into myofibroblasts, which are often involved in the wound healing 
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process, there was a reduction in the cell number of fibroblasts in the presence of Ag NPs [172]. 
This was also in agreement with the observed cell death in HDFs (Section 4.2). Such cell type-
dependent sensitivity towards the toxic effects of Ag NPs appears to be related to the structural 
and functional aspects of the two cell types. HEKs are the predominant cell type of the epidermis, 
the protective outermost layer of the skin, whereas HDFs are found in the underlying dermis 
layer [173]. This could explain why Ag NPs can be widely used in topically applied antibacterial 
products without overwhelming safety issues [174-176]. Ag NPs are known to exert cytotoxic 
effects in a number of other cell types, supposedly due to generation of reactive oxygen species 
and release of Ag ions [177-179]. One of the reasons behind the cell type-specific cytotoxicity 
could be due to differences in antioxidant capacities of various cell types [180], and such 
intrinsic differences between cell types could in turn be a result of differential expression 
patterns of, for example, enzymes, membrane receptors and/or transporters. It is therefore 
essential to address such cell type-dependent responses towards drugs and chemicals, and to 
make sure that the most relevant cell type is employed in the development of in vitro models for 




5.3 Validation of an in vitro method for the prediction of drug-induced nephrotoxicity 
As explained above, here I have developed an in vitro model for the prediction of drug-induced 
nephrotoxicity in humans. The model was based on HPTCs, which are the most relevant cell 
type for such application. Standard human and animal cell lines, HK-2 and LLC-PK1 cells were 
also used for comparison. The endpoints used were expression levels of IL-6 and IL-8, and 41 
test compounds were used to validate the model. Results revealed that when three batches of 
HPTCs were used, the mean and median values for the major performance metrics (see Section 
4.3) were highest and ranging between 0.76 and 0.85. These values suggested high predictivity 
of the model and it would be expected that 76% ~ 85% of the predictions made regarding the PT-
specific toxicity of test compounds would be accurate. 
 
The high predictivity of this model could be mainly attributed to the use of HPTCs. My results 
showed that the major performance metrics were substantially lower (between 0.60 and 0.79) 
when HK-2 or LLC-PK1 cell lines were used. This could be probably due to the differences 
between expression patterns of drug transporters and metabolic enzymes between HPTCs and the 
cell lines, as described in the Introduction of this thesis. In addition, rat primary renal tubular or 
cortical cells and tissues also have long been used as a model cell type for nephrotoxicology 
[181-183], but similar to many other studies (as outlined in Introduction), very limited numbers 
of drugs were tested and no useful data on predictivity could be obtained regardless of which 
endpoint was used. 
 
However, one problem commonly associated with primary PTCs cultured in vitro is de-
differentiation. There is increasing evidence that after renal injury, surviving PTCs 
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dedifferentiate and expand the cell population again as a repair mechanism [184, 185]. A recent 
study has shown that such mechanisms are also activated in PTCs cultured in vitro [186], which 
are subject to physical disruption of renal cortical tissues during the isolation procedures. This is 
in agreement with my results which showed that the untreated PTCs in vitro already appeared to 
be in a “pre-injured” state, as indicated by high background expression levels of   VIM, NGAL 
and KIM-1 (see Section 4.3). This could be one of the reasons why there was no significant 
nephrotoxicant-induced up-regulation of novel AKI biomarkers after treatment with 
nephrotoxicants in vitro, as found here in agreement with other results6. Currently there is no 
known in vitro cell culture method which can fully recapitulate the well differentiated in vivo-
like state of HPTCs. These deviations from physiological conditions are probably one of the 
main reasons for false-positive and false-negative results obtained with in vitro models. This 
problem cannot be solved with cell lines, as suggested by the lack of nephrotoxicant-induced up-
regulation of novel AKI biomarkers in a recently developed PTC line6. Typically, PTC-derived 
cell lines are also de-differentiated and drug-transporters are down-regulated [59, 187]. 
 
Another major contributing factor to the high predictivity of the current model is the choice of 
endpoints. The sensitivity was only at 42% when cell numbers were used as the endpoint with 
HPTCs after drug treatment, and the results showed that only strongly toxic compounds could 
induce significant cell death. It can be argued that higher sensitivity might be possible at later 
time points (e.g. 72 h), but specificity may also be compromised. Moreover, increasing the 
length of treatment times would substantially lower the throughput of the model, giving rise to a 
                                                 




disadvantage where rapid experimental procedures are usually preferred for large-scale 
screenings. A highly sensitive endpoint, on the contrary, should be able to detect less drastic 
toxic effects. In the case of IL-6 and IL-8, a broad variety of stimuli and injury mechanisms can 
induce their up-regulation in a large number of cell types [188-191]. This includes PT and PT-
derived cells, which have been shown to express both inflammatory cytokines in vivo and in 
vitro [64, 130-133]. Studies have also shown that IL-6 are IL-8 were increased in injured and 
diseased kidneys [80-82] and these pro-inflammatory cytokines play an important role in the 
pathophysiology of AKI (nephrotoxicant-induced or otherwise) [7, 98]. Furthermore, significant 
up-regulation of IL-6 was induced by nephrotoxicants in a PT-based kidney culture model [135]. 
These findings are in agreement with my results which showed that IL-6 and IL-8 were 
specifically up-regulated in vitro by PT-specific nephrotoxicants.  
 
One feature of this model is that test drugs were used at much higher concentrations as compared 
to their therapeutic doses and could be orders of magnitude higher than serum concentrations in 
vivo. For in vitro assays it is important to work at concentrations where a high sensitivity can be 
obtained without compromising specificity. The high sensitivity and specificity of this model 
show that the concentration range used was appropriate. Typically, it is recommended to work at 
concentrations of up to 100 times of Cmax [192]. This often exceeds the maximum concentration 
used in this study (1000 g/ml). 
 
However, despite the high predictivity of this in vitro model developed here, only binary 
information (positive and negative) on the PT-specific nephrotoxicity of test compounds can be 
derived from test results. Although clinical data are available for all of the compounds tested, 
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dose-related evaluation of the compounds requires more detailed quantitative correlation analysis 
of in vitro results. My preliminary data suggested that the current IL-6/IL-8-based endpoint 
appeared to be unsuitable for such analysis due to variations in magnitudes of gene expression 
levels (but not in overall expression patterns, data not shown). Such variations could be 
attributed to fluctuations in background expression levels of IL-6/IL-8 between different 
experiments (not shown). Also, the large step size between test concentrations do not allow 
accurate calculation of the IC50 values of test compounds. Due to low throughput of the qPCR-
based method, it is inappropriate to include large numbers of concentrations in order to 
accurately determine the IC50 values. Therefore, for a comprehensive investigation on the dose-
dependent relationships between in vitro and clinical data, it is important to identify additional 
appropriate endpoints. For example, our group is also developing an alternative model based on 
high content screening (HCS), which allows fast screening of large numbers of test compounds 
at more refined concentration intervals. The current endpoint used in the HCS-based model is 
nuclear translocation of NF-B, which was also shown to be functionally linked to the up-
regulation of IL-6/IL-8 in Section 4.5. In addition, a green fluorescence protein (GFP)-IL-6 
reporter cell line is also currently under development in order to improve the throughput of the 
interleukin-based model. The reporter cell line would also allow rapid screening of more 
concentrations as drug-induced GFP expression can be efficiently measured using a plate reader 
or the HCS system. 
 
Nevertheless, the binary information provided by the IL-6/IL-8-based endpoint would be useful 
for a fast and accurate pre-clinical classification of large amounts of drug candidates into the 
positive and negative groups, which would greatly facilitate subsequent stages of drug evaluation. 
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This would provide important early information on drug candidates and allow to either reject 
compounds or to follow up by including additional relevant tests. Reliable early predictions of 
PT-specific toxicity would also help in making well-informed decisions such as whether patients 
with pre-existing conditions (which increase the risk of nephrotoxicity) should be excluded from 
Phase II studies. For example, though tetracycline was consistently tested to be positive in this 
thesis, it usually has no prominent nephrotoxic effects per se, and only in patients with pre-
existing kidney disease it can induce AKI and ESRD [193, 194].  
 
In addition, the analysis using threshold-based classifier method was not optimal. In order to 
improve this aspect, all qPCR data obtained were re-analyzed using computerized automated 
classification by machine learning, which lead to even higher predictivity [195]. This analysis 
method was established by our collaborators at the Bioinformatics Institute (BII, Singapore) 
using the same qPCR dataset as presented here. Nevertheless, even with a sub-optimal analysis 
method the predictivity of the models developed by me was already high when HPTCs were 
used. 
 
Though my results showed that HPTCs were a more appropriate cell type than standard cell lines 
for such an in vitro model, one major limitation is that primary cells are inevitably affected by 
inter-donor variability in their responses towards toxicants. Further, the source for normal human 
kidney tissue is limited. In view of these problems, stem cell-derived HPTC-like cells [9] appear 




5.4 Application of stem cell-derived HPTC-like cells 
As mentioned earlier, the use of HPTCs is often associated with limited cell sources, inter-donor 
variability, and functional changes due to passaging. In order to address these problems, human 
stem cell-derived HPTC-like cells were applied in the model described in Section 4.3. The 
differentiation protocol was developed based on hESCs by our group in collaboration with Prof. 
Jackie Ying’s group in IBN [9]. HPTC-like cells obtained with this protocol showed similar 
marker expression and functionality as HPTCs [9]. As previously mentioned in Section 1.3, a 
number of alternative protocols have also been developed more recently based on human or 
murine stem cells [88-93]. However, these protocols recapitulate embryonic kidney development 
and are not suitable for the generation of monocultures of HPTC-like cells. Therefore, here we 
employed the protocol as detailed in [9] for the generation of hESC- and hiPSC-derived HPTC-
like cells which were used for toxicity testing of compounds. The results based on hESC-derived 
cells were published [10], and this is in fact the first reported application of such stem cell-
derived HPTC-like cells. 
 
Before the hESC- and hiPSC-derived HPTC-like cells were used for toxicity testing, it is critical 
to assess their state of differentiation by thorough characterization of these cells. As a routine 
procedure in the lab, marker expression of differentiated cells was regularly analyzed with a 
panel of marker genes (including drug transporters, renal progenitor markers and markers of 
other renal cell types, see supplementary data, Figure S3) and compared with that of HPTCs. It is 
also crucial to monitor cell morphology, epithelium formation (Fig. S3) as well as functional 
properties. These features are also indications of proper differentiation and affect cellular 




Here hESC- and hiPSC-derived HPTC-like cells were applied in the IL-6/IL-8-based in vitro 
model for the prediction of PT toxicity in humans. AUC (of the ROC curves) values of 0.80 and 
0.76 were achieved with hiPSC- and hESC-derived cells, respectively, indicating somewhat 
lower overall predictivity than that obtained with HPTCs. Reduced overall predictivity was due 
to the relatively low sensitivity obtained with hESC-derived HPTC-like cells and relatively low 
specificity obtained with hiPSC-derived HPTC-like cells. These features could be explained by 
some biological differences compared to HPTCs. For example, hESC-derived HPTC-like cells 
expressed low levels of megalin [9, 10], which plays an essential role in cellular uptake of 
aminoglycosides such as gentamicin [25-27]. This is in agreement with the observation that 
though gentamicin was tested positive with HPTCs, false negative results were obtained with 
hESC-derived HPTC-like cells. On the other hand, hiPSC-derived HPTC-like cells showed low 
expression levels of efflux drug transporters (Huang et al., unpublished data). This could 
contribute to intracellular accumulation of test compounds, giving rise to false positives, which 
in turn translated into the observed relatively low specificity of hiPSC-derived HPTC-like cells. 
 
However, despite the biological differences between HPTCs and HPTC-like cells, the latter still 
performed better than widely used PT-derived cell lines in terms of almost all major performance 
metrics (only specificity of hiPSC-derived HPTC-like cells was lower compared to HK-2 cells). 
In terms of overall predictivity, the different cell types could be grouped and ranked as HPTCs > 
stem cell-derived HPTC-like cells > PT-derived cell lines. Though currently there seems to be a 
trade-off between the unlimited cell sources of stem cell-derived HPTC-like cells and their 
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predictivity, it is expected that the predictive performance HPTC-like cells can be further 
improved by optimizations of the differentiation procedures. 
 
Though my results showed that expression levels of IL-6 and IL-8 were highly reliable as 
predictive endpoints for PT toxicity in humans, it was necessary to address the underlying 
mechanisms of observed toxic effects. Here, well-established standard in vitro toxicity assays 
were performed and their results were compared with the IL-6/IL-8 model. The results showed 
that these assays generally had low sensitivity (~ 50%), and each assay identified a different 
subset of compounds (with overlaps) as positive. This could be due to the fact that a mechanism-
specific endpoint, such as ATP depletion, could only detect the toxic effects mediated by this 
particular mechanism. For example, my results showed that tacrolimus, which reduces oxidative 
phosphorylation [196], induced ATP depletion in HPTCs. However, when the full list of 41 test 
compounds of various toxicity mechanisms was used, the sensitivity of ATP depletion assay was 
only 48%. This is also in agreement with a recent Pfizer study on organ-specific toxicity [45]. In 
order to account for variability in ATP depletion among different types of cells, hESC-derived 
HPTC-like cells were also tested, and similarly low sensitivity (50%) was obtained. Thus, the 
fact that better results were obtained with the IL6/IL8 assay was not specific for HPTC1.  
 
On the other hand, IL-6/IL-8 expression is commonly associated with activation of inflammatory 
pathways, which occurs in response to different nephrotoxicants both in vivo [7, 134, 197, 198] 
and in vitro (current thesis and [135]). It appears that such inflammatory reaction is a general 
response to nephrotoxicants in a relatively unspecific manner, and thus explains why false-
negative rates remained low when IL-6/IL-8 expression levels were used as the endpoints. As 
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such, it would be highly interesting to further explore drug-induced inflammatory pathways in 
PTCs in order to identify potential alternative endpoints as well as to elucidate the underlying 




5.5 The role of the NF-B pathway in nephrotoxicant-induced up-regulation of IL-6/IL-8 
Here, I investigated the connection between nephrotoxicant-induced nuclear translocation of NF-
B p65 and up-regulation of IL-6 and IL-8 in human renal PTCs. As mentioned in the 
Introduction section, it is well established that such cytokines mediate inflammatory or 
immunologic responses which often play an important role in the pathogenesis of ischemic 
kidney injury [98, 199], and they are often up-regulated in injured or diseased kidneys [80-82]. 
In fact, these interleukins, along with IL-18 had been proposed as potential novel biomarkers for 
the detection of drug-induced nephrotoxicity [83]. Also, interleukin expression is often regulated 
by the NF-B pathway in different cell types [200-204]. Studies have also shown that the 
promoter regions of IL-6 and IL-8 contained binding sites for NF-B, and these sites were 
essential for activating IL-6 and IL-8 in different cell types [144-146].  
 
My RNAi results suggested that the lipofectamine-based transfection of NF-B p65-specific 
siRNA was more efficient in HK-2 cells, whereas in HPTCs the cellular NF-B p65 level was 
only reduced moderately. This is in agreement with the common knowledge that primary cells 
are intrinsically more resistant to foreign genetic materials as compared to established cell lines, 
possibly due relatively low proliferation rate of primary cells [205] or active degradation of 
nucleic acids [206]. Efficient transfection of primary cells often requires more rigorous 
transfection methods such as eletroporation and pre-treatment of cells [207, 208]. 
 
The lack of siRNA-induced silencing effects on IL-6 and IL-8 expression could be due to the 
possibility that the residual amount of NF-B was sufficient to induce the downstream process. 
136 
 
This is in agreement with another study which showed that the activation of the NF-B signaling 
pathway did not correlate with the amount of NF-B present in the cells [209]. In addition, while 
RNAi did not lead to a reduction in puromycin-induced IL-8 expression, IL-6 was even further 
up-regulated as compared to non-target siRNA controls in both HK-2 cells and HPTCs after 
transfection with siRNA. This unexpected result could be possibly explained by the interaction 
between different regulators of IL-6 expression. For instance, it has been shown that 
CCAAT/enhancer-binding protein beta (CEBPB, also known as nuclear factor for interleukin-6 
(NF-IL-6)) could form a complex with the p50/p65 heterodimer of NF-B [210] and the ternary 
complex had synergistic effects on the expression of inflammatory cytokines such as IL-6 [144]. 
Another example is the crosstalk between the Smad2/3 pathway and the NF-B pathway, where 
inhibition of the latter might have led to disinhibition of the former, leading to up-regulation IL-6 
but not IL-8 [211, 212]. As such, it would be oversimplified to state that a general reduction in 
cellular levels of NF-B p65 could directly translate to inhibition of nephrotoxicant-induced IL-
6/IL-8 up-regulation. For future work, it would be interesting to further investigate the extensive 
network of different cellular pathways involved. 
 
However, these problems were absent when IKK inhibitors were used, suggesting the possibility 
that such interactions between different cellular pathways were more relevant in the cytoplasm.In 
case of inhibitors, the reduction in nuclear translocation of NF-B p65 was obvious and well-
associated with the observed negative effects on the up-regulation of IL-6 and IL-8 in both HK-2 
cells and HPTCs. These results are in agreement with studies which demonstrated anti-
inflammatory effects of the BAY 11-7082 and BAY 11-7085 in various cell types [213-215]. In 
addition, it is interesting to note that while IKK inhibitors only led to moderate negative effects 
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in HK-2 cells, puromycin-induced up-regulation of IL-6 and IL-8 was completely abolished in 
HPTCs. This observation suggested that HPTCs were more susceptible to the inhibitory effects 
of the BAY compounds. These results were also in agreement with the observation that BAY 11-
7085 induced a larger decrease in the nuclear NF-B p65/cytoplasmic NF-B p65 ratio in 
puromycin-treated HPTCs as compared to puromycin-treated HK-2 cells. 
 
Though different drugs and chemicals would be expected to stimulate PTCs via vastly different 
mechanisms, it appears that a large proportion of these compounds active the NF-B pathway, 
leading to up-regulation of the inflammatory cytokines IL-6 and IL-8. This is currently further 
evaluated in another study carried out by our group. Our recent findings indicated that when 
using nuclear translocation of NF-B p65 as an alternative endpoint, high predictivity of human 
PT toxicity could be achieved (Xiong et al., unpublished data). In this context, my results here 
provided essential evidence for the connection between the different endpoints by investigating 
the cellular and molecular mechanism underlying the high predictivity of the IL-6/IL-8-based 
model. Together, the results showed that the in vitro models established in my thesis allowed for 
the first time accurate prediction of drug-induced nephrotoxicity in humans. Follow-up projects 






This thesis describes the development of human in vitro models for predicting organ-specific 
toxicity. I first demonstrated that the TCPS was the most suitable culturing substrate that 
supported optimal performance of HUVEC and HPTC due primarily to its high stiffness (as 
shown in Section 4.1), and therefore TCPS-based platforms were the most appropriate for 
developing in vitro models based on these cell types.  
 
HUVECs were used as the major cell type in a model for the testing toxicity of hemostatic agents 
(Section 4.2). For comparison, other relevant skin cell types such as HDF and HEK were also 
treated with the same test compounds. Cell viability results showed that HUVECs were more 
sensitive to cytotoxic effects of layered clays with hemostatic properties, highlighting the 
importance of cell-type specificity in toxicity tests. Using this model, I have demonstrated that 
MCF-26 could be a much safer hemostatic material than currently used layered clays. 
 
On the other hand, as the main focus of this thesis, I developed a first human in vitro model for 
the prediction of drug-induced nephrotoxicity. The model (as described in Section 4.3) employs 
HPTC as the major cell type and up-regulation of mRNA expression levels (as determined by 
qPCR) of IL-6 and IL-8 has been identified as the endpoint. Predictive performance analysis on 
the qPCR results was based a thresholding method, and accuracy levels  of > 80% were obtained 
with predictions made with respect to 41 well-characterized nephrotoxic or non-nephrotoxic 
compounds. Predictivity obtained with HPTC was shown to be higher than that obtained with 
immortalized renal proximal tubular cell lines. 
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In addition, I also applied stem cell-derived HPTC-like cells as an alternative cell type in this 
model and similar predictivity was achieved (> 75%, Section 4.4). Both hESC- and hiPSC-
derived HPTC-like cells were used and the results were comparable to those obtained with 
HPTC. Furthermore, predictivity obtained with the IL-6/IL-8 endpoint (in both HPTC and hESC-
derived HPTC-like cells) was shown to be substantially higher in comparison to commonly used 
standard toxicity endpoints. This is also the first successful application of such stem-cell derived 
renal cells, and these cells could also be highly interesting in the field of in vitro toxicology. 
 
Lastly, I have also established that drug-induced up-regulation of IL-6/IL-8 could be functionally 
correlated to nuclear translocation of NF-B p65 (Section 4.5), a subunit of the NF-B 
transcription factor which mediates the expression of inflammatory cytokines. This result 
highlights that the in vitro model developed here could recapitulate the physiological scenario 




7. Recommendations for future research 
As discussed earlier, this model was developed based on a sub-optimal data analysis method 
(thresholding method), which still resulted in high predictivity. An improved, automated analysis 
method based on machine learning has already been developed by our collaborators at BII [195], 
and even higher predictivity was achieved with the same qPCR data set as that used in this thesis. 
Another area of improvement to this model is its throughput. To address this problem, my 
current work focuses on the development of a GFP-IL-6 reporter cell line, which would allow 
rapid screening of large number of compounds based on GFP expression that is supposedly 
linked to IL-6 expression levels. In principle, a similar GFP-IL-8 reporter cell line can also be 
developed and used in combination with the GFP-IL-6 reporter cells. This reporter system would 
also be compatible with HCS. 
 
Furthermore, it would also be interesting to look at alternative endpoints. My colleagues (S. 
Xiong, K. G. Eng, and F. Hussain, unpublished results) are currently developing an HCS-based 
model using nuclear translocation of NF-B p65 as endpoint. Preliminary results showed high 
correlation with those obtained by the model described in this thesis. For mechanistic insights 
into the nephrotoxic effects of compounds, more injury mechanism-specific endpoints should 
also be investigated. 
 
Finally, improvements can also be made to the stem cell-derived cell models described here. My 
colleagues have recently improved the differentiation protocol such that shorter time is required 
for differentiation and differentiated cells also showed proper proximal tubular cell functions 
(Kandasamy, Chuah et al., unpublished). On the other hand, it would also be interesting to look 
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into patient-specific iPSC-derived renal-like cells as a model for studying genetically pre-
disposed susceptibility to nephrotoxicity of drugs and chemicals. 
 
Together, these future research areas would address many limitations of the current qPCR-based 
model and broaden the spectrum of research, which would provide mechanistic insights into 
drug-induced nephrotoxicity as well as pharmacogenetic implications in clinical practice. Such 
information would be critical in developing future in vitro models for predicting drug-induced 
nephrotoxicity in humans, and allow pharmaceutical companies to make better-informed 
decisions in drug development. Eventually, such a multi-faceted predictive model would play an 
essential role in the primary motivation of this thesis: to address the high incidence of hospital- 
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Appendix i: List of abbreviations 
3D: Three-dimensional 
A*STAR: Agency for Science, Technology and Research 
Ag NP: Silver nanoparticle 
AKI: Acute kidney injury 
AQP: Aquaporin 
ATCC: American Type Culture Collection 
ATP: Adenosine triphosphate 
AUC: Area under the curve 
BCA: Bicinchoninic acid 
BCRP: Breast cancer resistance protein 
BSA: Bovine serum albumin 
CEBPB: CCAAT/enhancer-binding protein beta 
CG: Cover glass 
CKD: Chronic kidney disease 
DAPI: 4', 6-diamidino-2-phenylindole 
DMEM: Dulbecco’s Modified Eagles’ Medium 
DMSO: Dimethyl sulfoxide 
DOPA: 3, 4-dehydroxy-L-phenylalanine; levadopa 
ECM: Extracellular matrix 
ECVAM: The European centre for the validation of alternative test methods 
ELISA: Enzyme-linked immunosorbernt assay 
ESC: Embryonic stem cell 
ESRD: End stage renal disease 
FDA: United States Food and Drug Administration 
FITC: Fluorescein isothiocyanate 
FN: False negative 
FP: False positive 
GAPDH: Glyceraldehyde 3-phosphate dehydrogenase 
GFP: Green fluorescent protein 
GGT: Gamma-glutamyl transferase 
GLUT: Glucose transporter 
GSH: Glutathione 
HCS: High content screening 
hESC: Human embryonic stem cell 
hiPSC: Human induced pluripotent stem cell 
HDF: Human primary dermal fibroblast 
HEK: Human primary epidermal keratinocyte 
HK-2: Human kidney-2 
HPTC: Human primary renal proximal tubular cell 
HPV: Human papilloma virus 
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HUES: Human embryonic stem cell 
HUVEC: Human primary umbilical vein endothelial cell 
IBN: Institute of Bioengineering and Nanotechnology 
ICU: Intensive care unit 
IB: Inhibitor of kappa B 
IKK: Inhibitor of IB kinase 
IL: Interleukin 
iPSC: Induced pluripotent stem cell 
KIM-1: Kidney injury molecule-1 
LDH: Lactate dehydrogenase 
LLC-PK1: Lilly Laborateries Cell-porcine kidney 1 
MCAM: Melanoma cell adhesion molecule 
MCF-26: Mesocellular foam-26 
MDR: Multidrug resistance 
MEG: Megalin 
MES: 2-(N-morpholino)ethanesulfonic acid 
NF-IL-6: Nuclear factor for interleukin-6 
NF-B: Nuclear factor kappa B 
NGAL: Neutrophil gelatinase-associated lipocalin 
NLS: Nuclear localization sequence 
NPV: Negative predictive value 
NRU: Neutral red uptake 
NTUC: National Trades Union Congress 
NUHS: National University Health System 
NUS: National University of Singapore 
NUS-IRB: National University of Singapore, Institutional Review Board 
OAT: Organic anion transporter 
OCT: Organic cation transporter 
PBS: Phosphate-buffered saline 
PC: Polycarbonate 
PE: Polyethylene 
PECAM: Platelet endothelial cell adhesion molecule 
PLA: Poly(lactic acid)  
PPV: Positive predictive value 
PT: Proximal tubule 
PTC: Proximal tubular epithelial cells 
PVDF: Polyvinylidene fluoride 
qPCR: Quantitative real-time polymerase chain reaction 
REACH: Registration, evaluation, authorization and restriction of chemicals 
REGM: Renal epithelial growth medium 
RIPA: Radioimmunoprecipitation assay 
RNAi: RNA interference 
ROC: Receiver operating characteristic 
SDS: Sodium dodecyl sulfate 
TBS: Tris-buffered saline 
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TCPS: Tissue culture polystyrene 
TN: True negative 
TNF-: Tumor necrosis factor alpha 
TP: True positive 
TEER: Transepithelial electrical resistance 
TX: Thermanox 
VIM: Vimentin 
vWF: von Willebrand factor 




Appendix ii: Supplementary data 
 
Figure S1. Adhesion of MCF-26 to HUVECs. Images were captured with the CytoViva® 
system after fixation. a) Identical image as originally Figure 8c (see Section 4.2). 
HUVECs were washed with 1X PBS after 10 min exposure to MCF-26 at 1 mg/ml. b) 










Figure S2. Marker gene expression determined by qPCR in HPTC 1-4. The relative expression levels of 31 
marker genes (x-axis) are shown as mean percentage (± s.d., n = 3) of GAPDH expression (y-axis), 
Epithelial, HPTC-specific, renal and renal injury markers include: aquaporin-1 (AQP1), aminopeptidase N 
(CD13), zonula occludens 1 (ZO-1), N-cadherin (N-CAD), E-cadherin (E-CAD), -glutamyl transferase 
(GGT), 25-hydroxyvitamin D3 1α-hydroxylase (VIT D3), glucose transporter 5 (GLUT5), Na+/K+ ATPase, 
kidney-specific cadherin (KSP-CAD), neutrophil gelatinase-associated lipocalin (NGAL), kidney injury 
molecule-1 (KIM-1), Wilms’ tumor gene 1 (WT1), paired box gene 2 (PAX2), multidrug resistance gene 1 
(MDR1), megalin (MEG), Na+HCO3- co-transporter 1 (NBC1), organic anion transporter 1 (OAT1), OAT3, 
organic cation transporter 1 (OCT1), organic cation/carnitine transporter 2 (OCTN2), proton-coupled peptide 
transporter 2 (PEPT2),sodium-dependent glucose co-transporter 2 (SGLT2). Markers specific for other parts 
of the nephron include odocalyxin-like (PODXL, glomerulus), chloride channel Kb (CLCNKB, distal 
nephron), thiazide-sensitive sodium-chloride co-transporter (NCCT, distal tubule), Na+/K+/2Cl- co-
transporter (NKCC2, thick ascending loop of Henle), uromodulin (UMOD, thick ascending loop of Henle 
and distal convoluted tubules) and AQP3 (collecting duct). Markers for trans- and de-differentiation: α-
smooth muscle actin (SMA) and vimentin (VIM; bottom). Experiments performed by Dr. Karthikeyan 
Kandasamy. Figure adapted from [8] (Supplementary Information). Reproduced by permission of The Royal 






Figure S3. Marker gene expression determined by qPCR in HPTC and hESC-derived HPTC-like 
cells (bar charts). The relative expression levels of epithelial and HPTC-specific marker genes 
(x-axis) are shown as mean percentage (± s.d., n = 3) of GAPDH expression (y-axis). Asterisks 
indicate significant (P < 0.05) differences (which were also >3-fold) between HPTC and HPTC-
like cells. Experiments were performed by Dr. Karthikeyan Kandasamy. Marker expression was 
also shown by immunostaining (green; cell nuclei, blue) in HPTC-like cells. Scale bars: 100 m. 
Figure adapted with permission from [10]. Copyright 2014 American Chemical Society. 
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Table S1. Adapted with permission from [10] (Supplementary Information). Copyright 2014 
American Chemical Society. 
 
Comp. 






Acute tubular necrosis, renal tubular dysfunction, PT 
toxicity; accumulation in PTCs due to uptake by 
megalin / cubilin endocytotic receptors (this compound 
is an aminoglycoside antibiotic) 
+ [1, 2, 27] 
2 
Acute tubular necrosis, renal tubular dysfunction, PT 
toxicity (this compound is an aminoglycoside 
antibiotic) 
+ [1, 2, 49, 216] 
3 
Inflammation of the tubules, acute tubular necrosis and 
acute tubulo-interstitial nephritis most frequently 
observed; multiple renal tubular transport 
abnormalities; common in intermittent or interrupted 







Tubular damage by the compound in patients with pre-
existing kidney disease; uptake by organic anion 
transporters specifically expressed by PTCs 
+ [193, 221, 222] 
5 
Degeneration and/or regeneration of tubular epithelium 
and multifocal atrophy of glomeruli; PT necrosis; 
increased urinary albumin and NGAL showing 
dysfuncion of PT in addition to glomerular injury 
+ [223-226]
6 
Cephalosporins are associated with acute tubular 
necrosis; uptake by PTCs by organic anion 
transporters 
+ [140, 141] 




Necrosis and apoptosis of renal tubular cells; 
inflammatory response; uptake by PTCs through 
CTR1 and OCT2 
+ [20, 229, 230] 
9 
PT dysfunction and persistent Fanconi syndrome; 
uptake by OCT2 into PTCs; nephrotoxicity probably 
due to metabolite chloroacetaldehyde (CAA)  
+ [231-233]
10 
Acute renal failure, acute tubular necrosis, PT 
dysfunction, Fanconi syndrome; uptake of compound 






Acute and chronic renal failure; damage of PT due to 
their high reabsorptive activity during urinary 





Acute toxicity of this compound manifests as 
nephrotoxicity; strongest enrichment in kidney, acute 
and chronic renal failure, Fanconi syndrome, PT 
necrosis, compound binds to metal binding protein in 
PT and remains bound for long time periods  
+ [241-243]
13 Tubular dysfunction; Cd
2+ is enriched and bound by 
metallothioneins in PT + [244-247]
14 
Degeneration of kidney tubule epithelium, kidney 
failure; uptake by copper transporter CTR1 that is 
specifically expressed by PTCs 
+ [230, 248] 
15 
Acute renal dysfunction, vacuolar degeneration of 
renal tubular epithelial cells, distal tubules more 
strongly affected than PT; no or minor glomerular 
changes 
+ [249, 250] 




Acute and chronic renal failure; cells of PT most 
severely affected; nuclear inclusion bodies in PTCs; 
tubular disruption and dysfunction; renal effects 
require relatively high and persistent exposure 
+ [216, 253] 
18 
Acute tubular necrosis, acute kidney injury; direct 
toxic effects on PTCs associated with mitochondrial 
and lysosomal injury 
+ [254-256]
19 
Prerenal injury, thrombotic microangiopathy, tubular 
toxicity; epithelial vacuolization and direct toxic 
effects on renal PTCs; altered intraglomerular 
hemodynamics; tubular epithelial cells, vascular 
endothelial cells, arteriolar myocytes, and interstitial 
fibroblasts are all targets for cyclosporine and 
tacrolimus nephrotoxicity 
+ [1, 139] 
20 
Prerenal injury, thrombotic microangiopathy; epithelial 
vacuolization and direct toxic effects on renal PTCs; 
altered intraglomerular hemodynamics, chronic 
interstitial nephritis; tubular epithelial cells, vascular 
endothelial cells, arteriolar myocytes, and interstitial 




Cytoplasmic vacuolization of proximal convoluted 
tubules followed by necrosis; uptake into PTCs by 
organic anion transporters 
+ [216, 257-259] 
22 
PT dysfunction associated with acute kidney injury or 
chronic kidney disease; acute toxic tubular necrosis 
targeting PT; mitochondrial injury in PTCs; compound 
is secreted into filtrate by PTCs 
+ [1, 2, 260, 261] 
23 Nephrotoxicity manifests in humans as acute NE [2, 262, 
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interstitial nephritis; the exact incidence of nephrotoxic 
effects unclear is when the pure compound is used 
alone; nephrotoxicity is often associated with pre-
exisiting renal dysfunction or concomitant intake of 
other nephrotoxic agents 
263] 
24 
Epidemiologic studies revealed that habitual use of 
phenacetin is associated with the development of 
chronic renal failure and ESRD; withdrawn from the 
market; pathophysiology of renal damage unclear; 









Safe when used at therapeutic doses; renal failure 
secondary to acetaminophen poisoning is rare (1-2% of 
patients) and becomes in most cases evident after 
hepatotoxicity; acute nephrotoxicity manifests as acute 
tubular necrosis and significant reductions in 
glomerular filtration rate; chronic interstitial nephritis 
and renal papillary necrosis/calcification may occur 












Usually safe at therapeutic doses; excessive abusive 
consumption can be associated with chronic and/or 
acute renal papillary necrosis, chronic or acute 
interstitial nephritis, altered intraglomerular 
hemodynamics, glomerulonephritis, renal tubular 










27 Immune-mediated interstitial inflammation; nephrocalcinosis/nephrolithiasis in premature infants NE [1, 273] 
28 
Nephrogenic diabetes insipidus due to effects on 
collecting duct; chronic tubulointerstitial nephropathy 
with cysts originating from distal tubules or collecting 
ducts; necrosis of distal convoluted tubules; distal 
tubule dilatation and microcyst formation; chronic 











It is claimed in the literature that lindane is 
nephrotoxic. Nephrotoxic effects were observed in 
rats. The effects observed in rats are probably not 
relevant for humans.  
NE [277, 278] 
30 Calcium oxalate crystal-induced renal tubular damage that can be associated with acute renal failure - [279-281]
31 Thrombotic microangiopathy - [1, 282, 283] 
32 No direct relationship to renal damage, but rare cases of renal dysfunction observed - [284] 
33 No tubule-toxic effects; rare cases of immune- - [1, 285-
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mediated tubulointerstitial nephritis or crystal-induced 
nephropathy leading to acute renal failure, reversible 
upon discontinuation 
288] 







35 No nephrotoxic effects reported - [290-292]
36 No nephrotoxic effects reported - [293] 











38 No nephrotoxic effects reported - [295-297]



















Usually no direct negative effects on the kidney; in 

















Tables S2 – S11 
Expression levels of IL-6 and IL-8. Three different batches of HPTC (1-3) as well as HK-2 and 
LLC-PK1 cells were exposed to the 41 test compounds at concentrations of 1 g/ml, 10 g/ml, 
100 g/ml and 1000 g/ml (vehicle control: 0 g/ml drug concentration). The vehicle control 
contained the respective vehicle for the drug tested (see Materials and Methods). The tables list 
the levels of IL-6/IL-8 expression determined by qPCR. The numbers show the mean fold 
expression +/- s.d. (n = 3) relative to the vehicle control. In some cases the expression levels 
were not determined (ND) due to massive cell death. The highest levels of IL-6/IL-8 expression 
that were determined for a given drug and cell type/batch combination when the whole range of 
drug concentrations was tested (1 g – 1000 g) are highlighted (bold). These highest expression 
values obtained with a specific drug and cell type/batch combination were entered into Tables 5 
and 6 in the main thesis. Adapted from [8] (Supplementary Information). Reproduced by 






HPTC 1, IL-6 Expression 
0 1 10 100 1000 
1 1.0 ± 0.0 1.0 ± 0.0 1.2 ± 0.0 2.9 ± 0.1 16.9 ± 0.2
2 1.0 ± 0.2 1.3 ± 0.1 1.5 ± 0.1 1.8 ± 0.3 8.0 ± 0.9
3 1.0 ± 0.2 3.2 ± 0.5 3.1 ± 0.2 1.7 ± 0.9 38.9 ± 3.0
4 1.0 ± 0.0 1.1 ± 0.1 1.4 ± 0.9 6.3 ± 0.7 1.0 ± 0.1
5 1.0 ± 0.1 1.0 ± 0.1 8.5 ± 1.0 5.0 ± 0.4 6.8 ± 1.3
6 1.0 ± 0.2 0.9 ± 0.0 1.0 ± 0.0 0.7 ± 0.1 3.9 ± 0.1
7 1.0 ± 0.1 1.4 ± 0.2 1.7 ± 0.3 2.6 ± 0.1 3.6 ± 0.8
8 1.0 ± 0.1 2.9 ± 0.6 3.8 ± 0.6 1.0 ± 0.2 ND 
9 1.0 ± 0.1 1.5 ± 0.1 1.7 ± 0.2 1.6 ± 0.1 0.8 ± 0.1
10 1.0 ± 0.3 2.0 ± 0.5 2.4 ± 0.2 3.1 ± 0.7 2.4 ± 0.5
11 1.0 ± 0.1 1.1 ± 0.1 0.8 ± 0.1 0.4 ± 0.0 3.0 ± 0.1
12 1.0 ± 0.1 1.1 ± 0.3 1.1 ± 0.2 1.0 ± 0.4 ND 
13 1.0 ± 0.1 1.5 ± 0.1 6.6 ± 0.5 2.9 ± 1.5 ND 
14 1.0 ± 0.3 1.2 ± 0.2 1.4 ± 0.4 0.9 ± 0.1 10.4 ± 2.9
15 1.0 ± 0.1 0.8 ± 0.1 1.0 ± 0.4 1.2 ± 0.0 1.7 ± 0.5
16 1.0 ± 0.1 1.0 ± 0.1 1.7 ± 0.3 0.8 ± 0.1 10.0 ± 1.3
17 1.0 ± 0.1 1.4 ± 0.3 1.8 ± 0.6 2.4 ± 0.3 3.5 ± 0.4
18 1.0 ± 0.2 0.0 ± 0.0 0.3 ± 0.1 0.6 ± 0.1 1.7 ± 0.2
19 1.1 ± 0.6 7.7 ± 1.6 7.7 ± 0.4 11.7 ± 3.5 24.6 ± 5.7
20 1.0 ± 0.1 0.9 ± 0.2 1.1 ± 0.2 0.9 ± 0.1 0.6 ± 0.2
21 1.0 ± 0.1 1.1 ± 0.3 1.1 ± 0.1 0.6 ± 0.1 3.9 ± 0.7
22 1.0 ± 0.0 1.5 ± 0.2 1.6 ± 0.1 1.5 ± 0.1 0.8 ± 0.0
23 1.0 ± 0.2 1.3 ± 0.0 1.4 ± 0.2 1.3 ± 0.3 0.8 ± 0.2
24 1.0 ± 0.3 1.1 ± 0.2 1.2 ± 0.1 1.1 ± 0.2 0.1 ± 0.0
25 1.0 ± 0.1 1.2 ± 0.1 1.3 ± 0.0 1.0 ± 0.1 0.2 ± 0.0
26 1.1 ± 0.3 0.5 ± 0.1 0.8 ± 0.1 0.9 ± 0.1 2.6 ± 0.8
27 1.1 ± 0.5 0.3 ± 0.0 0.4 ± 0.0 0.2 ± 0.0 1.7 ± 0.4
28 1.0 ± 0.0 0.7 ± 0.1 0.4 ± 0.2 0.4 ± 0.0 0.1 ± 0.0
29 1.0 ± 0.2 0.9 ± 0.0 1.0 ± 0.3 1.0 ± 0.2 0.4 ± 0.0
30 1.0 ± 0.2 0.9 ± 0.1 1.0 ± 0.2 1.0 ± 0.1 0.7 ± 0.1
31 1.0 ± 0.1 1.3 ± 0.1 1.7 ± 0.4 1.1 ± 0.1 0.7 ± 0.3
32 1.0 ± 0.2 1.3 ± 0.1 1.1 ± 0.1 1.0 ± 0.0 0.9 ± 0.1
33 1.0 ± 0.1 1.6 ± 0.2 1.4 ± 0.2 2.3 ± 0.2 4.7 ± 0.6
34 1.1 ± 0.2 1.5 ± 0.1 0.9 ± 0.1 0.3 ± 0.0 0.3 ± 0.0
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35 1.0 ± 0.1 1.5 ± 0.1 1.6 ± 0.2 1.7 ± 0.2 1.4 ± 0.1
36 1.0 ± 0.1 0.9 ± 0.0 0.8 ± 0.0 0.9 ± 0.1 0.8 ± 0.1
37 1.0 ± 0.0 1.2 ± 0.1 1.0 ± 0.0 0.8 ± 0.0 0.1 ± 0.0
38 1.1 ± 0.3 1.1 ± 0.1 1.8 ± 0.0 0.4 ± 0.0 0.3 ± 0.1
39 1.0 ± 0.2 1.2 ± 0.1 0.9 ± 0.1 0.4 ± 0.1 3.4 ± 1.0
40 1.0 ± 0.4 1.6 ± 0.2 1.0 ± 0.1 0.9 ± 0.1 0.9 ± 0.0












HPTC 1, IL-8 Expression 
0 1 10 100 1000 
1 1.0 ± 0.3 0.9 ± 0.0 0.8 ± 0.1 0.7 ± 0.0 8.6 ± 1.3 
2 1.0 ± 0.2 1.2 ± 0.1 1.2 ± 0.1 1.5 ± 0.3 8.9 ± 1.2 
3 1.0 ± 0.4 6.9 ± 1.0 6.0 ± 0.7 4.1 ± 1.4 110.8 ± 39.0 
4 1.0 ± 0.0 0.9 ± 0.0 1.2 ± 0.1 1.5 ± 0.1 0.8 ± 0.0 
5 1.0 ± 0.0 0.3 ± 0.0 9.5 ± 0.6 8.8 ± 0.9 4.8 ± 0.5 
6 1.0 ± 0.3 0.9 ± 0.1 1.0 ± 0.1 2.2 ± 1.1 2.3 ± 0.2 
7 1.0 ± 0.0 1.2 ± 0.2 1.2 ± 0.2 2.4 ± 0.2 2.2 ± 0.4 
8 1.0 ± 0.1 13.6 ± 2.0 20.1 ± 2.2 13.4 ± 3.2 ND 
9 1.0 ± 0.1 1.4 ± 0.1 1.5 ± 0.2 1.5 ± 0.1 0.9 ± 0.2 
10 1.0 ± 0.2 2.6 ± 1.7 2.3 ± 0.1 5.9 ± 0.8 16.3 ± 4.6 
11 1.0 ± 0.0 1.1 ± 0.1 1.6 ± 0.2 0.8 ± 0.0 6.0 ± 0.1 
12 1.0 ± 0.0 1.6 ± 0.3 6.1 ± 0.5 11.9 ± 6.2 ND 
13 1.0 ± 0.0 1.9 ± 0.1 2.4 ± 0.1 9.7 ± 2.5 ND 
14 1.0 ± 0.2 1.4 ± 0.2 1.7 ± 0.4 3.6 ± 0.3 7.5 ± 4.4 
15 1.0 ± 0.2 0.8 ± 0.1 1.4 ± 0.3 1.5 ± 0.1 2.9 ± 1.7 
16 1.0 ± 0.0 0.8 ± 0.0 2.2 ± 0.7 1.4 ± 0.4 0.5 ± 0.1 
17 1.0 ± 0.1 1.2 ± 0.3 1.5 ± 0.2 2.6 ± 0.4 3.3 ± 0.1 
18 1.1 ± 0.5 0.5 ± 0.1 3.8 ± 1.0 2.2 ± 0.4 1.3 ± 0.4 
19 1.1 ± 0.4 3.5 ± 0.8 2.8 ± 0.2 3.9 ± 1.3 2.7 ± 1.1 
20 1.0 ± 0.0 1.0 ± 0.2 1.1 ± 0.2 2.6 ± 1.9 5.6 ± 1.3 
21 1.0 ± 0.1 1.3 ± 0.4 1.1 ± 0.2 0.7 ± 0.1 2.3 ± 0.7 
22 1.0 ± 0.1 4.1 ± 1.0 4.3 ± 0.4 4.0 ± 0.5 1.3 ± 0.0 
23 1.0 ± 0.3 1.3 ± 1.0 1.5 ± 0.3 1.6 ± 0.3 1.1 ± 0.2 
24 1.0 ± 0.1 1.2 ± 0.1 1.3 ± 0.1 1.0 ± 0.2 0.0 ± 0.0 
25 1.0 ± 0.1 1.4 ± 0.2 1.5 ± 0.1 1.1 ± 0.1 0.4 ± 0.1 
26 1.0 ± 0.2 0.3 ± 0.0 0.5 ± 0.1 0.2 ± 0.0 3.1 ± 1.4 
27 1.1 ± 0.4 0.5 ± 0.0 0.4 ± 0.0 0.2 ± 0.0 1.9 ± 0.5 
28 1.0 ± 0.0 0.5 ± 0.1 0.5 ± 0.1 0.2 ± 0.0 0.2 ± 0.0 
29 1.0 ± 0.3 1.0 ± 0.1 1.1 ± 0.3 1.1 ± 0.4 0.7 ± 0.1 
30 1.0 ± 0.2 1.1 ± 0.1 1.0 ± 0.2 0.9 ± 0.0 1.0 ± 0.2 
31 1.0 ± 0.1 1.3 ± 0.1 1.2 ± 0.0 1.2 ± 0.1 1.1 ± 0.1 
32 1.0 ± 0.1 1.2 ± 0.0 1.0 ± 0.0 0.9 ± 0.0 0.8 ± 0.0 
33 1.0 ± 0.3 1.5 ± 0.2 0.9 ± 0.1 0.6 ± 0.1 5.3 ± 1.1 
34 1.0 ± 0.1 1.4 ± 0.1 0.9 ± 0.0 0.6 ± 0.1 0.4 ± 0.0 
35 1.0 ± 0.2 1.9 ± 0.1 1.7 ± 0.1 2.0 ± 0.1 2.0 ± 0.1 
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36 1.0 ± 0.0 0.7 ± 0.1 0.8 ± 0.1 1.0 ± 0.0 1.1 ± 0.1 
37 1.0 ± 0.0 1.5 ± 0.3 1.3 ± 0.1 0.7 ± 0.0 0.0 ± 0.0 
38 1.1 ± 0.3 0.8 ± 0.0 1.3 ± 0.1 1.3 ± 0.1 0.3 ± 0.0 
39 1.0 ± 0.1 1.8 ± 0.1 1.3 ± 0.0 0.9 ± 0.1 1.6 ± 0.5 
40 1.0 ± 0.0 1.5 ± 0.1 0.8 ± 0.0 0.8 ± 0.1 0.7 ± 0.1 












HPTC 2, IL-6 Expression 
0 1 10 100 1000 
1 1.0 ± 0.0 0.9 ± 0.0 1.0 ± 0.0 1.0 ± 0.0 1.7 ± 0.1
2 1.0 ± 0.0 1.1 ± 0.1 0.9 ± 0.0 1.2 ± 0.1 1.4 ± 0.0
3 1.0 ± 0.1 1.7 ± 0.2 1.8 ± 0.1 1.2 ± 0.0 3.6 ± 0.7
4 1.0 ± 0.1 0.8 ± 0.1 1.0 ± 0.0 2.0 ± 0.1 2.3 ± 0.3
5 1.0 ± 0.1 1.2 ± 0.3 2.2 ± 0.2 49.9 ± 3.2 79.5 ± 1.7
6 1.0 ± 0.0 1.1 ± 0.0 1.1 ± 0.1 1.6 ± 0.1 3.6 ± 0.3
7 1.0 ± 0.1 2.1 ± 0.1 2.5 ± 0.1 4.8 ± 0.6 1.2 ± 0.4
8 1.0 ± 0.1 8.3 ± 0.2 9.3 ± 0.5 27.9 ± 0.8 3.6 ± 0.7
9 1.0 ± 0.1 0.9 ± 0.1 1.3 ± 0.3 1.2 ± 0.1 1.3 ± 0.1
10 1.0 ± 0.2 0.9 ± 0.1 1.4 ± 0.1 4.4 ± 0.6 7.5 ± 0.0
11 1.0 ± 0.0 1.1 ± 0.1 0.2 ± 0.0 1.6 ± 0.0 ND 
12 1.0 ± 0.0 0.8 ± 0.0 0.9 ± 0.0 1.6 ± 0.3 1.9 ± 0.3
13 1.0 ± 0.0 1.3 ± 0.0 12.9 ± 0.6 3.2 ± 0.1 3.1 ± 0.0
14 1.0 ± 0.0 1.2 ± 0.1 1.1 ± 0.0 5.4 ± 0.1 12.4 ± 1.4
15 1.0 ± 0.1 1.3 ± 0.1 1.1 ± 0.1 1.6 ± 0.2 3.6 ± 0.2
16 1.0 ± 0.0 1.1 ± 0.0 1.2 ± 0.1 3.1 ± 0.4 13.6 ± 1.0
17 1.0 ± 0.1 0.9 ± 0.0 1.1 ± 0.0 2.0 ± 0.4 8.6 ± 0.4
18 1.0 ± 0.0 0.8 ± 0.0 0.2 ± 0.0 0.8 ± 0.0 ND 
19 1.0 ± 0.1 1.4 ± 0.1 0.9 ± 0.0 37.6 ± 0.7 15.8 ± 0.6
20 1.0 ± 0.1 0.8 ± 0.1 3.4 ± 0.7 0.9 ± 0.0 1.4 ± 0.1
21 1.0 ± 0.1 0.9 ± 0.0 0.8 ± 0.1 0.3 ± 0.1 1.3 ± 0.1
22 1.0 ± 0.1 0.7 ± 0.0 0.7 ± 0.0 0.6 ± 0.0 0.6 ± 0.0
23 1.0 ± 0.0 1.4 ± 0.2 1.2 ± 0.2 1.1 ± 0.2 1.3 ± 0.1
24 1.1 ± 0.4 0.6 ± 0.0 0.8 ± 0.1 0.6 ± 0.0 0.1 ± 0.0
25 1.0 ± 0.1 1.4 ± 0.1 1.3 ± 0.2 1.6 ± 0.4 2.9 ± 0.2
26 1.0 ± 0.1 1.6 ± 0.0 1.7 ± 0.1 4.4 ± 0.1 16.1 ± 1.2
27 1.0 ± 0.1 2.4 ± 0.1 2.4 ± 0.0 2.6 ± 0.2 0.6 ± 0.1
28 1.0 ± 0.1 1.1 ± 0.0 1.0 ± 0.1 1.5 ± 0.1 17.4 ± 0.8
29 1.0 ± 0.1 0.8 ± 0.0 0.7 ± 0.0 0.7 ± 0.0 0.8 ± 0.0
30 1.0 ± 0.0 1.8 ± 0.1 1.3 ± 0.1 1.2 ± 0.1 1.1 ± 0.0
31 1.0 ± 0.1 1.2 ± 0.1 1.1 ± 0.1 1.2 ± 0.1 1.6 ± 0.3
32 1.0 ± 0.1 1.3 ± 0.1 1.2 ± 0.1 1.0 ± 0.0 1.2 ± 0.1
33 1.0 ± 0.2 1.3 ± 0.1 1.1 ± 0.1 0.9 ± 0.1 0.4 ± 0.1
34 1.0 ± 0.0 1.2 ± 0.1 0.8 ± 0.0 0.5 ± 0.1 0.7 ± 0.1
35 1.0 ± 0.1 2.7 ± 0.8 1.6 ± 0.1 1.5 ± 0.2 0.2 ± 0.0
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36 1.0 ± 0.0 2.7 ± 0.1 2.4 ± 0.1 1.8 ± 0.5 0.3 ± 0.0
37 1.0 ± 0.0 1.1 ± 0.3 0.8 ± 0.0 0.7 ± 0.0 0.3 ± 0.1
38 1.0 ± 0.1 1.0 ± 0.0 0.8 ± 0.1 1.2 ± 0.2 0.9 ± 0.1
39 1.0 ± 0.0 1.7 ± 0.5 1.2 ± 0.1 1.8 ± 0.3 3.1 ± 0.3
40 1.0 ± 0.0 1.1 ± 0.0 1.2 ± 0.0 1.1 ± 0.1 1.1 ± 0.0












HPTC 2, IL-8 Expression 
0 1 10 100 1000 
1 1.0 ± 0.0 1.1 ± 0.0 1.3 ± 0.0 1.4 ± 0.1 2.0 ± 0.1 
2 1.0 ± 0.0 1.3 ± 0.1 1.2 ± 0.1 1.3 ± 0.1 1.5 ± 0.1 
3 1.0 ± 0.1 1.9 ± 0.2 1.9 ± 0.0 1.8 ± 0.0 13.1 ± 3.0 
4 1.0 ± 0.1 0.7 ± 0.1 0.9 ± 0.0 2.2 ± 0.1 3.6 ± 0.8 
5 1.0 ± 0.0 1.4 ± 0.4 21.3 ± 4.7 89.1 ± 4.5 146.1 ± 3.1 
6 1.0 ± 0.2 1.6 ± 0.1 1.6 ± 0.2 9.2 ± 0.2 3.3 ± 0.2 
7 1.1 ± 0.3 1.9 ± 0.2 1.8 ± 0.2 3.8 ± 0.9 1.7 ± 0.2 
8 1.0 ± 0.1 4.6 ± 0.2 5.0 ± 0.2 32.7 ± 0.9 3.9 ± 0.7 
9 1.0 ± 0.1 1.2 ± 0.0 1.8 ± 0.4 1.4 ± 0.1 1.8 ± 0.2 
10 1.1 ± 0.3 1.0 ± 0.2 1.3 ± 0.2 5.7 ± 0.8 13.2 ± 0.3 
11 1.0 ± 0.1 1.2 ± 0.1 25.7 ± 3.8 2.3 ± 0.5 ND 
12 1.0 ± 0.1 1.2 ± 0.1 1.3 ± 0.0 3.3 ± 0.7 22.5 ± 2.0 
13 1.0 ± 0.1 1.9 ± 0.0 165.2 ± 14.7 3.1 ± 0.5 3.9 ± 0.1 
14 1.0 ± 0.1 1.4 ± 0.1 1.4 ± 0.2 119.0 ± 5.4 11.3 ± 0.7 
15 1.0 ± 0.1 1.5 ± 0.1 1.3 ± 0.1 1.7 ± 0.3 5.7 ± 0.2 
16 1.0 ± 0.0 1.4 ± 0.1 1.3 ± 0.2 8.3 ± 0.5 2.2 ± 0.2 
17 1.0 ± 0.1 1.2 ± 0.1 1.6 ± 0.2 4.1 ± 1.2 23.8 ± 2.9 
18 1.0 ± 0.1 1.8 ± 0.0 2.7 ± 0.3 2.0 ± 0.1 ND 
19 1.0 ± 0.1 0.9 ± 0.1 0.7 ± 0.0 29.3 ± 4.3 15.1 ± 0.3 
20 1.0 ± 0.1 1.7 ± 0.2 6.5 ± 1.6 5.5 ± 0.7 67.4 ± 3.1 
21 1.0 ± 0.1 1.6 ± 0.1 1.3 ± 0.1 4.9 ± 0.1 1.8 ± 0.2 
22 1.0 ± 0.2 1.0 ± 0.0 0.9 ± 0.0 0.7 ± 0.0 0.5 ± 0.0 
23 1.0 ± 0.1 1.8 ± 0.4 1.5 ± 0.4 1.5 ± 0.3 1.5 ± 0.2 
24 1.1 ± 0.3 0.6 ± 0.0 0.9 ± 0.2 0.4 ± 0.0 0.4 ± 0.1 
25 1.0 ± 0.1 1.4 ± 0.1 1.5 ± 0.1 1.5 ± 0.3 2.6 ± 0.1 
26 1.0 ± 0.1 0.6 ± 0.0 0.4 ± 0.0 1.1 ± 0.2 4.3 ± 0.3 
27 1.0 ± 0.0 2.6 ± 0.2 2.4 ± 0.0 2.3 ± 0.1 2.3 ± 0.1 
28 1.0 ± 0.1 1.1 ± 0.1 1.0 ± 0.1 0.6 ± 0.1 20.5 ± 0.8 
29 1.0 ± 0.1 0.9 ± 0.1 0.8 ± 0.0 0.8 ± 0.1 1.5 ± 0.1 
30 1.0 ± 0.1 2.0 ± 0.1 1.4 ± 0.1 1.3 ± 0.0 1.2 ± 0.0 
31 1.0 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 1.2 ± 0.2 
32 1.0 ± 0.1 1.3 ± 0.1 1.3 ± 0.1 1.2 ± 0.0 1.4 ± 0.1 
33 1.0 ± 0.1 1.6 ± 0.2 1.1 ± 0.1 1.0 ± 0.0 0.7 ± 0.1 
34 1.0 ± 0.0 1.2 ± 0.1 0.9 ± 0.0 0.8 ± 0.0 1.4 ± 0.1 
35 1.0 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 1.3 ± 0.0 0.3 ± 0.0 
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36 1.0 ± 0.0 2.8 ± 0.0 2.9 ± 0.0 2.4 ± 0.7 0.5 ± 0.0 
37 1.0 ± 0.1 1.2 ± 0.1 1.0 ± 0.0 0.7 ± 0.0 1.4 ± 0.2 
38 1.0 ± 0.1 1.2 ± 0.0 1.1 ± 0.2 3.1 ± 0.2 2.1 ± 0.1 
39 1.0 ± 0.1 1.6 ± 0.2 1.3 ± 0.0 2.0 ± 0.3 24.0 ± 3.4 
40 1.0 ± 0.0 1.1 ± 0.0 1.3 ± 0.0 1.2 ± 0.0 1.2 ± 0.0 












HPTC 3, IL-6 Expression 
0 1 10 100 1000 
1 1.0 ± 0.2 1.6 ± 0.1 0.9 ± 0.1 0.8 ± 0.1 0.9 ± 0.1 
2 1.0 ± 0.1 1.4 ± 0.1 1.1 ± 0.2 1.1 ± 0.0 1.2 ± 0.0 
3 1.0 ± 0.1 5.3 ± 0.4 2.9 ± 0.8 1.4 ± 0.3 ND 
4 1.0 ± 0.1 1.5 ± 0.2 1.4 ± 0.1 23.6 ± 2.8 3.5 ± 0.1 
5 1.0 ± 0.0 0.7 ± 0.1 9.3 ± 0.7 59.2 ± 2.6 80.4 ± 2.7 
6 1.0 ± 0.1 1.1 ± 0.0 1.2 ± 0.0 1.4 ± 0.1 0.2 ± 0.0 
7 1.1 ± 0.4 7.5 ± 1.0 5.9 ± 0.2 12.0 ± 1.8 0.5 ± 0.1 
8 1.0 ± 0.2 11.3 ± 0.7 12.1 ± 0.4 11.9 ± 0.9 5.2 ± 0.5 
9 1.0 ± 0.0 1.3 ± 0.1 1.1 ± 0.1 1.1 ± 0.0 2.9 ± 0.3 
10 1.0 ± 0.1 1.1 ± 0.1 1.4 ± 0.0 4.4 ± 0.1 11.8 ± 0.5 
11 1.0 ± 0.0 0.9 ± 0.0 0.2 ± 0.1 31.4 ± 12.8 ND 
12 1.0 ± 0.1 1.5 ± 0.1 1.3 ± 0.0 1.3 ± 0.1 4.0 ± 0.1 
13 1.1 ± 0.4 2.7 ± 0.2 10.8 ± 1.2 3.5 ± 0.1 6.0 ± 0.4 
14 1.0 ± 0.2 0.4 ± 0.1 0.5 ± 0.0 0.3 ± 0.0 0.9 ± 0.2 
15 1.0 ± 0.0 1.3 ± 0.1 1.1 ± 0.1 1.5 ± 0.0 2.2 ± 0.2 
16 1.0 ± 0.0 1.2 ± 0.1 1.1 ± 0.0 0.9 ± 0.1 5.8 ± 2.5 
17 1.0 ± 0.0 1.2 ± 0.1 1.3 ± 0.2 1.1 ± 0.2 2.3 ± 0.2 
18 1.0 ± 0.1 0.6 ± 0.2 0.3 ± 0.1 0.5 ± 0.0 0.4 ± 0.0 
19 1.0 ± 0.0 0.9 ± 0.0 1.0 ± 0.0 38.1 ± 1.2 8.3 ± 0.3 
20 1.0 ± 0.0 0.9 ± 0.1 0.9 ± 0.1 1.3 ± 0.1 ND 
21 1.0 ± 0.0 0.8 ± 0.0 0.8 ± 0.0 1.2 ± 0.3 2.3 ± 0.3 
22 1.0 ± 0.2 0.9 ± 0.0 1.1 ± 0.1 1.0 ± 0.1 0.8 ± 0.0 
23 1.2 ± 0.6 1.0 ± 0.4 0.9 ± 0.0 0.7 ± 0.1 0.6 ± 0.1 
24 1.6 ± 1.1 3.9 ± 0.5 3.1 ± 0.1 6.2 ± 1.0 0.6 ± 0.4 
25 1.0 ± 0.1 0.6 ± 0.1 0.8 ± 0.1 0.6 ± 0.1 0.2 ± 0.0 
26 1.1 ± 0.3 1.4 ± 0.6 0.5 ± 0.2 0.9 ± 0.2 2.9 ± 0.1 
27 1.1 ± 0.3 9.0 ± 0.6 8.4 ± 0.3 8.1 ± 0.2 0.6 ± 0.2 
28 1.0 ± 0.1 1.1 ± 0.2 0.9 ± 0.1 0.6 ± 0.1 0.2 ± 0.0 
29 1.0 ± 0.1 0.9 ± 0.2 0.9 ± 0.1 0.7 ± 0.1 0.9 ± 0.2 
30 1.0 ± 0.2 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 1.0 ± 0.2 
31 1.0 ± 0.0 1.2 ± 0.2 1.1 ± 0.0 1.4 ± 0.2 1.4 ± 0.2 
32 1.1 ± 0.3 1.0 ± 0.2 0.4 ± 0.0 0.4 ± 0.1 0.5 ± 0.1 
33 1.1 ± 0.4 1.1 ± 0.2 0.4 ± 0.0 ND 2.9 ± 0.1 
34 1.0 ± 0.2 1.2 ± 0.3 0.4 ± 0.0 0.5 ± 0.2 0.7 ± 0.3 
35 1.0 ± 0.0 1.0 ± 0.1 0.9 ± 0.1 0.8 ± 0.0 0.9 ± 0.1 
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36 1.0 ± 0.2 1.4 ± 0.2 1.0 ± 0.1 1.1 ± 0.1 0.9 ± 0.2 
37 1.0 ± 0.0 0.9 ± 0.1 0.8 ± 0.0 0.8 ± 0.0 0.1 ± 0.0 
38 1.1 ± 0.3 0.6 ± 0.1 0.3 ± 0.0 0.3 ± 0.0 0.2 ± 0.0 
39 1.0 ± 0.1 1.2 ± 0.1 1.2 ± 0.1 2.8 ± 0.4 3.4 ± 0.3 
40 1.0 ± 0.0 1.3 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 












HPTC 3, IL-8 Expression 
0 1 10 100 1000 
1 1.0 ± 0.2 1.9 ± 0.3 0.8 ± 0.1 0.8 ± 0.0 1.2 ± 0.1
2 1.0 ± 0.0 2.0 ± 0.1 1.3 ± 0.2 1.3 ± 0.0 1.8 ± 0.2
3 1.2 ± 0.5 3.2 ± 0.6 3.0 ± 0.4 7.3 ± 2.7 ND 
4 1.0 ± 0.1 1.6 ± 0.4 1.3 ± 0.1 35.5 ± 4.4 8.2 ± 0.9
5 1.0 ± 0.1 0.9 ± 0.0 18.9 ± 0.4 29.1 ± 3.6 46.4 ± 1.2
6 1.0 ± 0.2 1.1 ± 0.0 1.1 ± 0.1 2.4 ± 0.6 0.1 ± 0.0
7 1.0 ± 0.2 2.2 ± 0.2 2.6 ± 0.1 5.4 ± 0.4 4.4 ± 0.5
8 1.1 ± 0.3 17.2 ± 2.6 21.9 ± 0.8 18.8 ± 0.5 3.2 ± 0.5
9 1.0 ± 0.0 1.5 ± 0.1 1.3 ± 0.1 1.1 ± 0.0 2.6 ± 0.2
10 1.0 ± 0.1 0.8 ± 0.1 1.0 ± 0.0 3.3 ± 0.1 9.7 ± 0.2
11 1.0 ± 0.0 0.7 ± 0.0 5.3 ± 0.3 22.8 ± 4.0 ND 
12 1.0 ± 0.1 1.4 ± 0.2 1.2 ± 0.1 1.5 ± 0.3 9.6 ± 1.8
13 1.1 ± 0.4 2.2 ± 0.3 13.3 ± 1.4 2.4 ± 0.1 1.5 ± 0.1
14 1.1 ± 0.3 0.6 ± 0.1 1.5 ± 0.2 9.9 ± 1.1 2.6 ± 0.2
15 1.0 ± 0.0 1.3 ± 0.1 1.1 ± 0.0 1.5 ± 0.2 3.4 ± 0.5
16 1.0 ± 0.0 1.1 ± 0.1 1.3 ± 0.0 3.5 ± 1.0 1.0 ± 0.2
17 1.0 ± 0.1 1.3 ± 0.2 1.3 ± 0.2 1.1 ± 0.2 2.8 ± 0.4
18 1.0 ± 0.0 1.6 ± 0.3 2.2 ± 0.3 2.2 ± 0.4 10.1 ± 0.9
19 1.0 ± 0.0 1.1 ± 0.0 1.2 ± 0.0 25.0 ± 0.8 9.5 ± 0.3
20 1.0 ± 0.1 1.2 ± 0.1 1.2 ± 0.1 17.8 ± 1.6 ND 
21 1.0 ± 0.0 1.2 ± 0.0 1.1 ± 0.1 1.5 ± 0.1 1.3 ± 0.0
22 1.1 ± 0.3 1.4 ± 0.1 1.7 ± 0.1 2.0 ± 0.2 1.0 ± 0.2
23 1.3 ± 0.6 0.8 ± 0.2 0.7 ± 0.0 0.6 ± 0.1 0.5 ± 0.0
24 1.2 ± 0.5 1.4 ± 0.1 1.8 ± 0.1 3.6 ± 0.3 2.3 ± 0.7
25 1.0 ± 0.1 0.9 ± 0.0 0.9 ± 0.0 0.6 ± 0.0 0.2 ± 0.0
26 1.0 ± 0.1 0.7 ± 0.3 0.8 ± 0.1 1.5 ± 0.3 0.3 ± 0.1
27 1.0 ± 0.2 8.2 ± 0.7 7.5 ± 0.3 5.8 ± 0.1 3.8 ± 0.6
28 1.0 ± 0.1 1.3 ± 0.3 0.9 ± 0.1 0.8 ± 0.0 0.5 ± 0.0
29 1.0 ± 0.1 1.1 ± 0.2 1.0 ± 0.0 0.8 ± 0.0 1.2 ± 0.0
30 1.0 ± 0.1 1.2 ± 0.3 0.8 ± 0.2 0.9 ± 0.2 1.1 ± 0.1
31 1.0 ± 0.1 1.2 ± 0.2 1.1 ± 0.1 1.3 ± 0.2 1.0 ± 0.1
32 1.0 ± 0.1 1.1 ± 0.2 0.8 ± 0.1 0.8 ± 0.0 0.8 ± 0.1
33 1.0 ± 0.1 0.8 ± 0.1 0.5 ± 0.1 ND 3.2 ± 0.3
34 1.0 ± 0.1 1.0 ± 0.1 0.6 ± 0.1 0.8 ± 0.2 1.7 ± 0.4
35 1.0 ± 0.0 1.0 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 1.2 ± 0.1
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36 1.0 ± 0.1 1.7 ± 0.3 1.0 ± 0.2 1.0 ± 0.0 1.1 ± 0.1
37 1.0 ± 0.0 1.3 ± 0.1 1.2 ± 0.1 0.9 ± 0.0 1.3 ± 0.0
38 1.0 ± 0.2 1.0 ± 0.3 0.9 ± 0.0 1.2 ± 0.0 1.3 ± 0.2
39 1.0 ± 0.1 0.4 ± 0.0 0.4 ± 0.0 1.2 ± 0.3 5.1 ± 0.3
40 1.0 ± 0.1 1.2 ± 0.1 1.1 ± 0.1 1.3 ± 0.1 1.3 ± 0.1












HK-2, IL-6 Expression 
0 1 10 100 1000 
1 1.0 ± 0.0 1.2 ± 0.1 1.1 ± 0.2 1.0 ± 0.1 0.9 ± 0.1
2 1.0 ± 0.0 1.4 ± 0.2 0.9 ± 0.0 0.9 ± 0.2 1.0 ± 0.0
3 1.0 ± 0.1 8.3 ± 0.2 7.6 ± 0.3 6.1 ± 0.1 12.8 ± 1.7
4 1.0 ± 0.1 1.4 ± 0.3 0.9 ± 0.0 8.6 ± 1.3 4.0 ± 0.7
5 1.0 ± 0.2 0.7 ± 0.2 3.6 ± 0.2 25.2 ± 2.7 120.5 ± 26.1
6 1.0 ± 0.1 1.3 ± 0.1 1.0 ± 0.1 1.0 ± 0.0 2.6 ± 0.3
7 1.0 ± 0.2 3.6 ± 0.8 2.2 ± 0.2 2.8 ± 0.0 1.5 ± 0.0
8 1.0 ± 0.2 1.7 ± 0.1 1.1 ± 0.1 0.2 ± 0.1 ND 
9 1.0 ± 0.2 1.2 ± 0.1 0.7 ± 0.2 0.5 ± 0.2 0.8 ± 0.0
10 1.0 ± 0.0 1.1 ± 0.1 1.0 ± 0.0 1.2 ± 0.1 0.8 ± 0.1
11 1.0 ± 0.1 0.3 ± 0.0 1.6 ± 1.0 4.0 ± 1.4 5.9 ± 0.5
12 1.1 ± 0.3 0.7 ± 0.1 0.5 ± 0.0 0.8 ± 0.4 1.3 ± 0.0
13 1.0 ± 0.1 1.5 ± 0.0 2.3 ± 0.0 2.8 ± 0.8 2.6 ± 0.0
14 1.0 ± 0.1 1.0 ± 0.1 0.9 ± 0.0 0.5 ± 0.0 16.1 ± 1.1
15 1.0 ± 0.2 0.7 ± 0.1 0.7 ± 0.1 0.6 ± 0.0 0.3 ± 0.0
16 1.0 ± 0.1 1.6 ± 0.3 1.1 ± 0.2 1.1 ± 0.1 3.5 ± 0.5
17 1.0 ± 0.2 1.4 ± 0.2 0.9 ± 0.1 1.5 ± 0.2 2.0 ± 0.4
18 1.0 ± 0.1 0.1 ± 0.0 0.1 ± 0.0 0.6 ± 0.0 ND 
19 1.0 ± 0.1 4.0 ± 0.3 5.1 ± 0.2 7.8 ± 0.4 5.8 ± 1.6
20 1.0 ± 0.1 0.8 ± 0.1 0.6 ± 0.1 1.1 ± 0.1 1.2 ± 0.1
21 1.0 ± 0.1 1.5 ± 0.0 1.4 ± 0.0 1.3 ± 0.0 14.7 ± 1.5
22 1.0 ± 0.1 2.0 ± 0.3 1.8 ± 0.1 2.0 ± 0.1 1.1 ± 0.0
23 1.0 ± 0.1 0.8 ± 0.0 0.6 ± 0.0 0.4 ± 0.0 0.7 ± 0.1
24 1.4 ± 0.8 0.7 ± 0.1 0.5 ± 0.0 0.2 ± 0.0 0.4 ± 0.1
25 1.1 ± 0.3 1.2 ± 0.2 0.6 ± 0.1 0.7 ± 0.1 0.6 ± 0.1
26 1.0 ± 0.1 0.9 ± 0.5 0.3 ± 0.1 0.3 ± 0.0 ND 
27 1.1 ± 0.5 1.0 ± 0.1 0.7 ± 0.1 0.5 ± 0.0 0.2 ± 0.0
28 1.0 ± 0.1 1.6 ± 0.0 1.1 ± 0.0 0.9 ± 0.1 0.4 ± 0.0
29 1.0 ± 0.1 0.3 ± 0.0 1.5 ± 0.6 0.1 ± 0.0 0.1 ± 0.0
30 1.0 ± 0.2 1.3 ± 0.1 1.0 ± 0.2 1.0 ± 0.1 0.9 ± 0.0
31 1.1 ± 0.3 1.4 ± 0.0 0.7 ± 0.0 0.6 ± 0.0 0.8 ± 0.0
32 1.0 ± 0.1 0.8 ± 0.1 0.7 ± 0.0 0.9 ± 0.2 0.8 ± 0.0
33 1.1 ± 0.3 1.1 ± 0.1 0.8 ± 0.0 0.9 ± 0.1 ND 
34 1.0 ± 0.1 1.3 ± 0.1 0.8 ± 0.1 0.6 ± 0.1 0.7 ± 0.0
35 1.0 ± 0.1 1.3 ± 0.1 1.1 ± 0.0 0.8 ± 0.3 1.3 ± 0.0
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36 1.0 ± 0.2 1.0 ± 0.1 0.7 ± 0.1 0.6 ± 0.1 0.5 ± 0.0
37 1.1 ± 0.4 0.5 ± 0.1 0.3 ± 0.0 0.2 ± 0.0 0.8 ± 0.0
38 1.0 ± 0.1 1.5 ± 0.3 0.7 ± 0.2 0.6 ± 0.0 0.2 ± 0.0
39 1.0 ± 0.1 0.9 ± 0.1 0.5 ± 0.0 0.4 ± 0.1 2.4 ± 0.6
40 1.0 ± 0.1 1.2 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 0.8 ± 0.1












HK-2, IL-8 Expression 
0 1 10 100 1000 
1 1.0 ± 0.0 1.1 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 1.3 ± 0.5
2 1.0 ± 0.0 1.1 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.7 ± 0.0
3 1.0 ± 0.1 5.1 ± 0.2 4.3 ± 0.1 3.5 ± 0.1 4.1 ± 0.2
4 1.0 ± 0.0 1.6 ± 0.6 1.0 ± 0.1 13.9 ± 2.6 18.8 ± 5.3
5 1.0 ± 0.0 1.3 ± 0.4 5.0 ± 1.1 13.5 ± 1.8 30.5 ± 2.7
6 1.0 ± 0.1 1.2 ± 0.2 1.0 ± 0.1 1.0 ± 0.1 1.9 ± 0.3
7 1.0 ± 0.1 9.0 ± 0.7 8.6 ± 0.5 14.3 ± 1.2 0.9 ± 0.0
8 1.0 ± 0.2 2.5 ± 0.1 2.2 ± 0.1 1.6 ± 0.1 ND 
9 1.0 ± 0.2 1.7 ± 0.1 0.8 ± 0.0 0.6 ± 0.1 0.7 ± 0.0
10 1.0 ± 0.1 1.2 ± 0.1 0.9 ± 0.0 0.9 ± 0.1 1.4 ± 0.5
11 1.0 ± 0.1 0.2 ± 0.0 2.0 ± 1.0 1.3 ± 0.5 1.0 ± 0.1
12 1.0 ± 0.2 1.3 ± 0.1 1.2 ± 0.1 1.2 ± 0.1 3.0 ± 0.0
13 1.0 ± 0.1 0.9 ± 0.1 3.7 ± 0.7 2.3 ± 0.4 2.5 ± 0.0
14 1.0 ± 0.1 1.0 ± 0.0 0.8 ± 0.1 0.2 ± 0.0 1.2 ± 0.1
15 1.0 ± 0.1 1.5 ± 0.2 1.5 ± 0.2 1.5 ± 0.1 1.1 ± 0.2
16 1.0 ± 0.0 1.9 ± 0.4 1.5 ± 0.3 1.1 ± 0.2 0.4± 0.0
17 1.0 ± 0.1 1.4 ± 0.1 1.2 ± 0.2 2.1 ± 0.1 2.1 ± 0.4
18 1.0 ± 0.0 0.5 ± 0.1 0.6 ± 0.1 0.4 ± 0.0 ND 
19 1.0 ± 0.0 2.8 ± 0.1 2.1 ± 0.2 2.6 ± 0.3 2.5 ± 0.5
20 1.0 ± 0.2 0.6 ± 0.1 0.5 ± 0.0 1.3 ± 0.2 1.6 ± 0.3
21 1.0 ± 0.0 1.1 ± 0.0 1.1 ± 0.0 0.8 ± 0.1 1.7 ± 0.0
22 1.0 ± 0.0 3.9 ± 0.5 3.8 ± 0.4 3.1 ± 0.5 1.2 ± 0.2
23 1.0 ± 0.1 1.2 ± 0.2 0.8 ± 0.1 0.7 ± 0.1 0.7 ± 0.1
24 1.1 ± 0.3 4.7 ± 0.6 3.6 ± 0.8 2.2 ± 0.0 0.5 ± 0.3
25 1.0 ± 0.1 1.2 ± 0.1 1.2 ± 0.1 1.1 ± 0.1 1.1 ± 0.1
26 1.0 ± 0.0 0.5 ± 0.2 0.3 ± 0.0 0.4 ± 0.1 ND 
27 1.0 ± 0.2 8.3 ± 0.7 5.4 ± 0.2 3.2 ± 0.2 2.4 ± 1.0
28 1.0 ± 0.0 1.4 ± 0.1 1.3 ± 0.1 1.4 ± 0.1 0.8 ± 0.1
29 1.0 ± 0.0 0.3 ± 0.1 0.1 ± 0.0 0.4 ± 0.1 0.5 ± 0.0
30 1.0 ± 0.2 1.6 ± 0.1 1.2 ± 0.2 1.1 ± 0.1 1.3 ± 0.0
31 1.0 ± 0.1 1.7 ± 0.3 1.1 ± 0.1 1.0 ± 0.1 1.0 ± 0.0
32 1.0 ± 0.1 1.1 ± 0.1 1.0 ± 0.1 1.1 ± 0.2 1.1 ± 0.0
33 1.0 ± 0.2 0.9 ± 0.1 1.0 ± 0.1 1.2 ± 0.1 ND 
34 1.0 ± 0.0 1.2 ± 0.1 1.3 ± 0.1 0.8 ± 0.0 0.5 ± 0.0
35 1.0 ± 0.1 1.4 ± 0.1 0.9 ± 0.1 0.9 ± 0.0 1.5 ± 0.0
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36 1.0 ± 0.0 0.8 ± 0.1 0.6 ± 0.1 0.5 ± 0.0 0.4 ± 0.0
37 1.0 ± 0.1 0.3 ± 0.0 0.3 ± 0.0 0.2 ± 0.0 0.3 ± 0.0
38 1.0 ± 0.1 1.1 ± 0.0 0.8 ± 0.1 0.7 ± 0.0 1.2 ± 0.1
39 1.0 ± 0.0 0.4 ± 0.0 0.4 ± 0.0 0.4 ± 0.0 10.2 ± 3.5
40 1.0 ± 0.0 1.0 ± 0.0 0.9 ± 0.0 0.9 ± 0.1 0.9 ± 0.1












LLC-PK1, IL-6 Expression 
0 1 10 100 1000 
1 1.0 ± 0.1 0.7 ± 0.2 2.3 ± 0.8 5.2 ± 1.0 1.8 ± 0.5 
2 1.0 ± 0.1 0.9 ± 0.1 0.9 ± 0.0 1.0 ± 0.0 1.2 ± 0.0 
3 1.0 ± 0.1 1.4 ± 0.2 0.7 ± 0.1 0.5 ± 0.0 0.3 ± 0.1 
4 1.0 ± 0.1 1.1 ± 0.1 1.9 ± 0.7 1.0 ± 0.0 4.8 ± 0.3 
5 1.0 ± 0.1 1.2 ± 0.2 15.1 ± 2.7 313.7 ± 31.4 180.5 ± 16.1 
6 1.0 ± 0.2 0.6 ± 0.1 0.5 ± 0.0 0.9 ± 0.0 1.1 ± 0.0 
7 1.0 ± 0.1 1.6 ± 0.0 1.8 ± 0.1 1.8 ± 0.1 1.4 ± 0.0 
8 1.0 ± 0.0 1.4 ± 0.1 1.7 ± 0.1 1.1 ± 0.1 ND 
9 1.1 ± 0.3 1.0 ± 0.1 0.8 ± 0.1 0.8 ± 0.0 0.9 ± 0.0 
10 1.0 ± 0.0 1.1 ± 0.2 2.8 ± 0.3 6.3 ± 0.3 4.7 ± 0.5 
11 1.0 ± 0.2 0.3 ± 0.0 0.5 ± 0.0 0.9 ± 0.1 ND 
12 1.0 ± 0.1 0.9 ± 0.0 1.1 ± 0.1 1.3 ± 0.1 1.8 ± 0.1 
13 1.0 ± 0.1 2.2 ± 0.1 12.9 ± 7.2 ND ND 
14 1.0 ± 0.1 1.1 ± 0.0 1.1 ± 0.1 3.3 ± 0.5 3.7 ± 0.2 
15 1.0 ± 0.0 0.8 ± 0.0 0.9 ± 0.0 1.0 ± 0.0 2.4 ± 0.0 
16 1.0 ± 0.1 1.3 ± 0.0 1.1 ± 0.1 1.2 ± 0.1 2.8 ± 0.0 
17 1.0 ± 0.0 0.9 ± 0.0 1.3 ± 0.0 1.4 ± 0.0 2.5 ± 0.2 
18 1.0 ± 0.1 0.9 ± 0.0 0.5 ± 0.0 0.9 ± 0.0 0.7 ± 0.1 
19 1.0 ± 0.1 1.5 ± 0.1 1.5 ± 0.0 7.4 ± 1.0 1.4 ± 0.3 
20 1.1 ± 0.3 0.7 ± 0.1 1.1 ± 0.3 2.2 ± 0.2 2.4 ± 0.6 
21 1.0 ± 0.0 0.9 ± 0.1 1.0 ± 0.1 0.9 ± 0.0 1.7 ± 0.5 
22 1.0 ± 0.0 1.5 ± 0.1 1.5 ± 0.1 1.4 ± 0.0 1.4 ± 0.0 
23 1.0 ± 0.1 0.9 ± 0.1 0.7 ± 0.0 0.8 ± 0.1 0.9 ± 0.1 
24 1.0 ± 0.2 1.3 ± 0.1 0.8 ± 0.0 0.7 ± 0.0 0.8 ± 0.1 
25 1.0 ± 0.1 0.9 ± 0.1 1.3 ± 0.1 2.3 ± 0.4 1.7 ± 0.4 
26 1.0 ± 0.2 0.3 ± 0.0 0.3 ± 0.0 0.4 ± 0.1 2.1 ± 0.5 
27 1.0 ± 0.2 1.8 ± 0.1 1.9 ± 0.2 2.6 ± 0.1 1.6 ± 0.2 
28 1.0 ± 0.1 0.8 ± 0.0 1.0 ± 0.0 0.9 ± 0.0 1.0 ± 0.0 
29 1.0 ± 0.1 0.6 ± 0.1 0.5 ± 0.1 0.3 ± 0.1 0.9 ± 0.2 
30 1.0 ± 0.2 1.1 ± 0.1 0.8 ± 0.1 0.8 ± 0.0 1.0 ± 0.1 
31 1.0 ± 0.0 1.1 ± 0.1 1.2 ± 0.1 1.4 ± 0.2 1.6 ± 0.3 
32 1.0 ± 0.1 1.6 ± 0.1 1.6 ± 0.1 1.1 ± 0.2 0.9 ± 0.1 
33 1.0 ± 0.2 0.9 ± 0.0 0.9 ± 0.1 1.1 ± 0.2 8.2 ± 2.6 
34 1.0 ± 0.2 0.7 ± 0.0 0.5 ± 0.0 0.6 ± 0.1 1.8 ± 0.0 
35 1.0 ± 0.0 0.7 ± 0.0 0.7 ± 0.0 0.7 ± 0.0 0.9 ± 0.1 
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36 1.0 ± 0.0 0.7 ± 0.0 0.7 ± 0.0 0.7 ± 0.1 0.8 ± 0.0 
37 1.3 ± 0.7 0.5 ± 0.1 2.4 ± 0.3 1.1 ± 0.7 1.1 ± 0.5 
38 1.0 ± 0.0 0.7 ± 0.0 0.7 ± 0.1 0.8 ± 0.0 0.7 ± 0.0 
39 1.0 ± 0.0 0.6 ± 0.1 0.5 ± 0.0 0.7 ± 0.1 7.7 ± 0.6 
40 1.0 ± 0.1 1.0 ± 0.0 1.1 ± 0.0 1.1 ± 0.0 1.1 ± 0.0 












LLC-PK1, IL-8 Expression 
0 1 10 100 1000 
1 1.0 ± 0.1 1.3 ± 0.1 1.1 ± 0.3 2.7 ± 0.1 2.1 ± 0.5 
2 1.0 ± 0.0 1.0 ± 0.0 1.3 ± 0.1 1.8 ± 0.2 2.3 ± 0.2 
3 1.0 ± 0.1 7.8 ± 1.5 3.9 ± 0.4 2.1 ± 0.0 8.4 ± 0.1 
4 1.0 ± 0.1 0.9 ± 0.1 1.2 ± 0.4 1.0 ± 0.0 8.9 ± 0.3 
5 1.0 ± 0.0 0.9 ± 0.1 23.1 ± 3.9 413.7 ± 28.8 839.4 ± 305.9 
6 1.0 ± 0.1 0.7 ± 0.1 0.6 ± 0.0 1.6 ± 0.2 0.8 ± 0.0 
7 1.0 ± 0.1 10.1 ± 0.7 8.1 ± 0.7 9.1 ± 0.4 1.8 ± 0.0 
8 1.0 ± 0.1 1.0 ± 0.4 0.7 ± 0.3 1.2 ± 0.4 ND 
9 1.0 ± 0.2 1.7 ± 0.0 1.5 ± 0.2 1.5 ± 0.1 1.2 ± 0.1 
10 1.0 ± 0.1 0.5 ± 0.1 1.5 ± 0.1 20.3 ± 2.0 15.8 ± 2.1 
11 1.1 ± 0.3 0.8 ± 0.4 6.9 ± 0.3 0.4 ± 0.0 ND 
12 1.0 ± 0.1 0.7 ± 0.0 0.9 ± 0.0 1.7 ± 0.1 4.3 ± 0.9 
13 1.0 ± 0.1 2.1 ± 0.1 12.2 ± 4.3 ND ND 
14 1.0 ± 0.0 1.2 ± 0.1 1.8 ± 0.3 37.0 ± 4.4 1.6 ± 0.1 
15 1.0 ± 0.1 0.7 ± 0.1 1.0 ± 0.1 1.3 ± 0.1 2.5 ± 0.1 
16 1.0 ± 0.0 0.9 ± 0.1 1.2 ± 0.2 1.6 ± 0.3 0.7 ± 0.0 
17 1.0 ± 0.1 1.0 ± 0.1 1.6 ± 0.0 2.0 ± 0.2 16.3 ± 4.3 
18 1.0 ± 0.1 0.5 ± 0.0 0.4 ± 0.0 1.4 ± 0.2 0.4 ± 0.0 
19 1.0 ± 0.2 5.9 ± 0.4 7.1 ± 0.5 301.3 ± 27.5 47.9 ± 6.0 
20 1.0 ± 0.1 1.2 ± 0.3 0.7 ± 0.2 3.9 ± 0.1 4.9 ± 1.2 
21 1.0 ± 0.1 2.2 ± 0.2 1.8 ± 0.1 1.2 ± 0.2 2.6 ± 0.3 
22 1.0 ± 0.1 4.0 ± 0.3 2.2 ± 0.1 2.4 ± 0.2 1.5 ± 0.1 
23 1.0 ± 0.1 1.2 ± 0.1 0.4 ± 0.0 0.6 ± 0.1 0.7 ± 0.1 
24 1.1 ± 0.3 16.1 ± 0.4 8.4 ± 0.7 7.1 ± 1.3 1.4 ± 0.1 
25 1.0 ± 0.0 0.9 ± 0.1 1.1 ± 0.0 1.8 ± 0.3 0.5 ± 0.1 
26 1.0 ± 0.1 0.7 ± 0.1 0.5 ± 0.1 0.9 ± 0.0 2.9 ± 1.0 
27 1.0 ± 0.2 7.6 ± 1.1 5.7 ± 0.7 13.7 ± 1.2 0.4 ± 0.0 
28 1.0 ± 0.1 0.6 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 1.0 ± 0.1 
29 1.1 ± 0.2 0.9 ± 0.2 0.8 ± 0.1 0.6 ± 0.1 1.2 ± 0.1 
30 1.0 ± 0.0 2.6 ± 0.1 1.8 ± 0.6 1.6 ± 0.3 1.5 ± 0.0 
31 1.0 ± 0.1 0.8 ± 0.0 1.0 ± 0.0 1.3 ± 0.1 1.3 ± 0.0 
32 1.0 ± 0.0 2.1 ± 0.1 1.3 ± 0.1 1.1 ± 0.2 0.7 ± 0.0 
33 1.0 ± 0.2 0.9 ± 0.0 0.8 ± 0.1 0.8 ± 0.0 9.1 ± 0.6 
34 1.0 ± 0.1 0.8 ± 0.0 0.7 ± 0.1 0.7 ± 0.0 0.5 ± 0.0 
35 1.0 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.7 ± 0.0 1.0 ± 0.0 
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36 1.0 ± 0.1 0.6 ± 0.0 0.6 ± 0.1 0.7 ± 0.1 0.6 ± 0.0 
37 1.2 ± 0.5 0.7 ± 0.1 2.6 ± 0.2 1.3 ± 0.7 0.9 ± 0.3 
38 1.0 ± 0.0 0.9 ± 0.1 1.0 ± 0.2 0.8 ± 0.1 1.1 ± 0.0 
39 1.0 ± 0.0 0.8 ± 0.0 0.7 ± 0.0 0.7 ± 0.1 164.4 ± 4.0 
40 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.0 1.0 ± 0.0 1.1 ± 0.0 
41 1.1 ± 0.2 2.4 ± 0.3 1.8 ± 0.1 2.0 ± 0.1 11.0 ± 1.0 
 




Table S12, S13 
 
IL-6 and IL-8 expression levels. hESC-derived HPTC-like cells (batch 1) were exposed to the 41 
test compounds at concentrations of 1 g/ml, 10 g/ml, 100 g/ml and 1000 g/ml. The column 
“0” (0 g/ml compound concentration) displays the values obtained with the vehicle control. The 
table lists the levels of IL-6/IL-8 expression determined by qPCR. The numbers show the mean 
fold expression +/- s.d. (n = 3) relative to the vehicle control. In one case the expression levels 
were not determined (ND) due to massive cell death. The highest levels of IL-6/IL-8 expression 
that were determined for a given compound when the whole range of concentrations was tested 
(1 g/ml – 1000 g/ml) are highlighted (bold). These highest expression values obtained with a 
specific compound were entered into Table 13. Adapted with permission from [10] 









0 1 10 100 1000 
1 1.0 ± 0.0 1.3 ± 0.0 1.3 ± 0.0 1.4 ± 0.1 1.9 ± 0.1 
2 1.1 ± 0.3 1.5 ± 0.3 1.0 ± 0.1 1.1 ± 0.2 1.0 ± 0.0 
3 1.0 ± 0.1 2.6 ± 1.0 3.3 ± 0.4 3.7 ± 0.6 14.9 ± 5.3 
4 1.0 ± 0.1 0.8 ± 0.1 0.7 ± 0.0 8.2 ± 0.2 16.5 ± 5.4 
5 1.0 ± 0.0 17.7 ± 1.5 1252.9 ± 126.5 509.6 ± 58.3 335.1 ± 15.4 
6 1.0 ± 0.1 0.9 ± 0.0 1.0 ± 0.1 1.1 ± 0.1 6.8 ± 0.4 
7 1.0 ± 0.2 1.9 ± 0.0 2.1 ± 0.3 1.7 ± 0.1 1.1 ± 0.1 
8 1.0 ± 0.1 2.1 ± 0.0 1.8 ± 0.2 1.3 ± 0.5 ND 
9 1.0 ± 0.1 1.1 ± 0.1 1.2 ± 0.1 1.2 ± 0.0 1.0 ± 0.0 
10 1.0 ± 0.0 1.2 ± 0.0 1.5 ± 0.1 3.7 ± 0.1 8.4 ± 1.5 
11 1.0 ± 0.0 0.5 ± 0.0 8.7 ± 0.2 1.9 ± 0.1 1.9 ± 0.5 
12 1.0 ± 0.0 1.1 ± 0.0 1.2 ± 0.1 3.0 ± 0.3 42.7 ± 2.5 
13 1.0 ± 0.0 7.6 ± 0.4 3.2 ± 0.3 1.7 ± 0.2 3.7 ± 0.4 
14 1.0 ± 0.0 1.2 ± 0.1 1.7 ± 0.1 10.2 ± 0.6 8.4 ± 2.5 
15 1.0 ± 0.2 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 0.6 ± 0.0 
16 1.1 ± 0.4 0.8 ± 0.1 1.2 ± 0.3 3.6 ± 0.4 46.4 ± 5.6 
17 1.0 ± 0.0 1.1 ± 0.2 1.8 ± 0.0 2.4 ± 0.1 27.8 ± 3.0 
18 1.0 ± 0.0 0.2 ± 0.0 0.9 ± 0.2 1.5 ± 0.3 1.3 ± 0.2 
19 1.0 ± 0.1 3.4 ± 0.8 1.6 ± 0.1 45.2 ± 13.8 3.3 ± 1.8 
20 1.0 ± 0.1 1.6 ± 0.5 1.7 ± 0.4 36.1 ± 10.4 10.3 ± 2.7 
21 1.0 ± 0.1 1.1 ± 0.0 1.1 ± 0.0 6.0 ± 1.4 1.0 ± 0.2 
22 1.0 ± 0.2 1.5 ± 0.2 1.4 ± 0.1 1.5 ± 0.1 0.7 ± 0.0 
23 1.0 ± 0.2 0.7 ± 0.3 1.0 ± 0.1 1.1 ± 0.0 2.4 ± 0.2 
24 1.0 ± 0.0 0.6 ± 0.0 0.6 ± 0.1 0.0 ± 0.0 0.7 ± 0.3 
25 1.0 ± 0.0 0.9 ± 0.1 0.8 ± 0.0 0.5 ± 0.0 0.1 ± 0.0 
26 1.0 ± 0.1 0.3 ± 0.0 0.3 ± 0.0 0.7 ± 0.1 0.3 ± 0.0 
27 1.2 ± 0.4 1.4 ± 0.2 1.6 ± 0.0 1.1 ± 0.1 0.9 ± 0.1 
28 1.0 ± 0.1 1.1 ± 0.1 0.8 ± 0.2 0.5 ± 0.2 0.5 ± 0.0 
29 1.0 ± 0.2 0.2 ± 0.1 0.3 ± 0.0 0.4 ± 0.1 0.9 ± 0.4 
30 1.0 ± 0.0 1.1 ± 0.0 1.1 ± 0.0 1.2 ± 0.0 1.2 ± 0.1 
31 1.0 ± 0.1 1.0 ± 0.0 1.9 ± 0.6 1.4 ± 0.1 3.2 ± 0.1 
32 1.0 ± 0.1 1.3 ± 0.1 1.2 ± 0.1 1.2 ± 0.1 1.2 ± 0.1 
33 1.0 ± 0.1 1.1 ± 0.0 1.8 ± 0.1 1.3 ± 0.1 54.8 ± 2.9 
34 1.0 ± 0.0 1.1 ± 0.1 1.0 ± 0.1 0.8 ± 0.0 0.8 ± 0.0 
35 1.0 ± 0.0 1.1 ± 0.2 1.0 ± 0.1 0.8 ± 0.0 0.8 ± 0.0 
36 1.0 ± 0.1 1.0 ± 0.0 1.0 ± 0.1 0.9 ± 0.0 0.7 ± 0.1 
37 1.0 ± 0.2 0.7 ± 0.1 1.0 ± 0.1 0.5 ± 0.1 0.1 ± 0.0 
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38 1.0 ± 0.1 1.3 ± 0.0 1.3 ± 0.1 1.2 ± 0.0 3.8 ± 0.2 
39 1.0 ± 0.1 0.2 ± 0.0 0.5 ± 0.0 1.8 ± 0.1 1.6 ± 0.7 
40 1.0 ± 0.1 1.2 ± 0.2 1.0 ± 0.1 1.1 ± 0.1 0.8 ± 0.0 








0 1 10 100 1000 
1 1.0 ± 0.0 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.0 0.9 ± 0.0 
2 1.1 ± 0.3 0.3 ± 0.1 0.4 ± 0.0 0.3 ± 0.0 0.4 ± 0.0 
3 1.1 ± 0.3 3.0 ± 0.5 2.6 ± 1.2 2.6 ± 0.6 87.5 ± 38.8 
4 1.0 ± 0.1 0.7 ± 0.1 0.3 ± 0.1 0.9 ± 0.4 29.0 ± 10.4 
5 1.0 ± 0.0 169.6 ± 27.8 1471.4 ± 170.9 1988.2 ± 193.0 2765.7 ± 23.6 
6 1.0 ± 0.1 1.0 ± 0.1 0.9 ± 0.1 1.8 ± 0.1 3.2 ± 0.5 
7 1.0 ± 0.1 1.8 ± 0.3 1.4 ± 0.3 1.6 ± 0.5 4.3 ± 0.2 
8 1.0 ± 0.1 1.4 ± 0.2 1.0 ± 0.1 2.3 ± 0.2 ND 
9 1.0 ± 0.0 0.9 ± 0.1 0.9 ± 0.1 0.7 ± 0.0 0.4 ± 0.0 
10 1.0 ± 0.1 1.0 ± 0.1 0.9 ± 0.1 1.0 ± 0.1 1.8 ± 0.5 
11 1.0 ± 0.0 0.4 ± 0.0 0.5 ± 0.0 0.1 ± 0.0 0.2 ± 0.1 
12 1.0 ± 0.1 1.0 ± 0.0 1.0 ± 0.0 3.7 ± 0.3 36.1 ± 1.2 
13 1.0 ± 0.0 7.4 ± 0.5 0.4 ± 0.0 0.2 ± 0.0 0.4 ± 0.0 
14 1.0 ± 0.1 1.8 ± 0.0 3.7 ± 0.2 7.9 ± 0.4 0.9 ± 0.2 
15 1.0 ± 0.1 1.1 ± 0.1 1.0 ± 0.1 1.0 ± 0.2 0.7 ± 0.0 
16 1.0 ± 0.0 1.3 ± 0.1 1.4 ± 0.7 2.1 ± 0.4 71.6 ± 26.2 
17 1.0 ± 0.0 1.0 ± 0.1 0.6 ± 0.0 1.3 ± 0.1 3.9 ± 0.1 
18 1.0 ± 0.1 0.7 ± 0.1 0.9 ± 0.1 0.5 ± 0.1 0.3 ± 0.0 
19 1.0 ± 0.2 2.2 ± 0.5 1.8 ± 0.2 549.3 ± 46.2 258.5 ± 144.9 
20 1.0 ± 0.1 2.8 ± 1.1 2.7 ± 0.4 100.3 ± 9.3 242.2 ± 4.8 
21 1.0 ± 0.1 1.2 ± 0.1 1.3 ± 0.3 3.5 ± 1.8 0.7 ± 0.2 
22 1.0 ± 0.2 1.3 ± 0.2 1.2 ± 0.2 1.8 ± 0.3 3.0 ± 0.2 
23 0.9 ± 0.2 0.8 ± 0.1 1.0 ± 0.1 0.8 ± 0.1 3.5 ± 0.4 
24 1.1 ± 0.3 1.1 ± 0.2 1.1 ± 0.4 0.7 ± 0.1 1.2 ± 0.6 
25 1.0 ± 0.2 1.1 ± 0.2 0.8 ± 0.1 0.6 ± 0.1 0.3 ± 0.1 
26 1.1 ± 0.3 0.2 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.4 ± 0.0 
27 1.8 ± 0.9 6.8 ± 1.3 6.5 ± 2.7 7.4 ± 1.3 3.0 ± 0.6 
28 1.0 ± 0.0 1.0 ± 0.3 1.0 ± 0.2 0.6 ± 0.3 0.5 ± 0.2 
29 1.0 ± 0.2 0.1 ± 0.0 0.1 ± 0.0 0.0 ± 0.0 0.1 ± 0.0 
30 1.0 ± 0.0 1.0 ± 0.1 1.0 ± 0.0 1.0 ± 0.1 1.1 ± 0.1 
31 1.0 ± 0.2 0.8 ± 0.1 0.9 ± 0.0 1.0 ± 0.0 2.1 ± 0.1 
32 1.0 ± 0.1 1.0 ± 0.1 0.9 ± 0.0 0.9 ± 0.0 0.7 ± 0.1 
33 1.0 ± 0.0 1.0 ± 0.1 1.2 ± 0.0 1.1 ± 0.1 21.3 ± 0.9 
34 1.0 ± 0.0 1.0 ± 0.1 0.8 ± 0.0 0.5 ± 0.1 0.3 ± 0.0 
35 1.0 ± 0.2 0.8 ± 0.0 0.7 ± 0.0 0.5 ± 0.0 0.7 ± 0.0 
36 1.0 ± 0.0 1.1 ± 0.0 0.9 ± 0.0 0.8 ± 0.1 0.8 ± 0.0 
37 1.0 ± 0.2 0.9 ± 0.1 1.2 ± 0.3 0.8 ± 0.1 2.2 ± 0.5 
38 1.0 ± 0.0 0.9 ± 0.0 0.7 ± 0.0 0.3 ± 0.0 0.1 ± 0.0 
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39 1.0 ± 0.2 0.1 ± 0.0 0.1 ± 0.0 0.2 ± 0.0 1.6 ± 0.7 
40 1.0 ± 0.1 1.0 ± 0.1 0.9 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 




Table S14. IL-6 and IL-8 expression levels in batch 2 of HPTC-like cells. A second batch of 
HPTC-like cells was differentiated from hESC. These HPTC-like cells were exposed to test 
compounds 6, 19 and 40 at concentrations of 1 g/ml, 10 g/ml, 100 g/ml and 1000 g/ml. The 
column “0” (0 g/ml compound concentration) displays the values obtained with the vehicle 
control. The table lists the levels of IL-6 and IL-8 expression determined by qPCR. The numbers 
show the mean fold expression +/- s.d. (n = 3) relative to the respective vehicle control. In one 
case the expression levels were not determined (ND) due to massive cell death. The highest 
levels of IL-6 and IL-8 expression that were determined for a given compound when the whole 
range of concentrations was tested (1 g/ml – 1000 g/ml) are highlighted (bold). These highest 
expression values obtained with a specific compound were entered into Table 17. Adapted with 
permission from [10] (Supplementary Information). Copyright 2014 American Chemical Society. 
 
Compound Marker 0 1 10 100 1000 
6 IL-6 1.0 ± 0.2 0.7 ± 0.6 0.4 ± 0.3 3.9 ± 1.0 2.8 ± 2.0 IL-8 1.0 ± 0.3 1.3 ± 0.9 2.4 ± 0.8 67.8 ± 23.1 4.5 ± 2.8 
19 IL-6 1.0 ± 0.2 7.5 ± 0.2 10.0 ± 1.3 70.5 ± 10.5 ND IL-8 1.0 ± 0.0 9.2 ± 2.0 7.8 ± 0.1 206.1 ± 51.5 ND 
40 IL-6 1.0 ± 0.4 1.1 ± 0.3 1.2 ± 0.2 1.9 ± 0.2 2.4 ± 0.8 IL-8 1.0 ± 0.1 1.4 ± 0.6 1.5 ± 0.6 2.1 ± 0.4 3.7 ± 1.2 





Table S15, S16 
 
IL-6 and IL-8 expression levels. hiPSC-derived HPTC-like cells were exposed to the 41 test 
compounds at concentrations of 1 g/ml, 10 g/ml, 100 g/ml and 1000 g/ml. The column “0” 
(0 g/ml compound concentration) displays the values obtained with the vehicle control. The 
table lists the levels of IL-6/IL-8 expression determined by qPCR. The numbers show the mean 
fold expression +/- s.d. (n = 3) relative to the vehicle control. In one case the expression levels 
were not determined (ND) due to massive cell death. The highest levels of IL-6/IL-8 expression 
that were determined for a given compound when the whole range of concentrations was tested 
(1 g/ml – 1000 g/ml) are highlighted (bold). These highest expression values obtained with a 




hiPSC-derived HPTC-like cells, IL-6 Expression 
0 1 10 100 1000 
1 1.0 ± 0.1 1.1 ± 0.0 1.3 ± 0.0 5.3 ± 0.2 86.0 ± 1.5 
2 1.0 ± 0.1 0.8 ± 0.0 0.9 ± 0.1 1.9 ± 0.1 36.5 ± 7.0 
3 1.0 ± 0.2 11.8 ± 0.7 10.6 ± 0.8 6.1 ± 0.3 27.3 ± 2.7 
4 1.0 ± 0.1 1.1 ± 0.0 1.9 ± 0.3 6.2 ± 2.0 60.9 ± 15.6 
5 1.0 ± 0.1 2.7 ± 0.4 266.0 ± 22.2 56.0 ± 4.4 40.2 ± 6.7 
6 1.0 ± 0.0 1.0 ± 0.0 0.9 ± 0.1 1.4 ± 0.1 4.0 ± 0.3 
7 1.1 ± 0.3 12.6 ± 0.8 12.5 ± 0.6 10.0 ± 1.1 2.0 ± 0.3 
8 1.1 ± 0.5 9.4 ± 1.1 8.0 ± 1.7 15.2 ± 1.5 20.0 ± 1.6 
9 1.0 ± 0.2 0.9 ± 0.0 1.1 ± 0.1 1.2 ± 0.2 1.1 ± 0.1 
10 1.0 ± 0.0 0.9 ± 0.1 1.2 ± 0.1 2.3 ± 0.2 3.1 ± 0.9 
11 1.0 ± 0.1 0.7 ± 0.0 3.5 ± 0.5 1.4 ± 0.3 ND 
12 1.0 ± 0.1 1.0 ± 0.1 2.4 ± 0.3 13.3 ± 3.4 31.8 ± 2.0 
13 1.0 ± 0.1 3.4 ± 0.8 11.0 ± 1.3 5.2 ± 0.9 4.6 ± 1.4 
14 1.0 ± 0.1 1.2 ± 0.2 1.6 ± 0.1 1.6 ± 0.2 96.5 ± 13.8 
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15 1.1 ± 0.2 1.0 ± 0.2 1.0 ± 0.2 2.3 ± 0.5 1.6 ± 0.5 
16 1.0 ± 0.0 1.0 ± 0.0 1.0 ±0.1 6.5 ± 1.4 23.0 ± 3.7 
17 1.0 ± 0.1 1.1 ± 0.1 1.5 ± 0.1 3.4 ± 0.2 19.8 ± 0.7 
18 1.0 ± 0.2 0.4 ± 0.1 0.1 ± 0.0 0.6 ± 0.3 0.7 ± 0.1 
19 1.1 ± 0.3 4.4 ± 0.5 3.2 ± 0.5 57.8 ± 3.4 61.7 ± 3.4 
20 1.0 ± 0.1 4.7 ± 0.2 5.7 ± 0.3 10.4 ± 2.0 49.1 ± 6.4 
21 1.0 ± 0.2 1.6 ± 0.2 1.6 ± 0.2 3.0 ± 0.0 5.2 ± 0.3 
22 1.0 ± 0.2 0.6 ± 0.3 0.9 ± 0.2 1.5 ± 0.3 2.3 ± 0.5 
23 1.1 ± 0.4 1.4 ± 0.1 1.2 ± 0.0 1.7 ± 0.1 2.2 ± 0.1 
24 1.1 ± 0.3 1.0 ± 0.0 0.9 ± 0.2 0.2 ± 0.0 1.8 ± 0.3 
25 1.0 ± 0.1 1.1 ± 0.1 1.0 ± 0.1 0.7 ± 0.0 0.1 ± 0.0 
26 1.0 ± 0.1 0.2 ± 0.0 0.3 ± 0.0 0.4 ± 0.0 2.5 ± 0.4 
27 1.1 ± 0.3 1.2 ± 0.1 1.2 ± 0.1 0.5 ± 0.0 2.1 ± 0.4 
28 1.0 ± 0.2 1.2 ± 0.0 1.3 ± 0.1 1.0 ± 0.1 0.6 ± 0.1 
29 1.0 ± 0.2 0.3 ± 0.0 0.4 ± 0.0 0.9 ± 0.1 1.6 ± 0.2 
30 1.0 ± 0.0 0.9 ± 0.1 0.8 ± 0.1 0.7 ± 0.1 0.8 ± 0.0 
31 1.0 ± 0.1 1.4 ± 0.1 1.6 ± 0.1 1.8 ± 0.2 3.5 ± 0.4 
32 1.0 ± 0.1 1.1 ± 0.1 1.2 ± 0.1 1.6 ± 0.3 2.7 ± 0.4 
33 1.0 ± 0.1 0.9 ± 0.1 1.1 ± 0.1 1.6 ± 0.1 80.1 ± 7.6 
34 1.0 ± 0.1 1.1 ± 0.1 0.8 ± 0.0 0.6 ± 0.0 0.4 ± 0.0 
35 1.0 ± 0.1 1.3 ± 0.1 1.4 ± 0.1 1.2 ± 0.0 1.9 ± 0.1 
36 1.0 ± 0.1 1.1 ± 0.2 1.0 ± 0.1 0.9 ± 0.0 0.7 ± 0.0 
37 1.0 ± 0.1 1.9 ± 0.1 1.4 ± 0.1 0.6 ± 0.1 0.2 ± 0.0 
38 1.0 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 0.4 ± 0.1 1.6 ± 0.3 
39 1.0 ± 0.1 0.4 ± 0.1 0.3 ± 0.0 0.8 ± 0.0 0.8 ± 0.0 
40 1.0 ± 0.1 1.0 ± 0.0 0.9 ± 0.0 1.0 ± 0.1 1.0 ± 0.1 







hiPSC-derived HPTC-like cells, IL-6 Expression 
0 1 10 100 1000 
1 1.0 ± 0.2 1.1 ± 0.1 1.5 ± 0.1 4.8 ± 0.6 860.1 ± 30.9 
2 1.0 ± 0.2 1.0 ± 0.2 1.2 ± 0.3 1.6 ± 0.2 86.3 ± 20.4 
3 1.0 ± 0.1 14.2 ± 1.7 14.2 ± 2.2 23.2 ± 1.5 15.3 ± 4.2 
4 1.5 ± 0.9 0.7 ± 0.1 1.3 ± 0.1 2.4 ± 0.6 4710.3 ± 1107.7 
5 1.0 ± 0.0 193.4 ± 11.7 499.1 ± 83.5 615.2 ± 45.7 964.2 ± 34.2 
6 1.0 ± 0.1 1.0 ± 0.1 0.8 ± 0.2 58.4 ± 16.5 2.5 ± 0.3 
7 1.2 ± 0.5 1.8 ± 0.4 1.7 ± 0.4 2.3 ± 0.4 11.2 ± 1.3 
8 1.1 ± 0.4 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.3 ± 0.0 
9 1.0 ± 0.2 1.0 ± 0.0 1.6 ± 0.5 1.3 ± 0.4 1.9 ± 0.1 
10 1.0 ± 0.1 1.0 ± 0.0 1.2 ± 0.1 3.1 ± 0.3 3.3 ± 0.7 
11 1.0 ± 0.1 1.2 ± 0.1 3.8 ± 0.1 0.5 ± 0.0 ND 
12 1.0 ± 0.2 7.0 ± 2.3 84.9 ± 19.2 1311.2 ± 84.1 4321.1 ± 254.3 
13 1.0 ± 0.2 11.1 ± 0.9 9.9 ± 2.2 ND ND 
14 1.0 ± 0.2 0.9 ± 0.2 1.7 ± 0.0 13.8 ± 1.2 12.8 ± 1.7 
15 1.1 ± 0.4 0.8 ± 0.2 0.7 ± 0.1 1.8 ± 0.4 2.0 ± 0.6 
16 1.2 ± 0.4 1.5 ± 0.1 2.3 ± 0.2 ND ND 
17 1.0 ± 0.2 0.8 ± 0.1 1.9 ± 0.3 6.1 ± 0.9 58.7 ± 14.5 
18 1.1 ± 0.4 0.2 ± 0.0 1.4 ± 0.3 0.2 ± 0.0 0.1 ± 0.1 
19 1.1 ± 0.3 0.6 ± 0.2 0.5 ± 0.2 48.5 ± 3.3 8.4 ± 2.1 
20 1.0 ± 0.2 1.2 ± 0.3 2.2 ± 0.7 25.4 ± 11.8 1246.9 ± 70.5 
21 1.2 ± 0.4 2.0 ± 0.4 1.9 ± 0.1 19.2 ± 7.7 2.4 ± 1.2 
22 1.2 ± 0.4 0.3 ± 0.2 0.1 ± 0.0 0.0 ± 0.0 0.1 ± 0.0 
23 1.1 ± 0.4 0.7 ± 0.1 0.7 ± 0.1 0.9 ± 0.2 2.8 ± 0.0 
24 1.1 ± 0.3 1.7 ± 0.3 2.0 ± 0.4 1.5 ± 0.1 3.0 ± 1.2 
25 1.1 ± 0.3 0.8 ± 0.2 1.0 ± 0.2 0.6 ± 0.1 0.6 ± 0.1 
26 1.0 ± 0.2 0.1 ± 0.0 0.1 ± 0.0 0.4 ± 0.1 0.4 ± 0.1 
27 1.0 ± 0.2 1.5 ± 0.1 2.1 ± 0.9 1.4 ± 0.2 2.8 ± 0.9 
28 1.1 ± 0.3 1.0 ± 0.0 1.4 ± 0.4 1.0 ± 0.1 1.9 ± 0.3 
29 1.0 ± 0.1 0.0 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 1.1 ± 0.1 
30 1.0 ± 0.1 1.0 ± 0.2 0.8 ± 0.2 0.9 ± 0.2 1.2 ± 0.1 
31 1.0 ± 0.1 1.2 ± 0.2 1.1 ± 0.1 3.1 ± 0.4 20.0 ± 1.8 
32 1.0 ± 0.2 1.0 ± 0.0 1.3 ± 0.2 1.7 ± 0.5 9.2 ± 2.5 
33 1.0 ± 0.1 1.3 ± 0.2 1.2 ± 0.3 2.4 ± 0.4 1140.9 ± 74.3 
34 1.1 ± 0.3 1.1 ± 0.2 0.8 ± 0.1 0.5 ± 0.1 0.4 ± 0.0 
35 1.0 ± 0.0 1.1 ± 0.1 1.5 ± 0.2 1.8 ± 0.1 6.1 ± 1.0 
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36 1.0 ± 0.0 1.0 ± 0.2 0.8 ± 0.0 1.0 ± 0.2 1.2 ± 0.1 
37 1.1 ± 0.3 1.8 ± 0.1 1.4 ± 0.2 0.8 ± 0.2 1.7 ± 0.3 
38 1.0 ± 0.2 0.8 ± 0.3 0.6 ± 0.0 0.9 ± 0.1 1.8 ± 0.3 
39 1.0 ± 0.2 0.4 ± 0.1 0.3 ± 0.1 2.8 ± 0.2 0.5 ± 0.1 
40 1.0 ± 0.2 0.7 ± 0.1 0.6 ± 0.0 1.0 ± 0.0 1.3 ± 0.1 
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